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ABSTRACT 
Impact of Trade Related Intellectual Property 
Rights (TRIPs) on the Pharmaceutical Industry in 
India 
The agreement on Trade Related Intellectual Rights (TRIPS) was 
one of the most controversial and bitterly fought agreements that 
ultimately formed part of the World Trade Organization (WTO) 
agreement in 1995. TRIPs was and continues to be an unfair agreement 
balanced heavily in favour of Multinational Corporations (MNCs). 
During the Uruguay Round of negotiations that led to the WTO 
Agreement there was a wide consensus in India against agreeing to 
TRIPs, but the Government of the day had proceeded nonetheless 
disregarding popular sentiments. 
The TRIPs agreement, once signed, placed a number of 
obligations on countries like India, specifically related to the 
amendment of the Indian Patents Act, 1970. The most important of 
these was the condition that required India to change to a product 
patent regime in the area of pharmaceutical, from the earlier system 
provided in the Patent Act 1970, which did not provide for product 
patents in this area. It may be noted here that it was this simple 
provision in the Indian Patent Act which had catapulted India to a 
position where it is the 4th largest producer of pharmaceuticals and a 
large supplier of cheap generic drugs to poor developing countries. 
Upon coming into effect on January 1, 1995, TRIPS set out 
transitional periods for WTO members to introduce legislation 
complying with the obligations under TRIPs. For developing countries, 
like India, the deadline for complying with TRIPS was the year 2000. In 
addition. Article 65.4 of TRIPS provided a special transitional provision 
for countries like India, which did not grant product patents. The 
provision provided an additional five years (until 2005), from the initial 
TRIPs transitional period, to introduce product patent protection. 
In order to conform to TRIPs agreement the Indian Government 
brought in three set of amendments to the Indian Patent Act, 1970. India 
first amended Indian Patent Act (1970) in 1999 and again in 2002. On 
March 23, 2005, the Indian Parliament passed the Patent Amendment 
Act, 2005. It was the third and final amendment to the Indian Patent 
Act, 1970. The amended Patent Act conforms to requirements set forth 
by the World Trade Organization's (WTO) Agreement on Trade-Related 
Intellectual Property Rights (TRIPs). Under the new product patent 
law, Indian drug makers can no longer manufacture and market 
reverse-engineered versions of drugs patented by foreign drug 
producers. Accordingly, there are serious concerns regarding the role 
and performance of domestic Indian generic pharmaceutical industry in 
the new product patents regime. The present study is an attempt to 
analyze possible impact of TRIPs Agreement of WTO on Indian 
pharmaceutical industry. 
From the foregoing comprehensive literature review it peters out 
that studies on TRIPS Agreement, and its impact on pharmaceutical 
industry have covered almost all possible aspects, but the studies made 
on impact assessment of TRIPs on Indian pharmaceutical industry are 
very few with analytical framework, except some reports of concerned 
agencies. There is still a gap for studying various issues related to 
strengthening the intellectual property rights and its impact on Indian 
pharmaceutical industry which has been neglected by the authors of 
Indian and foreign based studies. It is seen that most of the studies are 
concerned with innovation and creativity, price of medicines, 
affordability, technology transfer, R&D success factors, SMEs survival, 
FDl inflow, and human rights under new product patent regime. Some 
of them are based on primary surveys to measure the impact of TRIPs. 
The issues, such as pharmaceutical production, R&D, export and import 
of pharmaceutical by Indian pharmaceutical industry have not been 
covered in-depth with analytical framework, under any of the studies 
under reference. 
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The present study differs from the earlier studies, which covers 
almost all the aspects of TRIPs and analyzes its impact on Indian 
pharmaceutical production, R&D, export and import with analytical 
framework. While many of the studies assumes Post TRIPs era after 
signing of TRIPs Agreement, the present study assumes Post TRIPs era 
after India actually amended its Patent Act towards TRIPS compliance. 
The study makes an earnest attempt to trace out the major impact of 
TRIPs Agreement with regard to Indian pharmaceutical industry. 
The study on impact of TRIPs on Indian pharmaceutical industry 
has covered a span of one and half decade, i.e. from 1991-02 to 2005-06 
and further the researcher bifurcated this period according to need of 
the study into Pre TRIPs period and Post TRIPs period. This span of 
period would be more than sufficient to find out the impact of TRIPs 
provisions on pharma industry. The present stuciy has focused mainly 
on four aspects of pharmaceutical industry i.e. pharmaceutical industry 
production, R&D, export and import. The Researcher is of a strong 
opinion that the analysis on these four aspects of the pharmaceutical 
industry would be able to represent the impact of TRIPs on Indian 
pharmaceutical industry. Finally, the pharmaceutical industry 
production, R&D, export and import has been considered according to 
financial year in Indian currency. 
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The objectives which have been pursued to study analyze the 
impact of TRIPs in Indian pharmaceutical industry are to study the 
provisions of Trade Related Intellectual Property Rights (TRIPs), to 
study the provisions of Indian Patent Act, 1970 and its amendments 
towards compliance with TRIPs provisions, to study the Indian 
pharmaceutical industry, to find out the trends in production, R&D, 
export and import of Indian pharmaceutical industry, to analyze the 
impact of TRIPs regime on pharmaceutical production, R&D, export 
and import of Indian pharmaceutical industry and finally, to make 
suggestions and recommendations for strengthening the Indian 
pharmaceutical industry under the new TRIPs compliance patent 
regime. 
In order to fulfill and achieve stated objectives of the research, the 
study has been made on the basis of certain hypotheses according to 
various dimensions of Indian pharmaceutical industry under the new 
TRIPs compliance era and according to the need, importance and 
objectives of the study. The following hypotheses have been 
formulated: 
Hypothesis- 1: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of TRIPs regime on production of 
Indian pharmaceuticals industry whereas the alternative Hypothesis of 
the study (Hi) assumes that there is significant impact of TRIPs regime 
on production of Indian pharmaceuticals industry." 
HypotJiesis- 2: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of the TRIPs regime on export of 
Indian pharmaceuticals industry whereas the alternative Hypothesis of 
the study (H2) assumes that there is a significant impact of TRIPs regime 
on export of Indian pharmaceuticals industry." 
Hypotliesis- 3: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of the TRIPs regime on import of 
Indian pharmaceutical industry whereas the alternative Hypothesis of 
the study (H2) assumes that there is a significant impact of the TRIPs 
regime on import of Indian pharmaceutical industry. 
Hypothesis- 4: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of the TRIPs regime on Research and 
Development (R&D) expenditure of Indian pharmaceuticals industry 
whereas the alternative Hypothesis of the study (H4) assumes that there 
is a significant impact of the TRIPs regime on Research and 
Development (R&D) expenditure of Indian pharmaceuticals industry. 
The study is an empirical work based mainly on secondary data. 
Primary data also have been collected from various sources for the 
fulfillment of truthfulness of analysis and interpretations and then to 
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ensure the quality of research study. The secondary data for the study 
have been collected from various secondary source of information such 
as, published Reports of Indian Drug Manufactures Association of India 
(IDMA), Bulk Drug Manufactures Association of India (BDMAI), 
Organization of Pharmaceutical Producers of India (OPPI), Director 
General of Commercial Intelligence and Statistics (DGCIS), Kolkata and 
Ministry of Chemical and Fertilizers of India. Other reports such as 
various reports from Ministry of Commerce, Ministry of Finance, 
Department of Company Affairs, Planning Commission of India and 
Economic Survey of India etc are also collected for supporting the 
literature references. The publications and review bulletins of 
regulatory bodies and institutions, such as. Drug Price Control Order 
(DPCO), National Pharmaceutical Pricing Authority (NPPA), Patent 
Office Government of India and World Trade Organization (WTO) are 
also taken into reference for holding up the analysis. Altogether the 
relevant Books, Journals and periodicals. Research Papers, Published 
Thesis, Articles, News Dailies, Financial Dailies, Websites, are also 
consulted by the Researcher for better referencing. The primary sources 
can be: the personal interviews with the CEO of the pharmaceutical 
companies, experts of intellectual property rights and Director of OPPI, 
IDMA and few experts of Intellectual Property Law. 
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The statistical tools which have been used for the analysis and 
interpretations are: Mean, Maxima, Minima, Standard Deviation (SD) 
and Coefficient of Variance (CV), CAGR, Multiple Linear Regression. 
For test of significance t-test has been done. 
For the purpose of analysis and testing of the hypothesis, the 
period of the study has been bifurcated into two periods i.e. Pre TRIPs 
Period and Post TRIPs Period. The Pre TRIPs Period (1991-92 to 1998-
99) of Indian pharmaceutical industry starts immediately after the 
liberalization of Indian economy and ends in 1998-99, when India 
started amendments in its Patent Act, 1970 towards TRIPs compliance. 
During this period the Indian pharmaceutical industry was governed 
by the Indian Patent Act, 1970 which recognized process patent only, 
and term of patent was 7 years from date of application of patent and 5 
years from date of grant of patent. The Post TRIPs Period (1999-00 to 
2005-06) of Indian pharmaceutical industry begins from 1999-00 
onwards with implementation of TRIPs provisions in pharmaceutical 
sector. Government of India amended Patent Act, 1970 in 1999, 2002 
and finally in 2005 towards TRIPs compliance. During this period the 
Indian Government fully implemented the TRIPs provisions in 
pharmaceutical sector, which recognized product patent only and term 
of patent is 20 years. 
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Further, the Researcher used the Interrupted Time Series Model 
to test the hypothesis at 1 percent level of significance. 
From the model summary of first hypothesis of the study 
regarding the impact of Trade Related Intellectual Property Rights 
(TRIPs) on pharmaceutical production of Indian pharmaceutical 
industry, the t- static of the time i.e. 4.103, is significant at 0.2 percent 
level of significance and the t-static of dummy variable X2 i.e. immediate 
impact of TRIPs regime is -1.797, which is insignificant up to 10 percent 
level of significance; i.e. far beyond the level of significance. But in case 
of Post-Intervention variable X3 i.e. for impact of TRIPs regime in long 
run the t-static is 6.311, which is significant at any percent level of 
significance. Therefore, Null Hypothesis of the study (Ho) is rejected 
and alternative hypothesis is accepted. Hence, TRIPs Agreement has 
significant impact on production of Indian pharmaceutical industry in 
the long run. From the coefficients, it is indicative of the fact that TRIPs 
Agreement has increased the production of Indian pharmaceutical 
industry in the long run, compare to the production of Pre TRIPs 
period. It means under the TRIPs regime the production of Indian 
pharmaceutical industry has grown more compare to the Pre TRIPs 
regime growth. 
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From the model summary of second hypothesis of the study 
regarding the export of Indian pharmaceutical industry, the t- static of 
the time i.e. -.081, is significant at any percent level of significance and 
the t-static of dummy variable X2 i.e. for immediate impact of TRIPs 
regime is -2.434, which is insignificant at 1 percent level of significance. 
But in case of Post-Intervention variable X3 i.e. for impact of TRIPs 
regime in long run the t-static is 7.998, which is significant at any 
percent level of significance. Therefore, Null Hypothesis of the study 
(Ho) is rejected and alternative hypothesis is accepted. TRIPs has 
significant impact on export of Indian pharmaceutical industry in the 
long run. From the coefficient, it is indicative that TRIPs Agreement has 
increased the export of Indian pharmaceutical industry in the long run. 
On the other hand, under the TRIPs regime the export of Indian 
pharmaceutical industry has grown more compare to the Pre TRIPs 
regime growth. 
From the model summary of third hypothesis of the study 
regarding the impact of Trade Related Intellectual Property Rights 
(TRIPs) on pharmaceutical import of Indian pharmaceutical industry, 
The t- static of the time i.e. 4.103, is significant at any percent level of 
significance and the t-static of dummy variable X2 i.e. for immediate 
impact of TRIPs regime is -7.398, which is significant at any percent 
level of significance. Therefore, Null Hypothesis of the study (Ho) is 
rejected and alternative hypothesis is accepted. In case of Post-
Intervention variable X3 i.e. for impact of TRIPs regime in long run the 
t-static is 1.251, which is insignificant at 1 percent level of significance. 
Hence, TRIPs has affected the import of Indian pharmaceutical industry 
in short term. From the coefficients, it is indicative of the fact that TRIPs 
adversely affected the import of Indian pharmaceutical industry in 
short term i.e. immediate after implementation of TRIPs provisions in 
1999-00. 
From the model summary of last hypothesis of the study 
regarding the impact of Trade Related Intellectual Property Rights 
(TRIPs) on total Research and Development (R&D) Expenditure of 
Indian pharmaceutical industry, the t- static of the time i.e. .886, is 
insignificant at 1 percent level of significance and the t-static of dummy 
variable X2 i.e. for immediate impact of TRIPs regime is -2.851, which is 
insignificant at 1 percent level of significance. But in case of Post-
Intervention variable X3 i.e. for impact of TRIPs regime in long run the 
t-static is 6.588, which is significant at any percent level of significance. 
Therefore, Null Hypothesis of the study (Ho) is rejected and alternative 
hypothesis is accepted. Hence, TRIPs has significant impact on R&D 
expenditure of Indian pharmaceutical industry in the long run. From 
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the coefficient it is indicative that R&D expenditure of Indian 
pharmaceutical industry under TRIPs regime has grown more compare 
to the Pre TRIPs regime growth. 
Finally, the Researcher has come out with the other findings and 
suggestions along with the strategies for overcoming the existing 
problems. Coping with challenges have also been offered for further 
strengthening the Indian pharmaceutical industry. The direction for 
future researches has also been identified by the researcher. 
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Preface 
The Trade Related Intellectual Property Rights (TRIPs) 
agreement, once signed, placed a number of obligations on countries 
like India, specifically related to the amendment of the Indian Patents 
Act, 1970. The most important of these was the condition that required 
India to change to a product patent regime in the area of 
pharmaceutical, from the earlier system provided in the Patent Act 
1970, which did not provide for product patents in this area. It may be 
noted here that it was this simple provision in the Indian Patent Act 
which had catapulted India to a position where it is the 4th largest 
producer of pharmaceuticals and a large supplier of cheap generic 
drugs to poor developing countries. 
In order to conform to TRIPs agreement the Indian Government 
brought in three set of amendments to the Indian Patent Act, 1970. India 
first amended Indian Patent Act (1970) in 1999 and again in 2002. On 
March 23, 2005, the Indian Parliament passed the Patent Amendment 
Act, 2005. It was the third and final amendment to the Indian Patent 
Act, 1970. The amended Patent Act conforms to requirements set forth 
by the World Trade Organization's (WTO) Agreement on Trade-Related 
Intellectual Property Rights (TRIPs). Under the new product patent 
law, Indian drug makers can no longer manufacture and market 
reverse-engineered versions of drugs patented by foreign drug 
producers. Accordingly, there are serious concerns regarding the role 
and performance of domestic Indian generic pharmaceutical industry in 
the new product patents regime. The present study is an attempt to 
analyze possible impact of TRIPs Agreement of WTO on Indian 
pharmaceutical industry. 
The past studies to analyze the impact of TRIPs on Indian 
pharmaceutical industry were concerned with innovation and 
creativity, price of medicines, affordability, technology transfer, R&D 
success factors, SMEs survival, FDl inflow, and human rights. The 
issues, such as pharmaceutical production, R&D, export and import of 
pharmaceutical by Indian pharmaceutical industry have not been 
covered in-depth with analytical framework, under any of the studies. 
The present study differs from the earlier studies, which covers almost 
all the aspects of TRIPs and analyzes its impact on Indian 
pharmaceutical production, R&D, export and import with analytical 
framework. While many of the studies assumes Post TRIPs era after 
signing of TRIPs Agreement, the present study assumes Post TRIPs era 
after India actually amended its Patent Act towards TRIPs compliance. 
An intense investigation as the study will generate, will surely 
help policy makers and pharmaceutical companies for better 
understanding the TRIPs provisions and its impact on Indian 
pharmaceutical industry. The study will also help policy makers and 
pharmaceutical companies to take appropriate measures for 
strengthening the domestic pharmaceutical industry under the TRIPs 
regime. The study itself holds significance by contributing to the 
literature of international business from a developing country 
perspective taking Indian pharmaceutical industry as a case study. 
Lastly, it contributes to the ongoing debate of impact of strengthening 
IPR on developing countries pharmaceutical industry. 
Pre-view of Chapters 
The thesis is divided into five chapters according to the 
importance of the topics. The first chapter is the research framework 
and design which consists of problem, review of literature, research 
gap, scope, objectives, importance, methodology, and the hypotheses of 
the study. 
The second chapter presents an overview of Indian 
pharmaceutical industry. It presents an introduction to global 
pharmaceutical industry, evolution and history of Indian 
pharmaceutical industry, Indian pharmaceutical industry current 
status, pharmaceutical production cycle and SWOT analysis of Indian 
pharmaceutical industry. Further, Mc Kinsey projection and brief 
profiles of top five leading pharmaceutical companies in India have also 
been discussed in detail in this chapter. 
The third chapter attempts to highlights the concept of 
intellectual property rights, pros and cons of pharmaceutical patents, 
main provisions of TRIPs related to pharmaceutical patent, difference 
between TRIPs and Indian Patent Act, 1970. While presenting the 
overview of Indian Patent Act, 1970 amendments in Patent Act towards 
TRIPs compliance are also highlighted. Various flexibilities for health 
purpose available in TRIPs Agreement have also been discussed in this 
chapter. 
The fourth chapter attempts to assess the impact of TRIPs on 
production, export, import and R&D expenditure of Indian 
pharmaceutical industry with analytical framework. The hypotheses of 
the present study have also been tested in this chapter. 
The fifth chapter discussed the main findings of the study. It also 
discussed the problems and prospects of Indian pharmaceutical 
industry. Finally, this chapter gives some suggestion for further 
strengthening the Indian pharmaceutical industry under the TRIPs 
regime. 
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Introductory Background, Research Design 
and Framework of the Study 
1.1. Introduction 
Trade Related Intellectual Property Rights (TRIPs) were brought 
in with the prospects purpose of universalising the standards of 
Intellectual Property Rights and frame the rules of the game of the 
developing countries on par with the developed countries. Several 
factors like the continuous advancement in science, new breakthroughs 
in bio-technology, the growing participation of the private sector in the 
cost intensive research and development in the knowledge based 
pharmaceutical sector and the relative strength demonstrated by the 
developing nations in adapting the results of the scientific innovations 
to the local environment have prompted the industrialised nations to 
seek stronger protection for their innovations in all the countries. 
The Paris Convention, one of the oldest treaties governing the 
protection of industrial intellectual property was fairly liberal in 
protecting the Intellectual Property Rights (IPR). Under this 
convention, member countries were free to determine the standards of 
protection, the subject matter of protection and the period of protection 
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and thus maximum divergence were observed in case of protection of 
innovations in the pharmaceutical sector. Several countries fearing that 
the patent protection in pharmaceuticals will limit the spread of 
knowledge and thus prevent the scientific innovations reaching the 
general and the needy public, neither protected the processes of 
manufacturing a drug nor the final drug. This is because, once a 
product is patented (product patents), the same product cannot be 
produced by an alternate method or process during the protection 
period. However, if the process alone is protected (process patents), 
then an alternative process which is mostly Invented ' around the 
earlier process could be used to produce a similar product, since in 
pharmaceuticals, a product can be produced by more than one method. 
While many of the industrially developed resource rich countries 
chose to reward the innovators and adopted product patents to 
promote further innovations, some of the developing countries realised 
the potential of the process patents in developing the domestic industry 
and adopted the same. Thus, the developing countries with process 
patent protection were able to take advantage of the innovations made 
by early innovators. When a subsequent product is based on an 
innovation made earlier, the late entrant enjoys the reduction in the cost 
of developing the product without of course sharing the 
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benefits/profits derived by the new product with the early innovator. 
But the capacity to exploit the earlier innovations to its advantage 
depends on the technological development of the country, capacity of 
the domestic industry, the market size and the type of technology that is 
used in developing the product. Of the many countries that adopted 
process patents, developing countries like India, China, Korea and 
Brazil have developed expertise to develop new products, which were 
mostly around the earlier innovations of the developed countries 
As per the minimum standards mentioned in the TRIPs 
agreement, patent shall be granted for any inventions, whether 
products or processes, in all fields of technology provided they are new, 
involve an inventive step and are capable of industrial application 
without any discrimination to the place of invention or to the fact that 
products are locally produced or imported. Accordingly, now patents 
will have to be granted in all areas including pharmaceuticals and the 
effective period of protection is for twenty years from the date of filing 
the application. 
However, in order to smoothen out the differences in the level of 
protection and to make necessary amendments in the national laws to 
adopt product patents, countries with different developmental status 
have been given a transitional period to bring in reforms in the desired 
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areas and make the laws comparable with other countries. Thus 
developed countries had one year to make the suitable amendments 
and for the developing and least developed countries, the time 
provided was 10 and 15 years respectively. As per this, even US had to 
amend its patent law since; the effective term of protection was for a 
period of 17 years from the date of grant. India had to enforce the 
system of stronger patents from January 2005. 
Thanks to an array of measures post 1970, the Indian domestic 
pharmaceutical industry flourished in the absence of product patents. 
The competitive generic market resulted in production of generic 
versions of blockbuster drugs at very low prices.i These generic drugs 
cost about 5% of the price of similar drugs sold by US and EU 
pharmaceutical firms.^ Apart from the large domestic consumption, 
cheap Indian generic drugs have been favored by many millions of 
AIDS patients across the Third World. Generic drugs from India played 
a key role in lowering the price of antiretroviral treatment by as much 
as 98%, making it feasible to scale up treatment more rapidly for 3.7 
million Africans with AIDS lacking access to treatment. 
India became a party to the TRIPs Agreement in April 1994. At 
that time, India's current enactment of the Patent Act 1970 directly 
contravened the TRIPs Agreement. Upon coming into effect on January 
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1, 1995, TRIPs set out transitional periods for WTO members to 
introduce legislation complying with the obligations under TRIPs. For 
developing countries, like India, the deadline for complying with TRIPS, 
was the year 2000. In addition. Article 65.4 of TRIPS provided a special 
transitional provision for countries like India, which did not grant 
product patents. The provision provided an additional five years (until 
2005), from the initial TRIPs transitional period, to introduce product 
patent protection. India first amended Indian Patent Act (1970) in 1999 
and again in 2002. On March 23, 2005, the Indian Parliament passed the 
Patent (Amendment) Act 2005. It was the third amendment to the 
Indian Patent Act (1970). The amended Patent Act conforms to 
requirements set forth by the World Trade Organization's (WTO) 
Agreement on Trade Related Intellectual Property Rights (TRIPs). 
Under the new product patent law, Indian drug makers can no longer 
manufacture and market reverse-engineered versions of drugs patented 
by foreign drug producers. Accordingly, there are serious concerns 
regarding the role and performance of domestic Indian generic 
pharmaceutical industry in the new product patents regime. 
1.2. Statement of the Problem 
With changes in India's patent laws in the early 1970s, which 
recognized process patent only, Indian pharmaceutical producers 
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became experts in 'reverse engineering' of patented drugs. During the 
process patent regime the Indian pharmaceutical industry became 
world's leading producer and exporter of less expensive copies of the 
world's best-selling patent-protected drugs. But as the TRIPs agreement 
has been implemented on Indian pharmaceutical industry, the Indian 
drug makers can no longer manufacture and market reverse-engineered 
versions of drugs patented by foreign drug producers. It would affect 
Indian generic pharmaceutical industry. There needs a detailed study to 
be made to assess the impact of TRIPs on the Indian pharmaceutical 
Industry. The present study is an attempt to analyze possible impact of 
TRIPs Agreement of WTO on Indian pharmaceutical industry. 
1.3. Review of the Literature: 
A good number of studies have been conducted in the areas of 
both Trade Related Intellectual Property Rights (TRIPs) and its impact 
on Indian pharmaceutical industry, consisting a number of research 
article, books, theses and various government and non-government 
publications. Some of glimpses are presented as below: 
Chaudhri Sudip (2005)3, in his book "The WTO and India's 
Pharmaceutical Industry. Patent Protection, TRIPs, and Developing 
Countries", done in-depth study of the TRIPs agreement of WTO and 
Indian pharmaceutical industry from various aspects. The basic 
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objective of his book is to assess the costs and benefits and to try to 
analyze the impact of TRIPs on Indian Pharmaceutical Production, 
innovation and prices in developing countries. He states that the two 
basic benefits claimed for developing countries are: 
First, as the MNCs begin to feel their intellectual assets are secure 
in developing countries, there will be an increase in the flow of foreign 
direct investment (FDl) and technology transfer, resulting in greater 
technological and economic growth in developing countries and 
second is, as the local pharmaceutical companies in developing 
countries feel they can reap the benefits from investments in R&D, there 
will be an increase in the resource devoted to R&D for developing new 
drugs for diseases neglected by the global MNCs. Further, he states that 
cost of implementing product patent regime for developing countries 
like India. With the introduction of Product patent protection from 
2005, the opportunities for domestic expansion will shrink. They will 
not be able to produce the new patented products and result will be 
high price of new drugs. 
Another paper (2007)^, entitled "Is Product Patent Protection 
Necessary in Developing Countries for Innovation: R&D by Indian 
Pharmaceutical Companies after TRIPS", concluded that R&D 
expenditure has dramatically increased for a segment of the Indian 
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pharmaceutical industry since around the mid-1990s when TRIPS came 
into effect. It is not only that the amount of R&D expenditure has gone 
up. There has also been a change in the structure of R&D activities of 
the Indian companies. While in the past they were primarily engaged 
with development of new processes for manufacturing drugs, now 
they are also involved in R&D for new chemical entities (NCEs) and 
modifications of existing chemical entities to develop new formulations 
and compositions. Patenting by the Indian pharmaceutical companies 
has also gone up significantly. 
In his one more research paper (2003)5, "The Effects of Extending 
Intellectual Property Rights Protection to Developing Countries: A Case 
Study of the Indian Pharmaceutical Market.", using a product-level data 
set from India, which is unique in terms of its detail and coverage, 
estimated key price and expenditure elasticities and supply-side 
parameters for the fluoroquinolones sub segment of the systemic anti-
bacterial (i.e., antibiotics) segment of the Indian pharmaceuticals market 
founds that total annual welfare losses to the Indian economy from the 
withdrawal of the four domestic product groups in the 
fluoroquinolones sub-segment was on the order of U.S. $713 million, or 
about 118% of the sales of the entire systemic anti-bacterial segment in 
2000. Of this amount, foregone profits of domestic producers constitute 
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roughly $50 million (or 7%). The overwhelming portion of the total 
welfare loss therefore derives from the loss of consumer welfare. In 
contrast, the profit gains to foreign producers are estimated to be only 
around $57 million per year. 
Mathur Vibha (2005)6, in his book "WTO and India: 
Development Agenda for the 21s' Century", writes that among the 
sectors that have experienced the greatest transformation in India, the 
pharmaceutical industry perhaps the most significant. India's WTO 
involvement during the last decade has encouraged the pharma 
companies to adopt a strategy of R & D based innovative growth. Thus, 
while Indian companies spent not even a fraction of a percent of their 
turnover on R & D ten years ago, today the larger Indian companies are 
spending in the region of 6 to 8 percent of their turnover on R & D. The 
transformed Indian pharma industry is itself looking for patent 
protection. 
Agarwal A. (2004)^, in "Strategic Approach to Strengthening the 
International Competitiveness in Knowledge Based Industries: The 
Indian Pharmaceutical Industry", done an extensive study on the 
international competitiveness of knowledge-based industries taking 
Indian pharma industry as a case study. She tried to study the main 
determinants driving Indian firms' competitiveness in the knowledge-
10 
Introductory Background, 
Research Design and Framework of the Study 
based industry. The methodology taken is multivariate technique using 
a multi-regression analysis method. The dependent variable taken is 
export intensity and the independent variables are technological 
capabilities, marketing capabilities, industry structure, and cost of 
production and government policy initiatives in the study. In her 
conclusion, she has given list long policy implications for the 
government to pursue to make the Indian knowledge based industries 
competitive in the TRIPs regime. 
Chadha Alka (2006)^, in her paper entitled "Destination India for 
the Pharmaceutical Industry" discussed that the immediate effect of 
product patents in India may be less severe than expected since many 
off-patented therapeutic equivalents are available to the consumer and 
only about 3 percent of the drugs marketed in India are patented. 
Further, many of the currently patented drugs are likely to go off patent 
in the next few years, clearing the way to follow the reverse-engineering 
strategy. But at the same time, new drugs would come under patent 
protection and the extension of the patent period would limit the 
availability of products to reverse-engineering. Her study suggests that 
R&D and patenting have been stimulated with the sighing of TRIPs and 
the enforcement of stronger patent protection rights in India. Further, 
small manufacturers that were dependent only on the marketing of 
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process inventions are likely to face survival concerns after the 
introduction of product patent rights. But, even these smaller firms with 
low research capability have an opportunity to gain by reorienting 
themselves as contract manufacturers for large pharmaceutical MNCs, 
provided they are able compete with other low-cost locations like china. 
She further discussed that the stricter patent regime will improve the 
greater FDI inflow in pharmaceutical sector. 
Another study of Dinar Kale and David Wield (2006)9, in their 
paper "Exploitative and Explorative Learning as a Response to the 
TRIPS Agreement in Indian Pharmaceutical Firms: Some Implications 
for Other Developing Countries", analyzed issues related with patents 
and impact of TRlPs agreement on the pharmaceutical industry 
especially in developing countries, using data from India. Changes in 
regulation as a result of the TRIPS agreement raise questions about 
survival and success of pharmaceutical firms in developing countries. 
Their paper explored some of these questions by studying the impact of 
TRIPS on the learning processes in Indian pharmaceutical firms. The 
findings reveal that Indian firms responded with an ambidextrous 
capability development approach. Firms exploited existing process 
R&D capabilities to create 'complimentary assets' while in parallel 
investing in developing capability for innovation. Entry into the 
12 
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generics markets of advanced countries helped Indian firms to 
overcome two extreme disadvantages: dislocation from frontiers of 
pharmaceutical research and irmovation; and, distance from advanced 
markets. This approach enabled the Indian pharmaceutical industry to 
emerge as a net foreign exchange earner and chief exporter of cheap 
generic drugs to the USA, UK, Latin America, and Africa. Analysis of 
the Indian pharmaceutical industry response to TRIPs suggests that 
these technological paths could be adopted by pharmaceutical firms in 
other countries. The ambidextrous capability development model and 
licensing strategy in product R&D practiced by Indian pharmaceutical 
firms is giving rise to a new pharmaceutical R&D business model which 
is characterized by a new division of labour and 'outsourcing' of 
pharmaceutical R&D functions. 
This has implications, not only for reducing the cost of healthcare 
in advanced countries, but also for the development of domestic 
pharmaceutical industries in other industrializing countries. The 
pharmaceutical industry in some countries, such as Brazil and China, 
has also developed basic and intermediate capabilities in process R&D 
and manufacturing. PharmaceuHcal firms in these countries could learn 
from the Indian model of ambidextrous capability development to 
move up the pharmaceutical R&D value chain. In this context, 
13 
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mechanisms adopted by the Indian pharmaceutical industry to develop 
more advanced levels of process and product capabilities, are applicable 
to further growth and development of pharmaceutical firms in other 
countries. 
Fink (2000)10, in "How Stronger Patent Protection in India 
Might Affect the Behavior or Transnational Pharmaceutical Industries" 
examines the impact of patent protection on the behavior of 
pharmaceutical multinationals and the market structure in India. His 
analytical approach builds around the calibration of a theoretical 
model to actual data from the Indian pharmacy market, to answer the 
hypothetical question of what the market structure would look like, if 
India allowed product patent protection on pharmaceuticals. He 
concludes that in case new on-patent drugs are newer varieties of off-
patented products in the same therapeutic class, it will not have a large 
impact on prices of drugs. But if they are altogether new products, of 
which off-patent generic versions are not available, price rises 
associated with such products may be high. The model also shows that 
the simulated welfare losses for the Indian consumers were quite large. 
Gupta Amit Sen (1998)", in "Impact of Policy Changes on Drug 
Policy and Drug Use", presents a different picture. His analysis shows 
that prices of ^older drugs', which are not patent protected are much 
14 
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higher in India compared to other countries, while prices of drugs that 
are patent protected or recently off patent are cheaper in India 
compared to the prices of drugs in the same set of countries. This 
anomaly he attributes to the price control mechanisms that are in 
operation in India 
Grace, Cheri (2004)i2 in his paper entitled "The Effect of 
Changing Intellectual Property on Pharmaceutical Industry Prospects in 
India and China" states that according to the Organization of 
Pharmaceutical Producers of India (OPPI), the industry trade 
association, there will be no rising in drug costs and financial hardships 
for many generic houses around the country because First off, the 
number of new drugs registered worldwide each year is only between 
25 and 35. Also, the National Pharmaceutical Pricing Authority (NPPA) 
maintains the power to control the prices of drugs if found excessive. 
Additionally, the patents of 97% of the drugs in the World Health 
Organization's (WHO) List of Essential Drugs have expired. Therefore, 
these drugs will continue to be available at current prices. 
James, et. al (2002)1'', in their paper "The Effects of Extending 
Intellectual Property Rights Protection to Developing Countries: A Case 
Study of the Indian Pharmaceutical Market.", did an analysis of the 
extreme policy experiment, whereby full access is granted to the 
15 
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existing stock of pharmaceutical products and presents the tradeoffs 
involved in a very stark light. Gains to existing consumers from full 
access would be considerable, on the order of $1 trillion dollars. The 
intensity of debate surrounding access by this interest group, and its 
representatives in the generic manufacturing sector. Congress, and 
elsewhere, is not surprising, given this result. At the same time, the lost 
opportunities to develop new drugs to address currently untreated 
illnesses, or to improve upon existing drugs, carry a considerably larger 
price tag. The lack of intense lobbying efforts by any consumer groups 
reflects the fact that many of the beneficiaries of innovation do not at 
present have a voice in the debate, beyond the extent to which their 
interests are represented by innovators. According to their demand 
analysis, we would lose 3 dollars in benefits of innovation for every 
dollar we gain due to easier access. This number is conservative, as 
indicated by our alternative analysis. Its implications for policies 
concerning periods of market exclusivity, pricing, review times, and 
other policy variables are the subject of our future research. 
A study of Jha Tara Kant {2007)i4 on "Impact of WTO on Indian 
Pharmaceutical Industry", describes that highly protective patent 
regime such as that of the TRIPs, India would attract substantial 
investment by foreign multinational drug companies and would 
16 
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become an attractive venue for clinical testing of drugs. Such 
investments, whether Greenfield investments, buyouts of, or mergers 
with, Indian producers could indeed be attractive. However, the 
downsides are significant. Most likely, prices of medicines in India will 
go up substantially. It is possible, though not inevitable, that foreign 
and domestic companies in India will tilt their research towards 
generating drugs, including the so called lifestyle drugs, for upscale 
world market, rather than work on developing drugs for diseases, such 
as malaria and tuberculosis, afflicting billions of the poor in the 
developing world. 
One of the significant study of Kamath N. (2002)i5, in "Operation 
Successful but Patient Dead?" cited that 1970 Patent Act although 
helped the domestic companies to grow, had a negative scientific 
culture, which did not promote creativity. The industry in particular 
and the economy more generally, suffered deadweight losses in 
general. In conclusion he wrote that forthcoming and continuing 
changes in the law required by TRlPs is in fact a blessing in disguise 
for an industry that is yet to receive its true creative potential. Laws 
that promote and reward creativity will enable dynamic gains for the 
local industry and, considering the level of development in India, such 
laws are to be welcomed rather than opposed. 
17 
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Kubo k. (2004)1^ in "Product Patents and Vertical Integration in 
the Post-TRIPS Indian Pharmaceutical Industry" examined the factors 
behind the observed patterns of R&D expenditure and patenting by 
Indian pharmaceutical companies after the signing of the TRIPS 
Agreement and found that R&D intensity and the patent to R&D ratio 
increased after 1995. It found that vertically integrated firms - those that 
produce both bulk drugs and formulations - are filing the majority of 
product patent applications, as well as a larger share of process patents 
than firms specializing in bulk drugs. This may be because the 
introduction of product patents created the possibility of opportunistic 
behavior between formulation manufacturers and bulk drug 
manufacturers. 
Lalitha N. (2003)i7, in "TRIPs and Pharmaceutical Industry: Issue 
and Prospects", estimates that impact of IPR will largely depend on the 
developmental status of the economy such as the availability of 
technical manpower and infrastructure, capacity of the domestic 
industry, and so on. A country with a strong domestic industry such as 
India is in a relatively advantageous position than a country where 
domestic industry does not have much presence and depends on 
multinationals. It is true that the impending WTO regime has 
stimulated the R&D investment in India. At present the future of the 
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thousands of small units is not very clear. Under normal circumstances, 
units that are producing the generic drugs should not get affected 
because these drugs are not patent protected. But it is likely that, they 
may face competition from large producers who may compete on larger 
volume and lower cost of production. As far as India's pharmaceutical 
industry is concerned, various options are possible in the WTO regime. 
These are to: (a) manufacture off patented generic drugs, (b) produce 
patented drugs under compulsory licensing or cross licensing, (c) 
invest in R&D to engage in new product development, (d) produce 
patented and other drugs on contract basis, (e) explore the possibilities 
of new drug delivery mechanisms and alternative use of existing drugs, 
and (f) collaborate with multinationals to engage in R&D, clinical trials, 
product development or marketing the patented product on a contract 
basis and so on. 
She done a SWOT analysis (2002)i8, entitled "Indian 
Pharmaceutical Industry in WTO Regime: A SWOT Analysis", and 
founds from her study that the major strength of the industry is in 
process development nurtured by the Patent Act of 1970, which has 
helped the industry to grow and has also benefited the consumers. She 
also pointed that on the basis of this built up capacity, in the WTO 
regime also, India could benefit by MNCs strategies such as the 
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outsourcing of R&D, production and marketing provided the local 
firms' current research interests, manufacturing capacity, technical and 
scientific manpower and the product profile matching the MNC 
interests. Towards that goal, strengthening the laboratory and 
manufacturing practices will improve the competitive advantage for 
India over others from the Asian region. Simultaneously efforts should 
also be geared towards improving the domestic R&D and increasing the 
FDI in R&D. Most importantly, the IPl needs to assure the common 
public that in the process of globalization and in the pursuit of new 
drug discovery, people's access to medicines and the interests of the 
consumers will not be adversely affected. 
In her one more research paper (2001)i^, "TRIPs and 
Pharmaceutical Industry: Issues of Strategic Importance", she 
concluded that stronger regime will bring in more resources in terms of 
royalty and license fee to the developed countries, whereas the 
developing countries will have to depend on the developed countries. 
Further, India has a fairly developed pharmaceutical industry, which 
caters to the domestic as well as the export market. Some of the big 
units have started strengthening their R&D and have also filed number 
of applications for patents and also there is some evidence available 
regarding the mergers and amalgamations to pool the human and 
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financial resources to strengthen the R&D in new product development. 
These firms will definitely benefit by the stronger protection. Some of 
the R&D and manufacturing facilities set up in these firms meet the 
international standards, and they have already been approached by 
multinationals for conducting research and undertaking manufacturing 
on their behalf. 
Dnnesh Abrol (2004)2o, in his paper "Knowledge Diffusion under 
the Emerging Post TRIPs Indian Pharmaceutical Scenario", analyzes the 
post-TRIPs behavior of domestic and foreign pharmaceutical firms in 
India in respect of technology acquisition, knowledge transfer and 
domestic R&D. It suggests that evidence available on the diffusion of 
knowledge contradicts the claim of TRIPs advocates that its adverse 
effect on prices of patented medicines would be adequately 
compensated by the benefits of technology transfer and domestic R&D. 
It assesses the prospects of capability development by the domestic 
firms in a scenario when they have also chosen to enter into the 
relations of subcontracting in R&D and production for the multinational 
corporations. It claims that due to the introduction of strong IPRs 
pharmaceutical multinationals are now advantageously placed to 
control the knowledge diffusion and integrate the local capabilities of a 
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country like India in to their own myopic and narrowly benefiting 
innovation strategies. 
Lanjouw Jean O. (1998)2i, in working paper entitled "The 
Introduction of Pharmaceutical Product Patents in India: Heartless 
Exploitation of the Poor and Suffering?" analyses how the introduction 
of product patents for pharmaceuticals may benefit or adversely affect 
India. She bases her analysis on information obtained over a period of 
six months, September 1996-March 1997, in India through interviews 
with a wide range of people in the pharmaceutical sector. Through this 
and documents supplied by various pharmaceutical organizations 
and governmental agencies, she tries to predict whether one 
might expect or not expect to see changes occurring. Her study 
suggests that the Indian firms are moving into the world generics 
market and, although the introduction of product patents will 
cause them to lose their first-mover advantage, their low 
manufacturing costs will continue to give them an advantage in 
competing for this market. It may become somewhat less profitable, 
since speed into the market seems to be important, but there does not 
seem to be any reason to expect that they will not be successful in 
increasing their participation in the generics sector. The bulk of 
production for the domestic market is drugs which are not on-patent. 
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As a result of these two features, the introduction of product patents 
should not have a strong adverse affect on employment in the 
industry or on the contribution of the pharmaceutical sector to the 
balance of payments. She proves that even if product patents result in 
significantly higher prices, much of the pharmaceutical market will 
not be affected. 
Madanmohan and Krishnan, (2003)22, in their paper on 
"Adaptive Strategies in the Indian Pharmaceutical Industry", suggest 
that in case of Indian Pharmaceutical firm's response to changes in 
patent law, the predominant strategy of Indian firms is to build capacity 
to achieve scale economics while the other preferred strategy is to 
stabilize and control the environment through developing alternative 
technology paths. 
Mishra (2001)23, i^ his paper on "World Trade Organization and 
India: The Background and Future Task", states that when new patent 
law come into force as required by the Duncle proposal. It is expected 
that patent holders will use their monopoly to effect sharp rise in drug 
prices. The growth of India's growing indigenous drug industry will be 
seriously affected. 
Murugavelu k. (2008)24, in his paper "Intellectual Property Rights 
and India's Trade Performance in Pharmaceutical Exports", describes 
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that TRIPs agreement will have s significant impact on India's 
successful bulk-oriented and formulation-oriented pharmaceutical 
industry. Indian companies will have to compete with multinationals 
by focusing on drug development and thereby producing their own 
patented products. Alternatively, Indian companies could focus on 
producing patented drugs under license from foreign companies or 
concentrate on generating revenues from producing generic drugs. 
Nagesh (2002)^ 5, in "Intellechial Property Rights, Technology and 
Economic Development: Experiences of Asian Countries" found that 
there has been a lot of controversy on the role of intellectual property 
protection (IPP) regime especially the patent system in fostering 
innovation, technology and industrial development of a country. 
Intellectual property rights protection is expected to encourage 
innovation by rewarding the inventor. Strong Intellectual property 
rights protection regime may also inhibit diffusion of knowledge and 
even technology development in the countries that are technology 
followers. Countries have to fine-tuned their Intellectual property rights 
protection regimes as per their developmental requirements. Against 
this backdrop, the on-going attempt to harmonize and strengthen the 
IPP regimes worldwide, as a part of the TRIPS Agreement, is widely 
seen to be adversely affecting the technological activity in developing 
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countries by choking the knowledge spillovers besides implications for 
the access and affordability to lifesaving drugs by the poor. 
Nauriyal D.K. (2006)26, in "TRIPs Compliant New Patent Act and 
Indian Pharmaceutical Sector: Direction in Strategy and R&D", traces 
the history and the current profile of the India pharmaceutical industry, 
taking note of the prominent changes in the new Act over the last Patent 
Act, 1970 and presents an analysis on the impact of such changes on the 
Indian pharmaceutical sector in terms of strategy choice and R&D 
direction. The study concludes that most dynamic Indian 
pharmaceutical players are likely to adopt a combination of 'cooperate 
and compete' strategies to insure a smooth transition from reverse 
engineering based to research-based pharmaceutical firms. The analysis 
also suggests that there may be considerable inflow of outsourcing 
business to the India in the realms of clinical trials, contract research 
and manufacturing. 
Prabhu Ram (2006)27, in his article "India's New TRIPs-
Compliant Patent Regime between Drug Patents and Right to Health", 
concluded that for India's domestic consumers, medicines patented pre-
1995 would continue to be available at the same prices. Consumers 
could expect a slight price increase for medicines that are the subject of 
mailbox patents. Prices for medicines that are the subject of patents 
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issued after 2005 would probably be higher The effective use of the 
compulsory licensing provisions could result in continued domestic 
access to medicines at cheap costs for the drugs in the mailbox and 
after. In addition, the National Pharmaceutical Pricing Authority 
(NPPA) and India's price regulatory policy, the Drug Price Control 
Order (DPCO), could play a key role in keeping a check on prices. With 
the new level playing ground from 2005 onwards, research-based 
Indian generic manufacturers could supply new markets with their low 
cost medicines, and claim higher levels of IPP the EU and the US. 
Indian companies are adopting new strategies to expand the market for 
their low cost drugs. 
Pradhan (2006)28, i^ "Strengthening Intellectual Rnpaty 
Rights Globally: Impact on India's Pharmaceutical Exports" 
assessed the impact of strengthening intellectual property rights on 
India's pharmaceutical exports. The study made on external 
determinants of export performance has found a positive effect of IPR 
on Indian pharma exports stating there exists a better market expansion 
opportunity for the pharma industry. The methodology undertaken 
was a gravity model using multi regression analysis model. The main 
analysis was on the income level, GDP and psychic distance such as 
common language/ culture/ cross border in between two countries and 
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taking intellectual property rights into consideration. Mainly the study 
has focused on external environment determinants of a firm in the 
analysis. 
Another study of Rane (1996)29, entitled "Analysis of Drug Prices, 
1988 to 1995" concluded that where significant differences persisted 
between the prices charged by different manufacturers for the same 
formulation. Mostly companies with substantial market power charged 
higher prices and the impact of DPCO did not percolate to the 
consumers at all. While stressing the fact that the present price controls 
will be applicable on patented products too and such controls would 
definitely benefit the customers. 
Rao R. Anita & Thakur R. Rajiv (2006)3o, in their article "Indian 
Pharmaceutical Industry; A Post 2005 Scenario", concluded that the 
new patent regime will stop the reverse-engineering of patented drugs. 
Post 2005, under new product patent regime the following options 
available for Indian pharmaceutical industry: 
To compete with the MNCs by producing their own inventions. 
To produce under license. 
To make drugs those are free from patents. 
Sethi Amarjit Singh (2008)3i, in his article "Intellectual Property 
Right and Pharmaceutical Sector in India", discusses the negative and 
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positive viewpoint of TRIPs, related to Indian pharmaceutical sector. He 
states that vital drugs for killer diseases like tuberculosis, pneumonia, 
malaria, HIV, etc., are becoming ineffective and, therefore, need 
immediate replacement. Multinational pharmaceutical companies are 
tenaciously defending their intellectual property rights in life saving 
drugs. Thus the drugs which are off patented now will be the patented 
ones after replacement and will, therefore become very costly. 
Introduction of IPR will leads to price jump, which may reach to 100-
200%, or even more, for pharmaceutical product under patents, 
depending upon the prior pricing level, elasticity of their demand, etc. 
With intellectual property rights protection, India would become a very 
attractive destination for R&D by private concerns, as a result of which 
quality drugs would become available to the public. India with a low 
production cost of generic drugs has an edge over its competitors in 
foreign markets. At the global level, drugs worth $ 40 billion would go 
off-patent this year and another $ 70 billion worth of drugs would go 
off-patent in 2008. Indian pharma companies would then raise their 
stake in the world market to 30 percent. As a result, Indian pharma 
industry would grow at 11 percent. Further, due to comparative 
advantage of cost of skilled and non-skilled labor, opportunities are also 
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opening up for Indian firms in contract manufacturing of drugs and 
contract research. 
Sharma Shashi (2007)3 ,^ in "New Patent Regime-Challenges for 
the Indian Pharmaceutical Industry", concluded that the new patent 
regime is not likely to affect India's domestic consumers as medicines 
patented prior to 1995 would continue to be available at the same prices 
or even at lesser prices due to improved productivity of Indian 
pharmaceutical manufacturers. However, there is a possibility of a 
slight increase in price for certain medicines which are the subject of 
mailbox patents. 
Another relevant study of Smith Eric Sean (2000)33, in his research 
paper "Opening Up to the World: India's Pharmaceutical Companies 
Prepare for 2005" founds a number of conclusions about the impact of 
reforms on the pharmaceutical industry. Increased patent protection 
need not spell disaster for Indian pharmaceutical companies, even 
though the current practice of profiting from other companies' IP will 
likely cease to be a strategic option. The future success of Indian 
pharmaceutical companies hinges on their ability to find productive 
roles for themselves in the post-2005 environment. 
The most publicized reaction of Indian firms to 2005 has been the 
development of drug discovery programs by companies such as DRL, 
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Ranbaxy, Wockhardt, and Dabur, who plan to use product patent 
protection as an incentive to produce their own Intellectual Property. To 
be sure, Indian drug discovery programs are still in their infancy and 
there remain considerable obstacles on the horizon. Indian companies 
have neither the capital bases nor the experience of their multinational 
company (MNC) competitors. Not all Indian pharmaceutical firms 
possess the resources, the will, or the know-how to initiate drug 
discovery, but there is hope for lesser-endowed companies after 2005. 
Consider the following points. First, 90 percent of the Indian 
pharmaceutical market consists of second and third generation drugs 
that are no longer subject to patent protection in the developed world. 
After 2005, Indian companies will be able to continue to produce such 
drugs. Second, Indian drug companies have advantages over MNCs in 
the Indian market in a number of non-technological areas, including 
marketing, distribution, and traditional medicines. Some Indian 
companies are leveraging these non-technological strengths (and even 
building entire businesses around them) as they approach 2005. Third, 
mergers and acquisitions (M&A) have become increasingly common. By 
matching companies with complementary strengths, the M&A process 
promises to better equip Indian companies to compete with MNCs in 
years ahead. 
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Four of the twelve firms in the sample of his paper were MNC 
subsidiaries. Accordingly, the paper also offers insights into these 
companies' 2005-related strategies. 
The Director of Indian Drug Manufacturers Association, Grover, 
O. P.34, in an interview replies that the impact of patent protection on 
the Indian drug industry that under TRIPs regime indigenous capability 
will be hit hard. Consumers will have to pay higher prices. The 
infrastructure created by local industry will remain unutilized. Local 
production will be confined to making age-old drugs, denying the 
benefits of new drugs and innovation. Local producers will have to wait 
20 years for the patent to expire on a new drug, before they can start to 
manufacture it, by which time its value will probably be undermined by 
a new drug in the market. 
Anita Kumari (2007)35, \j^ her study on "Liberalization, TRIPS 
and Technological Behaviour of Firms in Indian Pharmaceutical 
Industry", analyzed the impact of liberalization policies on technology 
imports in Indian Pharmaceutical Industry. Her study is based on capital 
line data on companies from 1995, die year when economic reforms 
actually trickled down to the pharmaceutical industry. The Tobit model 
has been used to identify the factors determining technology imports 
in the Indian pharmaceutical industry. It has been found on the 
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basis of estimated function that among factors determining 
technology imports, it is size of firm and not growth of firm or 
export orientation which has been significantly determining 
technology imports in the pharmaceutical industry. Thus large 
firms, because of availability of huge resources and risk taking 
capacity inherent with new product development have been 
found to be in a better position to take advantage of 
liberalization policies for import of technology. Profit has been found 
to be insignificant determinant to seek technology imports to avail 
the opportunities created by liberalization and face the challenges 
under TRIPs. Under the TRIPs regime, when technology component is 
going to be the driving force in the growth of Indian industry in 
general and pharmaceutical industry in particular with the 
introduction of product patent from 2005, Indian pharmaceutical 
industry will not be able to take the advantage of the reverse 
engineering. Therefore to be competitive, firms have to seek 
technology imports for producing new products. Research and 
development efforts should be further increased for adaptation of 
imported technology to Indian conditions. Smaller firms should also 
take advartage of new tednobgy by growing larger through mergers, 
acquisitions or partnership with either larger domestic firms or 
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foreign firm. Firms may also create their own resources through 
borrowing or equity financing. 
Shyama V. Ramani, Augustin Maria, (2005)3^ in their paper 
"TRIPS: Its Possible Impact on Biotech Segment of the Indian 
Pharmaceutical Industry", provides some insight into the impact of 
TRIPS on the innovative capacity of developing countries, by taking 
India to be representative of a technologically advanced developing 
country and biopharmaceuticals as an example of a knowledge 
intensive industry. The two central results of the paper can be 
summarized as follows. First, given the present state of the 
competencies of Indian pharmaceutical firms and the national system of 
innovation, the major focus of innovative activity is going to be either 
on racing to be the first or lowest cost producer of off-patent products, 
or on being a link in the international division of labour supporting the 
creation of innovations by western multinationals. Second, TRIPs is 
not going to have a significant impact on the two segments given 
above or on the other preoccupations of Indian pharmaceutical 
firms. Hence, the major effect of TRIPs will be to force Indian firms to 
put their re-engineered products on the market only when they get off 
patent. 
33 
Introductory Background, 
Research Design and Framework of the Study 
Singhatiya Arvind (2004)3 ,^ in his article "Impact on Product 
Patent on FDI in Indian Pharmaceutical Industry", suggests that 
product patent regime will help the pharmaceutical industry to tap 
outsourcing of clinical research. By participating in the international 
system of IPR protection, India, with its vast pool of scientific and 
technical personnel, and well-established expertise in medical treatment 
and health care, has unlocked vast opportunities in both export and 
outsourcing and has the potential to become a global hub in the area of 
R&D based clinical research. OPPI directory shows only 300 units out of 
10000 registered companies are in the organized sector. While process 
patent helped to flourish IPI into a world-class generic industry, 
product patent regime will filter the best from the pack and would be 
off favorable to players with build-in scientific and technical resources. 
The impact of new regulation will not deter the Indian pharma majors 
as they are already doing roaring business in the very countries where 
these patent laws are strictly in force. For India's pharmaceutical 
industry various options are available in the WTO regime. These are to: 
(a) manufacture off patented generic drugs, (b) produce patented drugs 
under compulsory licensing, (c) invest in R&D to engage in new 
product development, (d) produce patented and other drugs on 
contract basis, (e) explore the possibilities of new drug delivery 
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mechanism and alternative use of existing drugs, and (f) collaborate 
with multinationals to engage in R&D, clinical trials, product 
development or marketing the patented product on contract basis and 
so on. He anticipates that product patent is going to have a very little 
impact on FDI scenario in a country like India. 
Tancer R. (1999)38, in his study "Investing in the Indian 
Pharmaceutical Industry", found that, when India liberalized her policy 
towards foreign investment in 1991, there was a positive response from 
capital exporting countries. Yet, the multinational pharmaceutical firms 
did not participate in this opportunity. The major reason underlying 
their decision is the absence of pharmaceutical product patents in India. 
Clearly, the intellectual property environment in a country affects the 
flow of foreign investment, particularly in those industries heavily 
dependent on intellectual property protection. India is unique among 
developing countries, as she has a thriving pharmaceutical industry 
dedicated to providing healthcare at the lowest possible cost. India's 
growing pharmaceutical industry, however, is based on reverse 
engineering of existing drugs, not on innovative research. 
1.4. Research Gap, Need and Importance of the Study: 
From the foregoing comprehensive literature review it peters out 
that studies on TRIPs Agreement, and its impact on pharmaceutical 
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industry have covered almost all possible aspects, but the studies made 
on impact assessment of TRIPs on Indian pharmaceutical industry are 
very few with analytical framework except some reports of concerned 
agencies. There is still a gap for studying various issues related to 
strengthening the intellectual property rights and its impact on Indian 
pharmaceutical industry which has been neglected by the authors of 
Indian and foreign based studies. It is seen that most of the studies are 
concerned with innovation and creativity, price of medicines, 
affordability, technology transfer, R&D success factors, SMEs survival, 
FDI inflow, and human rights under new product patent regime. Some 
of them are based on primary surveys to measure the impact of TRIPs. 
The issues, such as pharmaceutical production, R&D, export and import 
of pharmaceutical by Indian pharmaceutical industry have not been 
covered in-depth with analytical framework under any of the studies 
under reference. The present study differs from the earlier studies, 
which covers almost all the aspects of TRIPs and analyzes its impact on 
Indian pharmaceutical production, R&D, export and import with 
analytical framework. While many of the studies assumes Post TRIPs 
era after signing of TRIPs Agreement, the present study assumes Post 
TRIPs era after India actually amended its Patent Act towards TRIPs 
compliance. The study makes an earnest attempt to trace out the major 
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impact of TRIPs Agreement with regard to Indian pharmaceutical 
industry. 
An intense investigation as the study generates, will surely help 
policy makers and pharmaceutical companies for better understanding 
the TRIPs provisions and its impact on Indian pharmaceutical industry. 
The study will also help policy makers and pharmaceutical companies 
to take appropriate measures for strengthening the domestic 
pharmaceutical industry under the TRIPs regime. 
1.5. Scope of the Study: 
The study on impact of TRIPs on Indian pharmaceutical industry 
covers a span of one and half decade, i.e. from 1991-02 to 2005-06 and 
further the researcher bifurcates this period according to need of the 
study into Pre TRIPs period and Post TRIPs period. This span of period 
would be more than sufficient to find out the impact of TRIPs 
provisions on pharmaceutical industry. The present study has focused 
mainly on four aspects of pharmaceutical industry i.e. pharmaceutical 
industry production, R&D, export and import. The Researcher is of a 
strong opinion that the analysis on these four aspects of the 
pharmaceutical industry would be able to represent the impact of TRIPs 
on Indian pharmaceutical industry. Finally, the pharmaceutical 
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industry production, R&D, export and import has been considered 
according to financial year in Indian currency. 
1.6. Objectives of the study: 
The following objectives have pursued to study the Impact of 
TRIPs on Indian pharmaceutical industry: 
• To study the provisions of Trade Related Intellectual Property 
Rights (TRIPs). 
• To study the provisions of Indian Patent Act, 1970 and its 
amendments towards compliance with TRIPs provisions. 
• To study the Indian pharmaceutical industry. 
• To find out the trends in production, R&D, export and import of 
Indian pharmaceutical industry. 
• To analyze the impact of TRIPs regime on pharmaceutical 
production, R&D, export and import of Indian pharmaceutical 
industry. 
• And finally to make suggestions and recommendations for 
strengthening the Indian pharmaceutical industry under the new 
TRIPs compliance patent regime. 
1.7. Hypotheses of the Study: 
In order to fulfill and achieve stated objectives of the research, the 
study has been made on the basis of certain hypotheses according to 
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various dimensions of Indian pharmaceutical industry under the new 
TRIPs compliance era and according to the need, importance and 
objectives of the study. The following hypotheses have been 
formulated: 
Hypothesis- 1: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of TRIPs regime on production of 
Indian pharmaceuticals industry whereas the alternative Hypothesis of 
the study (Hi) assumes that there is significant impact of TRIPs regime 
on production of Indian pharmaceuticals industry." 
Hypothesis- 2: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of the TRIPs regime on export of 
Indian pharmaceuticals industry whereas the alternative Hypothesis of 
the study (H2) assumes that there is a significant impact of TRIPs regime 
on export of Indian pharmaceuticals industry." 
HypotJtesis- 3: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of the TRIPs regime on import of 
Indian pharmaceutical industry whereas the alternative Hypothesis of 
the study (H2) assumes that there is a significant impact of the TRIPs 
regime on import of Indian pharmaceutical industry. 
Hypothesis- 4: -"The Null Hypothesis of the study (Ho) assumes 
that there is no significant impact of the TRIPs regime on Research and 
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Development (R&D) expenditure of Indian pharmaceuticals industry 
whereas the alternative Hypothesis of the study (H4) assumes that there 
is a significant impact of the TRIPs regime on Research and 
Development (R&D) expenditure of Indian pharmaceuticals industry. 
1.8. Methodology of the Study: 
The study is an empirical work based mainly on secondary data. 
Primary data also have been collected from various sources for the 
fulfillment of truthfulness of analysis and interpretations and then to 
ensure the quality of research study. 
1.8.1. Collection of Data 
(a) Secondary Data 
The secondary data for the study have been collected from various 
secondary source of information, such as, published Reports of Indian 
Drug Manufactures Association of India (IDMA), Bulk Drug 
Manufactures Association of India (BDMAI), Organization of 
Pharmaceutical Producers of India (OPPI), Director General of 
Commercial Intelligence and Statistics (DGCIS) Kolkata and Ministry of 
Chemical and Fertilizers of India. Other reports such as various reports 
from Ministry of Commerce, Ministry of Finance, Department of 
Company Affairs, Planning Commission of India and Economic Survey 
of India etc are also collected for supporting the literature references. 
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The publications and review bulletins of regulatory bodies and 
institutions, such as. Drug Price Control Order (DPCO), National 
Pharmaceutical Pricing Authority (NPPA), Patent Office Government of 
India and World Trade Organization (WTO) are also taken into 
reference for holding up the analysis. Altogether the relevant Books, 
Journals and periodicals. Research Papers, Published Theses, Articles, 
News Dailies, Financial Dailies, Websites, are also consulted by the 
Researcher for better referencing. 
(b) Primary Data 
The primary sources can be: the personal interviews with the 
CEO of the pharmaceutical companies, experts of intellectual property 
rights and Director of OPPl, IDMA and few experts of Intellectual 
Property Law. 
1.8.2. Analytical Tools 
The statistical tools that have been used for the analysis and 
interpretation are: Mean, Maxima, Minima, Standard Deviation and 
Coefficient of Variation, AAGR, CAGR, Stepwise univariate and 
multivariate regression. Both classical and log-linear fegression 
functions have also been applied. For test of significance t-test has been 
done. Considering the technical nature of certain statistical tools and 
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the frequent use of those tools in the study a brief discussion of some 
relevant tools are as follows: 
Standard Deviation: 
Standard deviation is the positive square root of the mean of the 
squares of the deviations of the given values from their mean. It is 
denoted by a i. e. 
a = M^' 
Where x is the mean of the distribution and A^  = ^ / ^ . 
/ = ! 
The Standard Deviation measures the absolute dispersion. A small 
Standard Deviation means a high degree of uniformity of the 
observation as well as homogeneity of the series; a large Standard 
Deviation means just opposite. 
Coefficient of Variation 
The Standard deviation Discussed above is an absolute measure 
of dispersion. The corresponding relative measure is known as the 
Coefficient of Variation. 
Coefficient of Variation or CV = (SD/Mean) xlOO 
That series for which the CV is greater is said to be more variable or 
conversely less consistent, less stable. On the other hand, the series for 
which CV is less said to be less variable or more stable. 
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Regression Technique 
One of the techniques used in the statistical analysis is the 
regression technique. It assumes a functional relation between the 
dependent variable and independent variable(s). If there is only one 
independent variable then the technique relevant is known as simple 
regression and if there are many independent variables then it is 
known as multiple regressions. The title of the present research 
suggests that the variable like production of pharmaceutical is a 
dependent variable, whereas there can be many independent variables 
like time and patent regime. (Also the other macro economic factors 
can be the independent variables) The single variable regression takes 
the linear form of functional relations like: 
Y= a + fi X. Where, Y is the 
dependent variable, 
'X' is the independent variable, 
'/? is the slope of the straight line 
'a is the Y-intercept. 
In case of multiple regressions the functional relation takes the 
following formula: 
y = a +y3J Xj + ^X2 + AX3 ... +A, X„ 
Where, Y is the dependent variable 
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'a' is the Y-intercept. 
Xj, X2, X3.. X„ are the independent variables, pi, pi, P2. 
.... Pn are the respective slope of the independent 
variables Xi, X2, X3 X„, 
In the present study on "Impact of TRIPs on the Pharmaceutical 
Industry in India", an earnest attempt has been made to use the 
adequate statistical techniques. For the analysis of trend in production, 
R&D, export and import for the entire period of 15 years i.e. from 1991-
92 to 2005-06, multiple regressions has been used between the 
dependent variable 'production, R&D, export and import' and 
independent variables 'time', 'TRIPs regime' which is assumed as 
dummy variable and Post-Intervention Variable. 
The regression equation that: 
Y = a + PiXi + p2X2+p3X3+E 
Where Y is the dependent variable, measured annually; Xi is a 
time counter (continuous) variable indicating time in years from the 
beginning of the observation period. The value of this variable is coded 
1 for the first year in the series, 2 for the second year, 3 for the third 
year, and so forth until the last year in the series. X2 (intervention) is a 
dummy predictor variable indicating for time before policy 
intervention and after time intervention (coded 0 for all observations 
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before intervention, and coded 1 for all observations after intervention. 
X3 (post-policy intervention) indicates a continuous predictor variable 
representing the years after intervention (coded 0 during the pre-
intervention period, and 1, 2, 3, and so on until all the post-policy 
intervention observations are accounted. Last, E denotes the error of the 
model i.e., residuals unexplained by the model. 
R-Squared 
The estimates of R-squared, alternatively known as the goodness 
of fit or the coefficient of determination in regression analysis 
measures the strength of linear relationship between the dependent 
variable and independent variable(s). Statisticians also interpret the 
sample coefficient of determination by looking at the amount of the 
variation in dependent variable that is explained by the regression line. 
When the dependent variable is Y and the average is called Y bar then 
the total variation is the summation of Y minus Y bar squared. If the 
regression estimates describes Y as Y hat (Y^) then the sum of total 
variations between the estimated Y and the average Y being squared is 
explained by the regression equation. The coefficient of determination 
represents the proportion of explained variations to the total 
variations. In the present study, r and r^ are used simultaneously for 
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the measurement of coefficient of correlation and coefficient of 
determination. The coefficient of correlation equation 
Ri.23 = —"" -r^ =- similarly R2.31 and R3.21 wui be 
calculated. Multiple correlation (R) and coefficient of determination (R^) 
are also calculated 
T-Test 
T-test is the test of the hypothesis that means of two normally 
distributed data set are significantly equal. Given two data sets, each 
characterized by its mean, standard deviation and number of data 
points; the t- test can be used to determine whether the means are 
distinct, provided that the underlying distributions can be assumed to 
be normal. All such tests are usually called Student's t- tests, though 
strictly speaking that name should only be used if the variances of the 
two populations are also assumed to be equal; the form of the test used 
when this assumption is dropped is sometimes called Welch's test. 
There are different versions of the t test depending on whether the two 
samples are 
a) Independent of each other (e.g., individuals randomly assigned 
into two groups) and 
b) paired, so that each member of one sample has a unique 
relationship with a particular member of the other sample 
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In the present study the Researcher has used t-test for testing of 
significance of correlation and for finding out the difference of means 
of two set of variable. 
Through applying the t-test equation 
t = ^ * V?? - 2 
v ' i - r -
Standard Error of Estimate 
The standard error of estimate is symbolized as E or SE and is 
similar to the standard deviation in that both are measures of 
dispersion. While the standard deviation measures the variability of 
the observed values from the mean, the standard error of estimate, on 
the other hand, measures the variability of the observed values around 
the regression line. The Researcher has taken in to consideration of SE 
estimated as a supporting tool for multiple regression techniques. 
1.9. Expected Contribution of the Study: 
The study is an empirical work based on both the sources of 
information. The study would not be only for the fulfillment of the 
requirement of the academic degree but also it is a part of my social 
commitment to bring out the facts and realities of the TRIPs agreement 
of WTO and its impact on pharmaceutical industry in India. The 
present study also makes an attempt to suggest the measures and 
strategies for Indian pharmaceutical industry to develop and to 
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compete with Developed World's pharmaceutical MNCs, under the 
TRIPs regime. The study itself holds significance by contributing to the 
literature of international business from a developing country 
perspective taking Indian pharmaceutical industry as a case study. 
Lastly, it contributes to the ongoing debate of impact of strengthening 
IPR on developing countries pharmaceutical industry. 
1.10. Limitations of the Study: 
• Scarcity of Data: in case of Indian pharmaceutical industry there is 
no organized database of unorganized sector of pharmaceutical 
industry by any of the government agencies or regulatory bodies. A 
few private corporate bodies are providing data but getting those 
data is also very difficult especially for academic purpose. 
• Lack of Coordination Among the Databases: The different agencies 
which are providing the information on pharmaceutical industry 
contradictory therefore it is very difficult to find authenticity. 
• Sampling Errors: The study is mainly based on secondary sources of 
the primary surveys conducted by BDMAI, IDMA and OPPI media 
therefore errors of primary surveys bound to be occurred. 
• Short Span of the Study: The study on "Impact of TRIPs on Indian 
Pharmaceutical Industry" assumes post TRIPs era after India first 
amended its Patent Act, 1970 towards TRIPs compliance in 1999. But, 
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actually India fully implemented TRIPs provisions on January, 2005. 
Therefore, actual impact of TRIPs would be take effect after January 
1, 2005 in the long run. This is the major limitation of this study. 
• Ignore Other Variables: The study analyzes impact of TRIPs only 
and neglects other variables such as DPCO, Pharmaceutical Policies 
of Indian Government and Economic Environment of India whereas 
these variables also affect pharmaceuticals industry. 
• Frequent Changes: The world of intellectual property is very fast 
and changes are happening frequently. The researcher may not be 
able to consider all the changes and therefore there will be a gap of 
time span for further studies in future However, the researcher is of 
strong opinion, that the result of the study in no way would be 
affected. 
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2.1. Introduction 
The previous chapter deals with the framework and desigii of the 
research study consisting of the statement of problem, objectives, 
hypotheses, literature review, scope and methodology of the study. The 
present chapter is an overview of pharmaceutical industry all over the 
world with special reference to India. The chapter covers the global 
pharmaceutical industry, evolution and history of Indian 
pharmaceutical industry, Indian pharmaceutical industry current 
scenario, pharmaceutical production cycle, SWOT analysis of Indian 
pharmaceutical industry, the pharmaceutical production cycle, Mc 
Kinsey projection and brief profiles of top five leading pharmaceutical 
companies in India. The chapter begins with an introduction to the 
pharmaceutical industry from a global perspective and continues with 
the growth and the structural changes in Indian pharmaceutical 
industry and present status of Indian pharmaceutical industry. 
2.2. The global pharmaceutical industry 
The pharmaceutical industry is a division of the chemical 
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industry and the first manufacturing units were set up in the late IQ*-" 
century. Some of the primary companies to set up globally were 
Glaxo and Beckham (UK), Bayer and Hoechst (Germany), Roche 
and Ciba-Geigy (Switzerland) and Pfizer, Merck and Eli Lilly (US). 
These companies were engaged in both manufacturing and drug 
research and are today still some of the industry leaders worldwide. 
The pharmaceutical industry is classified as one of the most 
high- tech and capital-intensive industries in the world. The industry 
is based on R&D and is generally exceptionally science intensive. A lot 
of the research is carried out in collaboration with universities and is 
publicly sponsored. Research in the pharmaceutical industry is 
mainly concentrated in the developed countries, with the US 
accounting for about 44% of the global research expenditure.^ Due to 
its characteristics, the industry requires a highly skilled, educated 
workforce and well-developed infrastructure. The innovations in the 
industry involve large and risky investments, where risk of failure is 
greater than in any other research-based industry. The success rate in 
research is low; with one of thousands of tested products making it 
to the market.2 Imiovation and research of drugs and the following 
market introduction are very expensive. A well-developed patent 
regime, which provides the inventor rights to exclusively produce and 
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market the products, is important for global pharmaceutical companies 
since they invest large sums of money to develop new products. 
In the end of the 1980s, many pharmaceutical companies were 
doing well financially, and large investments were made in R&D. 
However, the global pharmaceutical industry is today facing declining 
R&D productivity, increasing generic substitution in the prescription 
area of drugs, and loss of income due to patent expiration. There has 
been a decline in profitability for many major global firms, due to 
expiry of some major patents and also from increased governmental 
interventions. Therefore, many companies have started to form 
alliances and merged with other firms in order to strengthen their 
presence. Outsourcing of production and research activity is 
increasing as firms are constantly looking for cheaper alternatives. 
Outsourcing is carried out in certain parts of the production chain and 
is expected to expand further in the future. 
The technology and capital intensity of the industry, the risk, 
high costs in research activities and dependence on a well 
functioning intellectual property regime, explains why the 
pharmaceutical industry is mainly located to the developed 
economies. 
The global pharmaceutical industry is a multinational industry 
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that is a highly regulated, capital intensive and which driven by large 
research and development expenditures. The industry is primarily 
privately owned and is technologically sophisticated. Despite a growth 
rate of 7% down sliding from 2004 and the lowest since 1998, in 2006 
the total global pharmaceutical sales reached US$643.3 
Growth in pharmaceutical sales has been strongest in North 
America since 1998 (12.6% per year) compared to 9.3% in Europe and 
2.9% in Japan.4 North America accounts for the largest proportion of the 
world market (45%) and Europe (including the UK) accounts for 23% of 
total global sales.^ In 2006, Pifzer was the top pharmaceutical company 
worldwide by sales followed by Glaxo Smith Kline then Novartis. 
The total pharmaceutical sales from the top ten companies 
accounted for more than 40% of the total market. Fourteen 
pharmaceutical companies featured in the top 50 R&D spenders 
according to European Commission Research in 2006-07, including 3 in 
the top ten: Pifzer (ranked number 1), Johnson & Johnson (3), and Glaxo 
Smith Kline (7). Other companies to feature were Sanofi-aventis (12), 
Roche (15), Novartis (16), Merck (18), Astra Zeneca (27), Amgen (32), 
Bayer (34), Eli Lilly (36), Wyeth (36) and Abbott (49).^ Pharmaceutical 
companies ranked as the highest sector of R&D investment across the 
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world's top 1400 companies, spending over 70 million euros in the 
financial year 2006-077 
Global pharmaceutical export which was US$132.5 billion in 2001 
increased to US$ 247.2 billion in 2004 and finally reached the level of US 
$310.9 billion in 2006. 
2.3. Evolution and Growth of Indian Pharmaceutical 
Industry 
The first modern pharmaceutical establishment in India started 
in 1901 but the pharmaceutical industry was almost non-existing until 
1947. Multinational firms have been a part of the Indian 
pharmaceutical industry since its initial stage. It may be convenient to 
consider the following phases to understand the growth and the 
structural changes in the industry. 
2.3.1. The Initial Stage (till the early 1970s) 
The Indian pharmaceutical industry was small in terms of 
number of firms and production capacities from 1947 to 1970. In the 
1950s the Indian pharmaceutical industry was mainly based on 
imported bulk, which was later processed into formulations in 
India. The Indian government wanted to get rid of the industry's 
dependency on the import of bulk drugs and encouraged indigenous 
production of new drugs in order to become self-sufficient. After 
independence the Indian government objective was to industrialize 
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the country and "The Indian Policy Resolution" (IPR) was declared 
in 1948. The new policy was to increase the living standard of the 
people, and the pharmaceutical industry was considered an 
important industry, which required considerable investment or a 
high degree of technical skills.^ 
The government invested a lot in the pharmaceutical industry 
and the public sector is a large part of the industry. India received 
technical assistance and financial means from international 
organizations, such as the WHO and UNICEF, to set up plants and 
strengthen the domestic industry. The public unit Hindustan 
Antibiotics Ltd. was established in 1954 and was provided with 
technical support, purchasing of equipment and machinery from the 
WHO and UNICEF. Indian Drugs and Pharmaceuticals Ltd. (IDPL), 
another public sector firm, got free access to import technology from 
overseas and developed more modern manufacturing facilities.^ 
IDPL was incorporated by financial assistance, technology and 
know-how from the Soviet Union. These public units produced critical 
drugs, such as penicillin and other anti-infective medicine. A large 
mass of technology was imported into India. 
During the two decades 1950 to 1970s, many leading 
entrepreneurs got their training in pubic sector units and 
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institutions. For instance, the founder of Dr. Reddy's, one of the largest 
pharmaceutical firms in India today, worked at the IDPL, before he 
took off to start his own firm. 
Multinationals ( M N C s ) were, in addition to the public sector, a 
part of India's pharmaceutical foundation. Foreign companies entered 
the Indian market merely as trading companies with small 
investments. The new industrial policies emphasized the importance 
of foreign capital and industrial know-how. The Indian government 
carried out liberal FDI policies and incentives to invite foreign firms 
to start manufacturing facilities in order to get an inflow of know-
how in the sector. The leading pharmaceutical companies from the 
West came to India and established manufacturing facilities. 
Subsequently, the multinationals brought in technology and 
international manufacturing practices.^o Domestic firms were 
encouraged to tie up with foreign firms, with participation in 
capital, and there were collaboration agreements in the private 
sector. During this time product patent laws' which were favourable 
for the MNCs, were in force. 
India was attractive to foreign firms mainly due to its large 
market and increasing demand for drugs. At that time there was lack 
of competition in the Indian pharmaceutical industry and the MNCs 
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did well in India. They had good knowledge and technology to 
develop antibiotics and synthetic drugs and advantage of their 
f inancial assets and management abilities. Consumer preference for 
foreign world-wide known drugs was also an advantage for the 
MNCs in India. They were aggressive in marketing and managed 
to create a market for themselves in branded products. 
The Indian pharmaceutical industry was dominated by the 
MNCs with 68 percent market share in 1970. While the MNCs 
prevented the indigenous companies from producing new drugs, 
using the then existing patent law, they themselves were more 
keen to process imported bulk drugs than develop the industry 
from basic stages. As a result, on the one hand, because of lack of 
competition, d rug prices in India were very high. On the other 
hand, in the 1970s, India was dependent on import for many of 
essential bulk drugs. The import dependence constricted 
consumption in a country deficient in foreign exchange and 
inhibited the growth of the country.i^ 
2.3.2. The Self-reliance Stage (the late 1970s and 1980s) 
Multinational Corporations dominated the Indian pharmaceutical 
industry till 1970. During the 1970s, there were new drug policies 
introduced in India, which created a major opportunity for Indian 
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domestic firms to grow. Import substitution and self- reliance were the 
objective in the pharmaceutical industry in the years to come. A number 
of policies and regulations such as the Patent Act, 1970, Drug Price 
Control Order (DPCO) 1970, Foreign Exchange Regulation Act (FERA) 
1973, and Drug Policy 1978 were carried out to expand the domestic 
pharmaceutical industry in order to become self-relying and to keep 
prices of pharmaceuticals low. The government made a distinction 
between domestic and foreign firms, where Indian firms were given 
production incentives while the foreign firms faced tighter control. 
After the change in patent law, large scale product ion of 
bulk drugs were started by the indigenous sector in the late 
1970s, particularly in 1980s.^^ in this period, the production of 
both bulk and formulation increased, and the industry more than 
doubled dur ing the 1970s. The Indian companies took advantage 
of the new policies and produced molecules that were still under 
patent elsewhere. The Indian firms developed better production 
and marketing skills; consequently the mult inat ionals ' market 
share started to decline (table 2.1). Despite the tighter controls for 
foreign firms, they still had a large share of the production in India 
during this time.'^ 
As bulk drugs began to be produced in the country on a 
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large scale from 1970 onwards, on the one hand, imports were 
replaced while, on the other hand consumpt ion increased 
significantly. Production of bulk drug increased from Rs 900 
million in 1974-75 to Rs. 6,400 million in 1989-90 and formulation 
production from Rs. 4,000 million to Rs. 34,200 million dur ing 
the same period.i^ By the late 1980s imports of formulations 
accounted for only 1-2 percent of total availability. Export also 
started increasing steadily. From a mearge Rs. 20 million in 1963-
64 and Rs. 373.3 million in 1973-74, export of drugs and 
pharmaceuticals increased to Rs. 6,647 million in 1989-90.^^ Till 
1987-88, imports were larger than exports except for a few years. 
But with the steady growth in domestic product ion and exports, 
the country has become a net exporter since 1988-89. In US$ 
term, exports increased from 47.9 million in 1973-74 to 514.6 
million in 1989-90.16 
The growth was spearheaded by Indian companies. The 
result was that the MNCs lost their market share in the late 
1970s, their share declined to 40 percent by the early 1990s. 
The favourable environment also attracts the entry of a 
number of new firms. Among the top ten companies. Sun 
Pharmaceuticals, for example was set up inl983 and Dr Reddy's 
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Laboratories in 1984. A large number of specialized bulk d rug 
manufactures, set up since the 1970s particularly in the 1980s 
contributed immensely to the transformation of pharmaceutical 
industry. 
2.3.3. The Liberalization Stage (1985 onwards) 
During the decade of 80s, Indian policy makers realized that the 
competitiveness of the pharmaceutical firms suffered from growing 
technological obsolescence due to the highly protected market. The 
government therefore highlighted the importance of modernization 
of the industry. Another limiting factor for the domestic industry was 
the marketing channels, which were mainly dominated by the MNCs.i^ 
In the mid 1980s, the Indian government attempted to improve efficiency 
in the industry. A new drug policy was implemented in 1986, which was 
more favourable towards foreign firms. Trade barriers were reduced. 
India started to liberalize its economy in 1991. A series of 
economical reforms were declared and implemented. The liberalization 
of the Indian economy affected the pharmaceutical industry in several 
ways. The public units that had a production monopoly in certain 
drugs were opened up for competition and privatized.'*^ Also, the 
requirement for a certain ratio in bulk drug production was removed 
and equity share and approvals of FDI in the industry were relaxed. To 
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improve the attractiveness of the industry the government changed the 
Drug Price Control Order (DPCO) and reduced the number of drugs 
under price control from 347 in 1970 to 74 in 1995.^ 9 
Table 2.1 
Market Share of MNCs and Indian Companies in 
Pharmaceutical Industry in India 
Year 
1952 
1970 
1978 
1980 
1991 
1998 
2004 
MNCs (%) 
38 
68 
60 
50 
40 
32 
23 
Indian Companies 
(%) 
62 
32 
40 
50 
60 
68 
n 
Sources: Chaudhuri Sudip (2005), The WTO and India's Pharmaceuticals 
Industry: Patent Protection TRIPS and Developing Countries, Oxford 
University Press, New Delhi. 
The most rapid growth of the pharmaceutical industry has taken 
place from the 1990s onwards. Both production and export have grown 
remarkably fast. Both bulk drugs and formulations production started 
increasiiig sharply and steadily. From Rs. 6,400 million in 1989-90, bulk 
drugs increased to Rs. 90,340 million in 2004-05 and from Rs. 34,200 
million in 1989-90, formulation production increased to Rs. 319,460 
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million in 2004-05.20 
The Indian companies further consolidated their domination in 
the domestic market. Their share increased from 60 % in 1991 to 68 % in 
1998 and 17 % in 2004 (table 2.1). The growth has very fast in the export 
market. Export increased at an annual compound rate of growth of 5.2 
percent during 1989-90 to 1995-96. Export have increased from Rs. 31,777 
million in 1995-96 to Rs. 166,810 million in 2004-05, that is, at annual rate 
of growth of 20.8 percent.21 Growth in export has been associated with 
significant structural changes. After tackling the western MNCs at home, 
the larger Indian companies are themselves becoming MNCs. Ranbaxy, 
for example, has manufacturing facilities in six countries abroad. Among 
the other Indian companies involved in production abroad are, Dr 
Reddy's in the UK and China, Sun Pharmaceuticals in the USA and 
Bengladesh, Orchid in China, Aurobindo in China, and Wockhardt in the 
UK. Like the MNCs, some Indian companies have also started R&D for 
developing new drugs since the mid-1990s. Therefore, expenditure in 
R&D increased from Rs. 1,400 million in 1994-95 to Rs. 16,860 million in 
2004-2005.22 
Because of the rapid growth and sti-uctural transformation in the 
last decades or so, India now occupies an important position in the 
international pharmaceutical industry. 
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2.4. Current Status of Indian Pharmaceutical Industry 
The Indian pharmaceutical industry is one of the developing 
world's largest and most developed industries. It is one of the fastest 
growing segments of the Indian economy. Globally it holds 4* position 
in terms of volume after USA, Japan, and China and 13* in terms of 
value of pharma production. The Indian Pharmaceutical industry has a 
turnover about Rs. 550,000 million (approx US$12 billion) in 2005-06.23 
India occupies a significant position in the world Pharma market, 8% by 
volume and 1.5% by value.24 The total domestic market as estimated by 
ORG-IMS is about Rs 340,000 million. 
Indian pharmaceutical companies supply nearly all the country's 
demand for formulations and nearly 70 percent of its demand for bulk 
drugs. Indian firms produce nearly 60,000 generic brands in 60 
therapeutic categories and between 350 and 400 bulk drugs. 
Approximately 80 percent of domestic production consists of 
formulations, and more than 85 percent of those formulations are sold 
in the domestic market, whereas at least 60 percent of bulk drug 
production is exported. Nearly 97 percent of India's drug market 
consists of second-and-third generation drugs no longer subject to 
patent protection in the developed world. Nine of the top 10 Indian 
drug makers are Indian-owned firms accounting for more than 44 
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percent of total industry's sales. India's leading pharmaceutical 
companies in 2005-06, in terms of sales, are Ranbaxy Laboratories, Dr 
Reddy's Laboratories, Cipla, Sun Pharma Industries, Lupin Labs, 
Aurobindo Pharma, GlaxoSmithKline, Cadila Healthcare, Nicholas 
Piramal and Wockhardt. 
These companies manufacture a wide range of generic drugs 
(branded and non-branded), intermediates, and active pharmaceutical 
ingredients. The top ten brands based on retail sales are Corex 
(Chlorpheniramine Maleate); Voveran (Diclofenac Sodium); Becosules, 
(Vitamin B Complex, Vitamin C); Taxim (Cefotaxime); Human Mixtard 
(Insulin); Althrocin (Erythromycin); Sporidex (Cephalexin); Asthalin 
(Salbutamol); Betnesol (Betamethasone); Cifran (Ciprofloxacin). 
Table 2.2 
Principal Products of India's Leading Drug Manufacturers 
Company 
Ranbaxy 
Lab. 
Dr. 
Principal products: bulk and generic drugs 
Anti-infectives, cardiovascular. 
gastrointestinal, central nervous (diazepam. 
midazolan), ophthalmic & ointments. 
urologicals, nutritionals, sex hormones. 
analgesics, anti-asthma, cough & cold, 
vaccines. 
Cardiovascular, gastrointestinal, anti-
Percent 
of sales 
Bulk: 
22%, 
Generic: 
78% 
Bulk: 
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Reddy's 
Lab. 
Cipla 
Sun 
Pharma 
Lupin Lab. 
Aurobindo 
Pharma. 
Glaxo 
Smith KUne 
Cadila 
Nicholas 
Piramal 
infectives, pain management 
Antibiotics, anti-asthmatics, anti-AIDs and TB 
drugs, anabolic steroids, Analgesics-
antipyretics, antacids, anti-arthritis, anti-
inflammatory, anticancer, antidepressant 
agents, anti-diabetic, anit-epileptic, anti-fungal, 
anti-malarial. 
Neuro-psychiatry, cardiovascular, 
gastrointestinal, diabetic, gynecological, anti-
allergic, antidepressants, cholesterol reducers, 
anti-asthma, Parkinson, ADD, pain. 
Tuberculosis medication, antibiotics, 
cardiovascular. 
Antibiotics, anti-retrovirals, cardiovascular, 
central nervous system, gastroenterological, 
anti-allergy. 
Anti-infective, anti-inflammatory, analgesic, 
gastro-enterological, antiallergic, 
dermatological. 
Cardiovascular, gastrointestinal, anti 
inflammatory/ analgesic, antibiotics/ anti-
infectives, vaccines/immunomodulators, anti-
diabetics; vitamins. 
Analgesics-anti-inflammatory, antibiotics, 
antifungal, antihistamines, antiseptics, 
cardiovascular, central nervous system. 
40% 
Generic: 
60% 
Bulk 7%, 
Generic: 
93% 
Bulk: 
18% 
Generic: 
82% 
Generic: 
100% 
Generic: 
100% 
Generic: 
100% 
Generic: 
100% 
Generic: 
100% 
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Wockhardt 
diabetic, dermatologic, endocrinologic, gastro 
enterological, vitamins, pulmonary-respiratory, 
trauma emergency, gastrointestinal, NSAIDs. 
Anti-infectives, pain management, 
nutraceuticals 
Bulk: 
19%, 
Generic: 
81% 
Sources: Union Budget 2006-07. 
The Indian Pharmaceutical Industry which has established a 
strong presence in the global market is contributing around 22% in 
terms of value towards the global generic drugs market. The cost of 
drugs produced in India is amongst the lowest in the world. The largest 
number of US FDA approved manufacturing facilities outside USA are 
located in India. It also has the largest number of Drug Master Files 
(DMFs) filed which gives it access to the high growth generic bulk. 
According to Organisation of Pharmaceutical Producers of India 
(OPPI), the Indian pharmaceutical industry is highly fragmented with 
over 23,000 units. The "organized" sector of India's pharmaceutical 
industry consists of 250 to 300 companies, which account for 70 percent 
of products on the market, with the top 10 firms representing 30 
percent. There are approximately 34 foreign drug companies engaged in 
the Indian pharmaceutical market and among them are 15 of the 
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world's 20 largest pharmaceutical companies. The Indian 
pharmaceutical industry gives 5 million direct 24 million indirect 
employments. Pharmaceutical production costs are almost 50 percent 
lower in India than in Western nations, while overall R&D costs are 
about one-eighth and clinical trial expenses around one-tenth of 
Western levels. India is becoming a hub for outsourcing of Pharma 
products mainly because of the cost & quality advantage. Research 
Contracts & Clinical trials are coming at a fast pace to the country.^s 
India's long-established manufacturing base also offers a large, well 
educated, English speaking workforce with 700,000 scientists and 
engineers graduating every year, including 122,000 chemists and 
chemical engineers, with 1,500 PhDs. The industry provides the highest 
intellectual capital per dollar worldwide. It provides excellent cost 
advantage to the Indian drug manufacturers, leaving them with a 
definite competitive edge. Many Indian companies maintain highest 
standards in Purity, Stability and International SHE requirements 
namely Safety, Health and Environmental protection in production and 
supply APIs to MNCs as well as leading generic companies of the 
world like Teva, Apotex, Ivax, Watson. Keeping in view the highest 
standards set up by Indian companies like Shasun drugs, the original 
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innovator MNCs like Boots, GSK, Eli Lilly source APIs like Ibuprofen, 
Ranitidine, Nizatidine and Naproxens from Indian companies. 
Exports touched a level of over Rs. 215,789.6 million during 2005-
06 and constituted 4.74% of the country's overall exports.26 Exports 
constitute a very substantial part of the total production of 
pharmaceuticals in India. India export drugs to more than 200 countries 
including highly regulated markets. The industry ranks 17th in terms of 
export value of bulk actives and dosage forms. USA is the largest 
importer of Indian Pharmaceuticals amounting to Rs. 30 billion ($ 700 
Million). Other major export destinations are Germany, Russia, Canada, 
UK, China, Brazil, Mexico., Spain, Ireland, Netherlands and Japan those 
are highly regulated markets. The import of drugs and pharmaceutical 
was Rs 45,152.2 million in 2005-2006 with a trade balance of Rs. 
170,637.4 million. Some of the official estimates published by the 
government shows that the exports of pharma constitute nearly 40 per 
cent of the production, with formulations contributing 55 per cent and 
bulk drugs 45 per cent. 
The research and development expenditure of Indian 
pharmaceutical industry was more than Rs. 21,924 million about 3.9% of 
total turnover of the industry in 2005-06.27 7^^ y^st majority of India's 
pharmaceutical R«&D spending was concentrated on reverse 
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engineering and the adaptation of patented foreign drugs to the Indian 
market. Most of the industry's funding went to research rather than to 
new drug discovery and development. The n\ajor pharmaceutical R&D 
spenders companies in India are Ranbaxy Laboratories Ltd, Dr Reddy's 
Labs, Sun Pharmaceuticals, Cipla and Lupin Labs they are spending 
nearly 5 % to 17 % of their turnover. 
In addition to R&D in industry, substantial pharmaceuticals 
related R&D is carried out in publicly funded research organizations, 
mainly by the laboratories of Council of Scientific & Industrial Research 
(CSIR), Indian Council of Medical Research (ICMR), around 25 
universities and a few pharmacy colleges. Some of the new R&D units 
in industry and a few of the publicly funded laboratories are equipped 
with sophisticated laboratory equipment, instruments and pilot plant 
facilities. The R&D manpower is generally highly qualified and 
proficient in conventional techniques of pharmaceutical R&D. 
According to Department of Industrial Policy & Promotion, the 
Pharma industry has witnessed substantial inflow of Foreign Direct 
Investment (FDI) amounting to Rs. 7,600 million in 2005-06.28 The total 
inflow of Foreign Direct Investment (FDI) in pharma sector was 
amounting to US $ 1.00 billion (Rs. 43.13 billion) between August 1991 
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and April 2006. The Pharmaceutical sector is among tti&4ep-teri sectors 
• ^  
receiving FDI inflow during this period. f-n f^^-^y OCT^  
J[>{AC«. N« )^ 
2.5. SWOT analysis of Indian p h a r m ^ V t i c a l industw^/ 
The SWOT (Strength, Weakness, Opportufit ty^'^^'S^hreat) 
analysis of the industry reveals the position of the Indian pharma 
industry in respect to its internal and external environment. 
2.5.1. Strengths 
• The health statistics of India make it clear that India produces a 
sufficient number of medical and pharmacy graduates, which 
contributes to the strengthening of the Indian pharmaceutical 
industry. 
• The patent act and Drug Price Control Order (DPCO) of the 1970s 
forced MNCs to shrink their operation in India, thus providing 
space for indigenous pharmaceutical companies to expand in the 
local market. As a result, in the past two to three decades 
domestic pharmaceutical companies have established operations 
and self-sufficient in all aspects. 
• Indian manufacturers are one of the lowest cost producers of 
drugs in the world. With a scalable labor force, Indian 
manufactures can produce drugs at 40% to 50% of the cost to the 
rest of the world. In some cases, this cost is as low as 90%. 
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• Indian pharmaceutical industry posses excellent chemistry and 
process reengineering skills. This adds to the competitive 
advantage of the Indian companies. The strength in chemistry 
skill helps Indian companies to develop processes, which are cost 
effective. 
• The presence of other parallel drug/medical system also would 
be a major strength for the Indian pharmaceutical industry. It 
would provide a vast resource for the development of new drug 
molecule in the drug discovery programs. 
• Indian with a population of over a billion is a largely untapped 
market. In fact the penetration of modern medicine is less than 
30% in India. To put things in perspective, per capita 
expenditure on health care in India is US$ 93 while the same for 
countries like Brazil is US$ 453 and Malaysia US$189. 
• The growth of middle class in the country has resulted in fast 
changing lifestyles in urban and to some extent rural centers. This 
opens a huge market for lifestyle drugs, which has a very low 
contribution in the Indian markets. 
2.5.2. Weaknesses 
• Although the Indian pharmaceutical industry is large by Indian 
standards, in the world market its share is merely 1-2 %. Even if 
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25 % of gross sales are invested in R&D, the Indian 
pharmaceutical industry's total R&D budget is comparatively 
very small. Individual R&D budgets of many US companies 
probably amount to much more than the cumulative R&D budget 
of all the companies in India. Thus, unavailability of funds is a 
major weakness of the Indian pharmaceutical industry. 
• Majority of the Indian companies are dependent on 
replicating drugs developed by MNCs, hence Indian companies 
are viewed in not so good light. 
• Due to very low barriers to entry, Indian pharma industry is 
highly fragmented with about 300 large manufacturing units and 
about 18,000 small units spread across the country. This makes 
Indian pharma market increasingly competitive. The industry 
witnesses price competition, which reduces the growth of the 
industry in value term. To put things in perspective, in the year 
2003, the industry actually grew by 10.4% but due to price 
competition, the growth in value terms was 8.2% (prices actually 
declined by 2.2%) 
• Animal experiments are an essential part of pharmaceutical R&D. 
Every drug molecule must be screened using animal first to 
determine its efficacy and side or toxic effects. If Indian rights 
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activists block the use of animals in R&D experimentation, the 
Indian pharmaceutical industry will be force to turn to other 
countries for animal studies. A great need exist to provide 
appropriate information to animal activists in India so that a 
balance can be struck between animal rights and human rights. 
• A drug regulatory system is an essential part of the 
pharmaceutical sector. Drug discovery and development is risky, 
complex, and not fully understood. The Indian regulatory system 
is not set-up to accommodate the drug discovery/development 
processes and therefore does not have the proper infrastructure, 
enough manpower, or financial support to effectively move drug 
development operations forward. As a result, one might expect 
delays in the approval process. 
• The Indian pharma companies are marred by the price 
regulation. Over a period of time, this regulation has reduced the 
pricing ability of companies. The NPPA (National Pharma Pricing 
Authority), which is the authority to decide the various pricing 
parameters, sets prices of different drugs, which leads to lower 
profitability for the companies. The companies, which are lowest 
cost producers, are at advantage while those who cannot produce 
have either to stop production or bear losses. 
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• The American pharmaceutical industry has entered the era of 
pharmacogenomics and is venturing into the development of 
drug therapy tailored to individuals. Likewise, Indian 
pharmaceutical industry is investing significant funds in 
biotechnology and genomics. These fields are capital consuming 
and have no guarantee of success. 
• Gaining FDA approval of a drug can be a lengthy process. The 
organization has just enough manpower to oversee approval of 
products from US based companies. The Indian pharmaceutical 
industry's efforts to seek approval to market drugs in the United 
States could be time consuming because of FDA constraints, and 
the approval process could be major bottleneck for India's drug 
development industry. 
• Indian pharma market is one of the least penetrated in the world. 
However, growth has been slow to come by. As a result, Indian 
majors are relying on exports for growth. India accounts for 
almost 16% of the world population while the total size of 
industry is just 1% of the global pharma industry. 
• Outdated and restrictive labour laws are hampering all the 
industries in India and making it unviable for the MNCs to set 
up production base in India. 
81 
Indian Pharmaceutical Industry: An Overview 
2.5.3. Opportunities 
• A patent is granted to an invention that is novel, non- obvious, 
and useful. The Indian pharmaceutical industry has a clear 
opportunity to be a part of the international patent community in 
the acquisition of patents. This process will stimulate economic 
development, provide job opportunities, and to help India build a 
global reputation as a nation with a strong scientific community. 
It will also make modern medicines available to the entire Indian 
population. More important, indigenous R&D activities will help 
domestic companies discover drugs to treat tropical diseases. 
• In the pharmaceutical arena, patents can be granted for new 
molecules, new medical indications for an existing molecule, new 
ways to administer an existing molecule, or modification of an 
existing formulation with added value. Because India will not be 
able to produce the huge amount a capital needed to discover 
new drug molecule, it may be prudent to consider issuing patents 
for "Swiss-type" claims for new therapeutic uses of known 
molecules. Low manufacturing costs and skills are the Indian 
pharmaceutical industry's forte, and India would do well to make 
use of this important opportunity. 
• Large number of drugs going off-patent in Europe and in the US 
during 2005 to 2009 offers a big opportunity for Indian companies 
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to capture this market. Since generic drugs are commodities by 
nature, Indian producers have the competitive advantage, as they 
are the lowest cost producers of drugs in the world. 
• As it develops its infrastructure, the Indian pharmaceutical 
industry can look into economies of scale. Merging with a 
complementary domestic or an international company may 
provide sufficient funding and resource to manufacture 
formulation and bulk drugs on a large scale, which would 
decrease the cost of manufacture. This would help formulation 
and bulk drugs costs competitive in the world market, which 
then would boost the amount of exports. 
• Focused R&D and the development of centers for clinical trials in 
India would allow the Indian pharmaceutical industry to 
discover new drugs for diseases observed in tropical conditions. 
Such drugs could be marketed both in India and in neighboring 
countries with a similar tropical climate. 
• Being the lowest cost producer combined with FDA approved 
plants; Indian companies can become a global outsourcing hub 
for pharmaceutical products. 
• Opening up of health insurance sector and the expected growth 
in per capita income are key growth drivers from a long-term 
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perspective. This leads to the expansion of healthcare industry of 
which pharma industry is an integral part. 
2.5.4. Threats 
• Transition from "Process" patent to "Product" patent is the 
major threat Indian pharma industry is facing. Indian companies 
especially medium and small sized do not have capabilities to 
develop new molecules, and they may succumb to the giants. 
• The Indian pharmaceutical market may face the threat of the 
dumping of bulk drugs and formulations by neighboring 
countries. 
• Threats from other low cost countries like China and Israel exist. 
However, on the quality front, India is better placed relative to 
China. So, differentiation in the contract manufacturing side may 
wane. 
• There are certain concerns over the patent regime regarding its 
current structure. It might be possible that the new government 
may change certain provisions of the patent act formulated by the 
preceding government. 
• The extent of the problem of counterfeit drugs is unknown. 
Counterfeiting is difficult to detect and quantify. So, it is hard to 
know or even estimate the true extent of the problem. What is 
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known is that they occur worldwide and are more prevalent in 
developing countries. It is estimated that upwards of 10% of 
drugs worldwide are counterfeit, and in some countries more 
than 50% of the drug supply is made up of counterfeit drugs. 
2.6. The Pharmaceutical Production Cycle 
Pharmaceutical production consists of a number of discrete 
activities. Different phases of the pharmaceutical production cycle 
require different types of resources and levels of funding. In fact, many 
of the conclusions drawn in this study are relevant only within certain 
phases of the production cycle. The product cycle has four main 
components: 1) discovery, 2) clinical trials, 3) production and 
manufacturing, and 4) marketing and distribution.^^ Large MNCs 
typically have activities that span all of these areas. However, smaller 
companies in India and elsewhere often specialize in one or more 
functions. 
2.6.1. Discovery 
In principle, discovering new drugs is a straightforward process. 
First, chemists supply research scientists with compounds for testing, a 
process referred to as lead generation. Generally, such compounds are 
closely related molecules within a given disease area. In the West, 
because the success of a discovery operation is at least partially 
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contingent upon the number of leads, drug companies have recently 
turned to combinatorial chemistry in order to accelerate the lead 
generation process. (Combinatorial chemistry, with its high costs and 
unproven effectiveness, has not yet gained widespread acceptance in 
India.) Second, scientists screen molecules in a lab environment by 
conducting in vitro (petri dish) tests. Next, compounds with attractive 
medical qualities are advanced to an "animal house" for in vivo tests. 
In vivo tests are used to determine the minimum dosage necessary to 
produce the intended results (efficacy) and the maximum nonlethal 
dose (toxicity) of the drug in question in animal subjects. Companies 
usually file for patent protection of promising compounds midway 
through in vivo testing. Additionally, research scientists note any side 
effects that may be associated with the drug's administration. Following 
the completion of in vivo tests, companies may apply to conduct clinical 
trials on their compounds in their desired markets. Permission to 
conduct clinical trials depends on the results of both the in vitro and in 
vivo tests, and their conformity to generally accepted standards, as they 
are determined in individual countries. 
Practically drug discovery is not a simple process. First, 
government drug authorities around the world mandate that tests be 
conducted in controlled conditions that often entail the construction of 
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Specialized facilities and the procurement of highly trained personnel. 
Second, lab tests on new drugs typically take five years to administer. 
Third, only a very small percentage of lead compounds advance 
through the entire testing process; successes are generally accompanied 
by large numbers of failures. Finally, the profitability of a new drug is 
contingent upon the size of its distribution network. That is, companies 
without global distribution contacts are less likely to benefit from 
discovery than well positioned MNCs. For these reasons and others, 
new drug discovery is a difficult line of business for pharmaceutical 
companies to enter. Discovery requires sizable capital investments, the 
assumption of large amounts of risk, and the establishment of global 
marketing strategies. 
It is not surprising that large pharmaceutical companies with 
global reach have traditionally carried out most drug discovery. 
However, opportunities still exist for smaller firms in the discovery 
realm. In the Silicon Valley, for example, a range of small biotech 
companies has evolved in accordance with the venture capital funding 
model. When viewed in isolation, the financial prospects for small, 
discovery oriented companies are bleak because they lack the resources 
to pursue enough projects to reduce their risk to acceptable levels. 
Venture capitalists, however, are not concerned about the success of 
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individual companies. Rather, they focus on the economic viability of 
their overall portfolios. By investing in a large number of companies, 
their risk approximates that of major pharmaceutical companies, 
which—by simultaneously engaging in a number of projects— 
internalize their own risk. India's pharmaceutical industry does not yet 
employ much venture capital funding. But some Indian companies 
have entered drug discovery without being very large. They have done 
so by contracting other phases of the product cycle, such as clinical 
trials and marketing, to established foreign and domestic companies. 
2.6.2. Clinical Trial 
While testing on animals provides valuable and necessary 
insights into a drug's medical characteristics, regulatory authorities in 
virtually all markets require comprehensive clinical trials on human 
subjects before granting production and marketing approval. The 
standards for clinical trials are considerably more stringent than those 
for animal testing. Professionals who administer trials are required to 
pass reviews that are administered by independent Institutional Review 
Boards. Trials must employ double-blind test procedures. Production 
facilities should be in accord with Good Manufacturing Practice (GMP). 
This list is not exhaustive; clinical trials are exacting and, consequently, 
expensive to administer. Furthermore, since different countries have 
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different standards, it is necessary to conduct clinical trials in multiple 
locations to achieve global distribution. 
Several analysts have suggested that India is well suited for 
clinical trials because it has a strong university system capable of 
producing low-cost human capital, and a large population of poor and 
relatively disease-ridden potential test subjects. Some local companies 
namely Cadilla and Ranbaxy have begun to fill this role. However, the 
issues alluded to above still prevent global clinical trials from being a 
viable option for most Indian pharmaceutical companies. Therefore, 
while MNCs may begin to use India for clinical trials in the near future, 
local companies will likely enlist other firms to assist them in this 
capacity as they discover new drugs. 
2.6.3. Production and Manufacturing 
Pharmaceutical production consists of bulk drug manufacturing 
(in which active compounds are synthesized on an industrial scale), and 
formulation manufacturing (in which active and inactive ingredients 
are packaged into tablets, capsules, liquids, and injectibles). Bulk drug 
manufacturing is more technology-intensive than formulation 
manufacturing because, while the former draws from reverse-
engineering skills and requires knowledge of chemical processes, the 
latter merely approximates the job of the local pharmacist on a larger 
8Q 
Indian Pharmaceutical Industry: An Overview 
scale. Indian companies have proven themselves capable in both areas, 
as barriers to entry are modest and domestic manufacturing guidelines 
are liberal. However, to export products to developed markets, 
companies must bring their factories into conformance with GMP 
standards. U.S. Food and Drug Administration (FDA) and UK 
Department of Health and Social Services (DHSS) sanctioned factories 
are consequently premium assets in India. According to D.M. Gavaskar, 
managing director of Knoll Pharmaceuticals, GMP-compliant facilities 
are 25-30 percent more valuable than noncompliant facilities. This cost 
premium renders it difficult for smaller companies to compete in 
manufacturing. 
2.6.4. Marketing and Distribution 
Since fixed costs such as those for R&D and clinical trials 
represent a considerable portion of the total costs for developing drugs, 
pharmaceutical profit margins are largely contingent upon the number 
of customers reached. Therefore, companies strive to build their 
reputations with doctors who prescribe pharmaceuticals and the 
patients who use them. The largest pharmaceutical companies in India 
use field sales forces, ranging in size from 500 to over 2,000, to bring 
their products to the domestic market. Indian companies have a 
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decisive edge over MNCs in terms of distribution because they better 
understand the nuances of the Indian market for drugs. 
Until recently, the Indian market alone provided sufficient 
profitability for Indian pharmaceutical companies. But as this market 
becomes more congested and the costs for producing new products 
grow, it is increasingly necessary for companies to look for customers 
beyond India and the developing world. Unfortunately, most Indian 
companies do not produce enough products to justify investments in 
global marketing and distribution. Established MNCs, on the other 
hand, enjoy rapport throughout the world's pharmaceutical markets. 
When Merck develops a new product, for example, it can insert it into a 
large distribution system. In order for India's pharmaceutical 
companies to match the distiibution capabilities of the major 
international players, they will likely have to join their own local forces, 
or enlist the support of MNCs to supplement their efforts. 
2.7. Mc Kinsey Projection on Indian Pharmaceutical 
Market 
The report released by Mc Kinsey Global Institute, 'India Pharma 
2015: Unlocking the Potential of the Indian Pharmaceuticals Market', is 
the culmination of a year long research project by the Pharmaceuticals 
and Medical Products (PMP) practice of the consulting company. The 
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project was undertaken to assess the potential of the Indian 
pharmaceuticals market, identify opportunities and understand the 
implications for industry and policy makers. Some main projections 
made by the report about Indian pharmaceutical market are as follows: 
• India is projected to be the 10'^ largest pharmaceutical market by 
2015. From a market size of US$6.3 billion^o in 2005, the Indian 
pharmaceutical market will grow to about US$20 billion by 2015. 
This implies a compound annual growth rate of 12.3 percent. This 
growth will be materially higher than the annual growth rate of 9 
percent witnessed during 2000 to 2005. In terms of scale, the 
Indian pharmaceutical market is ranked 14* in world in 2005. By 
2015, it will rank among the top ten in the world, overtaking 
Brazil, Mexico, South Korea and Turkey. 
• By obsolete growth, India will be among the top 5 markets 
globally during 2005 to 2015. The US and China are expected to 
add US$200 billion and US$23 billion respectively. India, Canada 
and the UK are expected to be the next in line, with the growth 
expectation in the range of US$13-14 billion during this time 
frame. 
• Rising in disposable income, improvement in medical 
infrastructure, greater health insurance penetration, gradual shift 
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in disease profile and the population growth will drive 75 % of 
demand growth. 
• Generic products will continue to dominate the Indian 
pharmaceutical market. Over the next few years, the patent law 
will provide in impetus to the launch of patent-protected 
products. Such products have the potential to capture up to a 10 
percent share of total market by 2015, implying a market size of 
US$2 billion. Therefore the 10 percent of the Indian 
pharmaceutical market is likely to be patent protected by 2015. 
• Upcoming small city and rural areas will contribute almost as 
much to the pharma growth as metros and top-tier towns. Rural 
areas are expected to account for a third of the country's 
consumption growth in the next two decades. 
• Indians are expected to spend far more on healthcare than they 
are now. Healthcare's share of the wallet will rise as fast as that of 
education and three times as much as the share of food, 
beverages and tobacco. 
• By 2015, millions more will suffer from chronic, costly-to treat 
diseases such as diabetes, asthma and cancer than in 2005. 
2.8. Brief Profiles of Top Five Indian Pharmaceutical 
Companies: 
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2.8.1. Ranbaxy Laboratories 
Ranbaxy Laboratories Limited, India's largest pharmaceutical 
company, is an integrated, research based, international 
pharmaceutical company, producing a wide range of quality, 
affordable generic medicines, trusted by healthcare professionals and 
patients across geographies. The Company is ranked amongst the top 
ten global generic companies and has a presence in 23 of the top 25 
pharma markets of the world. The Company with a global footprint 
in 49 countries, world-class manufacturing facilities in 11 and a diverse 
product portfolio, is rapidly moving towards global leadership, riding 
on its success in the world's emerging and developed markets. 
Ranbaxy was incorporated in 1961 and went public in 1973. Bhai 
Mohan Singh was the founder of the company. He bought the 
company from his cousins Ranjit Singh and Gurbax Singh. Ranbaxy's 
name is a fusion of Ranjit and Gurbax's names. For the year 2006, 
the Company's Sales was at Rs. 40,587.1 million. The Company has a 
balanced mix of revenues from developed and emerging markets 
and is well positioned to leverage the growth potential offered by 
these markets. For the year 2006, North America was the Company's 
largest market. The Company's business in Asia was led by a strong 
performance in India with market leadership backed by its strorg btard-
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building skills. 
Ranbaxy is focused on increasing the momentum in the 
generics business in its key markets through organic and inorganic 
growth routes. It continues to evaluate acquisition opportunities 
in India, emerging and developed markets to accentuate its 
business and competitiveness. The Company's growth is weU 
spread across geographies with near equal focus on developed and 
emerging markets. Ranbaxy has entered into new specialty therapeutic 
segments like Bio-similars, Oncology, Peptides and Limuses. These 
new growth areas will add significant depth to its existing product 
pipeline. 
Ranbaxy views its R&D capabilities as a vital component of its 
business strategy that will provide the company with a sustainable, 
long-term competitive advantage. The Company today has a pool of 
over 1,200 scientists engaged in path-breaking research. 
Ranbaxy is among the few Indian pharmaceutical companies 
in India to have initiated its research program in the late 70's. To 
support its global ambition, a first of its kind world class R&D centre 
was commissioned in 1994. Today, the Company's multi-disciplinary 
R&D centre at Gurgaon, in India, houses dedicated facilities for generics 
research and innovative research. For the year ended 31 
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December 2006, the R&D e x p e n d i t u r e w a s Rs. 3,843.35 
mi l l ion . The Company's robust R&D environment for both drug 
discovery & development reflects the Company's commitment to be a 
leader in the generics space and offer value added formulations 
based on its Novel Drug Delivery System (NDDS) and New 
Chemical Entity (NCE) research outcomes. Ranbaxy has enhanced its 
focus on NCE research with the proposed De-merger of its New 
Drug Discovery Research (NDDR) unit into a separate entity, Ranbaxy 
Life Science Research Ltd, subject to requisite approvals. This 
significant step will open up new growth opportunities and provides a 
platform for increased collaboration. The new drug research areas at 
Ranbaxy include anti-infectives, inflammatory / respiratory, metabolic 
diseases, oncology, urology and anti-malaria. Presently, the Company 
has 8-10 programs comprising one anti-malaria molecule in Fhase-ll clinical 
triak The Company has two programs in Phase 1 and the remaining 
in the pre-clinical stage. This includes a collaborative research program 
with GSK. The Company's first significant international success using the 
NDDS technology platform came in September 1999, when Ranbaxy 
out-licensed its first once-a-day formulation to a multinational 
company. 
The Company is driven by its vision to achieve significant business in 
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proprietary prescription products by 2012 with a strong presence in 
developed markets. It aspires to be amongst the Top 5 global generic 
players and aims at achieving global sales of US $5 Bn by 2012. 
Driven by the passion of its over 12,000 strong multicultural 
workforce comprising 50 nationalities, Ranbaxy continues to 
aggressively pursue its mission to become a Research-based 
International Pharmaceutical Company and attain a true global 
leadership position. 
2.8.2. Cipla Ltd. 
India's second-largest drug manufacturer was originally 
established in 1935 as The Chemical, Industrial and Pharmaceutical 
Laboratories (Cipla). Cipla manufactures an extensive range of 
pharmaceutical & personal care products and has presence in over 170 
countries across the world. Cipla's product range includes 
Pharmaceuticals, Animal Health Care Products, Bulk Drugs, Flavours & 
Fragrances, and Agrochemicals. Cipla also provides a host of consulting 
services such as preparation of product and material specifications, 
evaluation of existing production facilities to meet GMP, definition of 
appropriate plant size and technologies etc. 
The origins of Cipla can be traced back to 1935, when Dr Khwaja 
Abdul Hamied set up "The Chemical, Industrial and Pharmaceutical 
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Laboratories Ltd", popularly known by the acronym Cipla, in a rented 
bungalow, at Bombay Central. Cipla was registered as a public limited 
company on August 17,1935. For the year 2006, the Company's Sales 
were at Rs. 32,080 million. 
Cipla opted for an aggressive product development (reverse 
engineering) strategy that catapulted it to the top league. 
According to Dr Hamied, the Chairman and Managing Director of 
Cipla, much of Cipla's progress is attributed to the company's 
strategy and focus on "from inception-to-R&D-to-commercialization 
and its thrust in making available the very latest in modem drugs and 
advanced delivery systems in a wide range of areas". The focus of the 
Company's R&D efforts was on Development of new drug formulations 
for existing and newer active drug substances and Patenting of newer 
processes/newer products/newer drug delivery systems/ newer 
medical devices/newer usage of drugs for both local and international 
markets. The company's R&D expenditure for the year was Rs. 1757.3 
million. 
In many therapeutic categories, such as anti-asthmatics, Cipla 
offers the widest range of possible products. Focusing on process 
research, Cipla has made substantial progress in NDDS and chiral 
synthesis. Cupola has already developed its first chirally resolved 
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molecule, salbutamol, which is an anti-asthma drug. Two of Cipla's 
anti-asthmatic devices, namely Rotahaler and Zerostat spacer, are 
patented internationally. The company commits significant resources 
to R&D, which currently is close to 5% of the company turnover and is 
expected to go up (company interview). The R&D work focuses on New 
Improved Chemical Entities (NICE), NDDS and development of 
patent-free processes for known molecules. 
Cipla has a strong pipeline of products and is expected to come 
out with innovative drugs through NDDS and chiral synthesis. Given 
the public knowledge that Cipla is working on improved chemical 
entities and drug delivery systems, the research pipeline of Cipla could 
be moving on a similar trajectory to Ranbaxy's. Discussions with the 
company's Director suggested that it is possible for Cipla to get into 
joint development partnerships with present patent holders of 
blockbuster molecules to develop improved versions by using chiral 
chemistry. 
Cipla's top management strongly believes that the key to 
success in the current environment is not basic research but 
technological innovation. Consequently, Cipla is aiming for continuous 
innovation and complements this by achieving operational and 
marketing excellence. The company has consistently come out with 
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modem drugp that multinationals introduce, far more cheaply in the 
domestic market. The strategy has been effective in a price-sensitive 
market. 
2.8.3. Dr. Reddy's Laboratories 
Dr. Reddy's Laboratories is India's leading pharmaceutical 
company with presence in over 100 countries. Dr Reddy's manufactures 
a range of products such as Active Pharmaceutical Ingredients, Generic 
& Branded Finished Dosages, Specialty Pharmaceuticals, and 
Biopharmaceuticals. 
Dr. Reddy's Laboratories was founded in 1984 by Dr Anji Reddy. 
In 1986, Dr. Reddy's went public and entered international markets 
with exports of Methyldopa. In 1987, Dr. Reddy's obtained its first US 
FDA approval for Ibuprofen API and started its formulations 
operations. Dr. Reddy's became the first Indian pharmaceutical 
company to out-license an original molecule when it licensed anti-
diabetic molecule (Balaglitazone), to Novo Nordisk. In 1998, Dr. 
Reddy's licensed anti-diabetic molecule, DRF 2725 (Ragaglitazar), to 
Novo Nordisk. In 1999, the company acquired American Remedies 
Limited, a pharmaceutical company based in India. In the year 2000, 
became the first Asia Pacific pharmaceutical company, outside Japan, to 
be listed on the New York Stock Exchange. In 2001, Dr. Reddy's 
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Laboratories became India's third largest pharmaceutical company with 
the merger of Cheminor Drugs Limited, a group company. In 2002, Dr. 
Reddy's made its first overseas acquisition - BMS Laboratories Limited 
and Meridian Healthcare in UK. In 2003, Dr. Reddy's launched 
Ibuprofen, first generic product to be marketed under the "Dr. Reddy's" 
label in the US. 
In 2005-06, Dr. Reddy's achieved a turnover of Rs.24, 077.2 
million. In the same year, Dr. Reddy's acquired Betapharm- the fourth-
largest generics company in Germany. Today, Dr. Reddy's Laboratories 
is leading pharmaceutical company in India in terms of turnover and 
profitability. 
Dr Reddy's Laboratories invested heavily in building R&D 
labs and are the only Indian company to have significant R&D being 
undertaken overseas. In the year 2005-06 the R&D expenditure was Rs. 
2,153 million more than 8.9 % of sales. Dr. Reddy's Research 
Foundation was established more than a decade ago, in 1992 and 
dedicated to research in area of new drug discovery. 
Dr Reddy's Laboratory's successful growth into a fully integrated 
pharmaceutical company in less than a decade was founded on a 
successful and targeted program of inorganic growth and investments 
in process R&D. It chose a high risk-high gain strategy to growth by 
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going into direct competition with existing patent holders. A major 
challenge for DRL is to find ways to de-risk its overall strategy. One 
way may lie in managing the cash flows from the 'safer' API and 
formulations businesses. Another way may be to seek out more 
experienced partners for the R&D business or use acquisitions to boost 
R&D resources and revenues. Evidence suggests that DRL is trying 
both. 
2.8.4. Aurobindo Pharmaceuticals Ltd. 
Aurobindo Pharma is another leading pharmaceutical company 
in India. Founded in 1986 by Mr. P.V. Ramprasad Reddy, Mr. K. 
Nithyananda Reddy and a small, highly committed group of 
professionals, the company became a public venture in 1992. It 
commenced operations in 1988-1989 with a single unit manufacturing 
active pharmaceutical ingredients. Aurobindo Pharma went public in 
1995 by listing its shares in various stock exchanges in the country. Over 
the years, Aurobindo Pharma has evolved into a knowledge driven 
company. For the year 2005-06 the company has a turnover of Rs. 14,722 
million. 
There are large capacities for manufacturing formulations. This is 
supported by huge manufacturing capacity for intermediates and active 
ingredients. The Company has one of the widest product portfolios of 
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300+ products. Major therapeutic segments covered Cardio vascular, 
Neuroscience, Anti-retroviral, Gastro-intestinal, Anti-infective, Pain 
management and Osteoporosis. 
Aurobindo is knowledge based company with intellectual 
property skills and has earned patents and product/plant approvals 
primarily due to the human energy within the organisation. 
The Company has skilled professionals manning all the 
functional areas. The employee strength has doubled in the last three 
years, and the attrition rate is way below the industry average. 
Aurobindo is a research led powerhouse with over 700 talented 
scientists leveraging the intellectual resources and experience to 
quicken the pace of growth. Such efforts have widened the product 
offering through intelligent research and fast tracked the company. The 
strengths of research at Aurobindo are primarily in its ability to offer 
what the market wants. The company has filed and received approvals 
for a very large number of products across several countries. With its 
research based chemistry capabilities and expertise in developing 
various dosage forms, the company has product offers in six key 
therapeutic segments that have demand pull. It is R&D focused, has a 
multi product portfolio with multi-country manufacturing facilities, 
and is becoming a marketing conglomerate across the world. The 
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company's R&D expenditure was stood at Rs 647.9 million for the year 
2005-06 which was 4.4 percent of the company's sales. 
Aurobindo Pharma created a name for itself in the manufacture 
of bulk actives, its area of core competence. After ensuring a firm 
foundation of cost effective production capabilities and a clutch of loyal 
customers, the company has entered the high value specialty generic 
formulations segment, with a global marketing network. 
Aurobindo's objective is to be one of the leading global 
pharmaceutical companies and to create lasting value and quality. 
2.8.5. Nicholas Piramal India Limited (NPIL) 
Nicholas Piramal India Limited (NPIL), India's leading 
Pharmaceutical Healthcare Company is a leader in the Cardio-vascular 
segment. It has a strong presence in Antibiotics and Respiratory 
segments. Pain management, Neuro-psychiatry and Anti-Diabetics 
segments. The company is also making forays into Biotechnology in key 
therapeutic areas for which it has formed several global alliances. For 
2005-06, NPIL's recorded a turnover of Rs 14,100 million. 
NPIL's biggest brands in the pharma business are Phensedyl, 
Ismo, Supradyn, Gardenal, Stemetil, Haemaccel and Rejoint - these 
bring in 67 per cent of the business, while its secondary brands which 
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include Paraxin, Flagyl and Omnatax contribute around 24 % of its 
revenues. 
NPIL is part of the Piramal Enterprises, one of the India's largest 
diversified business groups with interests in retailing, textiles, auto 
components and engineering. The Piramal enterprise was founded in 
1933 and until 1987 most of the group's revenues had come from textile 
business. Increasing uncertainties in the textile sector prompted the 
group to diversify and in 1984 it acquired a small glass company, 
Gujarat Glass which supplied bottles and vials for the pharmaceutical 
industry. NPIL came into existence in 1988 when it acquired Nicholas 
Laboratories from Sara Lee and in the last 15 years grown to its 
leadership position through a series of well managed acquisitions, 
mergers and alliances. Some of NPIL's major acquisitions include the 
Indian operations of Roche Products Ltd., Boehringer Mannheim India 
Ltd., Hoechst Marrion Roussel Ltd,'s Research Centre, Rhone Poulenc 
India Ltd., ICl India Ltd.'s Pharma Division and Aventis' Reseach 
facilities. 
NPIL's core strengths are its 2700-strong field force that offers it 
the depth and width in the Indian market; successful brand building -
today NPIL, together with its JVs, has 16 brands among the top 300 in 
the Indian Pharma Industry; state-of-the-art manufacturing plants -
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NPIL's Hyderabad plant is the only one in India to have USFDA 
approval for the entire facility, it is also accredited and approved by 
MCA of UK, TGA of Australia and the European and Canadian Drug 
Authorities, and its Pithampur plant in Central India is accredited by 
reputed organizations like Allergan, Novartis, Solvay and IVAX, among 
others, which use it for toll manufacturing.With the acquisition of 
Pfizer's Morepeth's manufacturing wife in UK, Nicholas Piramal 
through its wholly owned subsidiary NPIL Pharmaceuticals Limited, 
has emerged as one of the leading custom manufacturing organizations 
across the world. 
Today, NPIL, is well poised to take advantage of the 
opportunities that will emerge in the bulk actives and intermediates 
market for contract manufacturing at attractive price points of both on 
patent and off patent drugs for the regulated markets of Europe, US and 
Japan. The company's track record and credibility in respecting IPR is 
extremely good and is respected globally. NPIL also has major 
investments in R&D which focus on formulations development, new 
chemical entity research, and clinical research from laboratories in India 
and abroad. 
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3.1. Introduction 
The previous chapter deals with the pharmaceutical industry 
overview consisting of global pharma industry, evolution and history of 
Indian pharmaceutical industry and current status of Indian 
pharmaceutical industry. The present chapter is an overview of IPR, 
TRIPs, Indian Patent Act, 1970 and amendments in Indian Patent Act, 
1970 towards TRIPs compliance. 
3.2. Concept of and Types of Intellectual Property Rights 
(IPR) 
Intellectual Property can be characterised as the property in ideas 
or their expression.^ It is a creation of the mind, for example, a 
technological innovation, a poem, or a design. Intellectual property 
rights protect the rights of individuals and businesses who have 
transformed their ideas into property by granting rights to the owners of 
those properties. The WTO defines intellectual property as: 
"...rights given to people over the creation of their minds and creators 
can be given the right to prevent others from using their inventions, 
designs or other creations".2 
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The intellectual property rights is an asset and, as such, it can 
be bought, sold, mortgaged, licensed, exchanged or gratuitously 
given away like any other form of the property. Further, by 
acquiring a legal right over the property, the creator of the 
intellectual property seeks to ensure that he has exclusive right over it 
and that th^property can be put to use by others only with his 
consent. Intellectual property Rights can be classified into the following 
four categories: 
3.2.1. Copyright and Related Rights 
Copyright is used to protect original creative works, published 
editions, sound recordings, films and broadcasts. It exists 
independently of the recording medium, so buying a copy does not 
confer the right to copy. Limited copying such as photocopying, 
scanning and downloading without permission is possible, e.g. for 
research. Publication of excerpts or quotes needs acknowledgement. An 
idea cannot be copyrighted, just the expression of it. Nor does copyright 
exist for a title, slogan or phrase, although these may be registered as a 
trade mark. Copyright applies to the Internet with web pages protected 
by many different copyrights, so that permission should be asked to 
copy or print a page, or insert a hyperlink to it. Material cannot be 
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posted on a Web site (Intranet included) without permission from the 
copyright holder. 
Neighbouring rights, also known as rights neighbouring to 
copyright, were created for three categories of people who are not 
technically authors: performing artists, producers of phonogrammes, 
and those involved in radio and television broadcasting. 
3.2.2. Trade Marks 
A symbol (logo, words, shapes, a celebrity name, and jingles) 
used to provide a product or service with a recognisable identity to 
distinguish it from competing products. Trade marks protect the 
distinctive components which make up the marketing identity of a 
brand, including pharmaceuticals. In other words a trademark is a 
visual symbol in the form of a word, a device or a label applied to 
articles of commerce with a view to indicate to the purchasing 
person or a particular organization as distinguished from similar 
goods manufactured or dealt in by others. 
3.2.3. Geographical Indications 
Geographical Indications is a new concept. It is an indication 
used to identify the goods, whether natural or manufactured goods 
emanating from a particular area or territory known for particular 
quality or characteristics of the goods. Only associations can apply for 
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Geographical indications. For example Darjeeling Tea, Alfanso Mangoes 
etc. Protection for the brand of the region for its very own uniqueness 
has become necessary and inevitable, and without delay, through 
the protection of Geographical Indications. 
3.2.4. Industrial Designs 
Industrial designs may be identified as those elements that are 
incorporated into mass-produced products, aimed at er\hancing the 
attractiveness of the product by its appearancd. Industrial design 
protection is similar to copyright protection and aims to protect those 
who are the designers of the 'ornamental aspects' of useful articles. 
These "ornamental aspects" refer to the features of shape, the 
configuration or the pattern of the relevant product or article. Through 
the protection of an industrial design, only the holder of the right may 
legitimately reproduce the relevant design. 
3.2.5. Patents 
A patent may be defined as an exclusive right granted for any 
invention that provides mankind with a new manner of doing 
something or that offers a new technical solution to a problem. Patent 
is granted to a person who has invented a new and useful article or a 
new process of making an article or has improved an existing article 
The invention is "disclosed to the public in exchange for a limited 
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period of time to exclude others from using the invention 
without the owner's consent". In essence a patent entails the inventor 
showing the public what he invented and how it works. In return a 
right is conferred upon him to prohibit the public from use of the 
invention unless he permits it. Therefore, importantly, a patent does 
not confer a right upon the holder to reproduce or use the invention, 
but to prevent others from doing so without the required authority. 
3.2.6. Layout-Designs (Topographies) of Integrated Circuits 
Layout design (topography) of integrated circuits is a relatively 
new area in IP, which has appeared with computer technology and has 
acquired importance as the technology makes rapid advances. The 
programming instructions on a computer chip are implemented 
through a circuitry printed on semiconductor materials. The design of 
circuitry on the chip requires great investment of knowledge, skills and 
capital and it needs to be protected as IP. The right in topography aims 
to prevent copying of the layout design but reverse engineering to come 
up with improved design is regarded as fair. It may also be noted that, 
while for claiming a patent, an invention is required to meet the criteria 
both of novelty and non-obviousness, a layout design is only required 
to be original. Protection of layout design confers no monopoly right. 
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Independent development of a design, identical with a protected design 
is permitted. 
3.2.7. Undisclosed Information or Trade Secrets 
A trade secret is virtually anything that is not generally known 
and that gives the owner of a trade secret a competitive business 
advantage. A trade secret may be a formulae, devices, methods, 
techniques, processes, sources of supply, custon\er lists and other 
industrial or commercial ideas. In order to qualify as a trade secret, the 
owner must take precautions to ensure that it remains secret. The owner 
of a trade secret has the right to prevent use or dissemination of the 
trade secret by anyone who learned or derived the trade secret from the 
owner. The owner has no trade secret rights against anyone who 
independently discovers the trade secret. 
3.3. Benefits and Threats of Patents 
The reverse engineering of drugs is quite a simple procedure. So 
patents are especially valuable for pharmaceutical industry. The lack of 
intellectual property tights can lead to excessive use of new knowledge, 
which in turn can lead to minimization of the economic value of an 
innovation and decrease in motivation for other parties to improve the 
knowledge. Therefore intellectual property rights eliminate the 
incentives for free-riders. 
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An individual who created something new can feel secure about 
collecting and appropriate amount of money for his invention when 
holding a patent. And, thus, is motivated for further research. This also 
holds for pharmaceutical companies who are encouraged who invest in 
research and development when holding patents. 
However, patents can also limit the availability of drugs for 
people from third world. The reason is that cross-learning is hardly 
possible for other firms when one is holding a patent. 
All the companies have to start from the scratch and that slows 
down the progress and technology. "Patents produce a loss or 'dead-
weight burden' in so far as the benefits of the new knowledge to society 
would have been greater in the absence of a patent regime, and thus 
reduce the capacity for other firms to exploit the knowledge on a 
competitive basis." 
The direct investments can decrease because of the export of 
finished goods instead of transferring technology and production is 
highly concentrated in developed countries. TRlPs agreement gives the 
possibility for companies to maximize their profits by price 
discrimination. 
Nevertheless patents are considered to be vitally important for 
pharmaceutical industry; there still exist some significant arguments 
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against them. "Entrenched patent monopolist has weaker incentives 
then a 'would-be' entry firm to initiate and research and development 
program that would produce substitutes, even superior quality ones, 
than for goods, which were already profit-generating. This, in turn, 
results in sub-optimal outcomes for social welfare." Some arguments^ in 
favour and against patents in pharmaceutical market are as follows: 
Table 3.1 
Arguments in Favour and Against of Patents 
Arguments in favour of patents 
Granting patents stimulates 
investment for research and 
innovation because economically 
meaningful knowledge is 
expensive to generate. In absence 
of proper patent protection; the 
innovator's ability to recover R&D 
costs is limited. A delay in 
imitation through patent 
protection would stimulate R&D 
for innovation. An empirical study 
shows that in comparison to other 
industries like motor vehicles etc, 
in absence of patent protection, 
investment in R&D would be very 
less in the pharmaceutical 
Arguments against patents 
Patent holders can prevent others 
from using the innovations which 
may have a negative impact on 
further technological development 
in areas like medicine, software, 
and information technology where 
innovation is a cumulative and 
collaborative effort. The evidence 
received by the Royal Society 
indicates that 'patenting hardly 
delays publication significantly, 
but it can encourage a climate of 
secrecy that does limit the free 
flow of ideas and information that 
are vital for successful science.' 
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industry. 
Patent protection becomes 
important for the pharmaceutical 
industry because: 
a. The cost of developing new 
drug is high, 
b. The cost of developing processes 
for manufacturing a new drug is 
low. 
Patents have an impact on 
competition and technology 
diffusion. Patent holders are 
required to disclose the innovation 
which may have a positive impact 
on further innovations. 
Patent rights which exclude others 
from producing and marketing it 
leads to Inhibition of competition 
and hence high prices. 
(Affordability Vs Accessibility) 
Patents neglects development and 
accessibility of drugs. 
3.4. History and Background of TRIPs Agreement 
The proposal for the negotiation on intellectual property rights in 
GATT was for the first time launched during the Tokyo Round in 1978, 
as a response to the explosion of counterfeiting trademarked goods and 
dissatisfaction of the creators and users of intellectual property on the 
issue of enforcement of the existing international regime at that time the 
1970s and 1980s. 
The significant step on the possible negotiation of TRIPs under 
GATT took place in November 1985, when the contracting parties of 
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GATT established a Preparatory Committee to discuss a new rourid of 
multilateral negotiations. The Preparatory Committee was given a 
broad mandate to examine any possible agenda in the new round 
including the issue of intellectual property rights. During the 
negotiation, the United States with its economic power threatened to 
impose trade sanctions on the states, mostly developing countries that 
were allegedly to have infringed or to have given lack of protection to 
the U.S intellectual property rights in their countries. The United States 
promulgated the Trade Act of 1984 to protect the intellectual property 
rights under Section 301 of the Trade Act of 1974. The act provides that 
the president of the United States may impose trade sanction upon 
states that allegedly had not provided protection to the U.S intellectual 
property. 
Significant progress of the negotiation took place in 1986 when 
the contracting parties of GATT agreed to launch the Uruguay Round 
negotiations in 1986, which stipulated that TRlPs was one of the issues 
on the agenda of the negotiation. The Ministerial Declaration on the 
Uruguay Round laid down guidelines for the subject matters of the 
negotiations, which, among others, covered TRlPs (including trade in 
counterfeit goods). Finally, Trade Related Intellectual Property Rights 
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(TRIPs) was negotiated at the end of the Uruguay Round of the General 
Agreement on Tariffs and Trade (GATT) treaty in 1994. 
After the Uruguay round, the GATT became the basis for the 
establishment of the World Trade Organization. Because approval of 
TRIPs is a compulsory requirement of World Trade Organization 
(WTO) membership, any country seeking to obtain easy access to the 
numerous international markets, opened by the World Trade 
Organization must enact the strict intellectual property laws mandated 
by TRIPs. For this reason, TRIPs is the most important multilateral 
instrument for the globalization of intellectual property laws. States like 
Russia and China that were very unlikely to join the Berne Convention 
have found the prospect of WTO membership a powerful enticement. 
Furthermore, unlike other treaties on intellectual property, TRIPs 
has a powerful enforcement mechanism. States can be disciplined 
through the WTO's dispute settlement mechanism. 
3.5. Features^ of TRIPs Agreement 
The scope of TRIPs is quite extensive, as it covers copyright and 
related rights (i.e., the rights of performers, producers of sound 
recordings and broadcasting organizations); trademarks, including 
service marks; geographical indications, including appellations of 
origin; industrial designs; patents, including the protection of new 
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varieties of plants; the layout designs of integrated circuits; and 
undisclosed information, including trade secrets and test data. 
The three main features of the Agreement are: 
• Standards: In respect of each of the main areas of intellectual 
property covered by the TRIPs Agreement, the Agreement sets 
out the minimum standards of protection to be provided by each 
Member. Each of the main elements of protection is defined, 
namely the subject-matter to be protected, the rights to be 
conferred and permissible exceptions to those rights, and the 
minimum duration of protection. The Agreement sets these 
standards by requiring, first, that the substantive obligations of 
the main conventions of the WIPO, the Paris Convention for the 
Protection of Industiial Property (Paris Convention) and the 
Berne Convention for the Protection of Literary and Artistic 
Works (Berne Convention) in their most recent versions must be 
complied with. With the exception of the provisions of the Berne 
Convention on moral rights, all the main substantive provisions 
of these conventions are incorporated by reference and thus 
become obligations under the TRIPs Agreement between TRIPs 
Member countries. The relevant provisions are to be found in 
Articles 2.1 and 9.1 of the TRIPs Agreement, which relate, 
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respectively, to the Paris Convention and to the Berne 
Convention. Secondly, the TRlPs Agreement adds a substantial 
number of additional obligations on matters where the pre-
existing conventions are silent or were seen as being inadequate. 
The TRIPs Agreement is thus sometimes referred to as a Berne 
and Paris-plus agreement. 
• Enforcement: The second main set of provisions deals with 
domestic procedures and remedies for the enforcement of 
intellectual property rights. The Agreement lays down certain 
general principles applicable to all IPR enforcement procedures. 
In addition, it contains provisions on civil and administrative 
procedures and remedies, provisional measures, special 
requirements related to border measures and criminal 
procedures, which specify, in a certain amount of detail, the 
procedures and remedies that must be available so that right 
holders can effectively enforce their rights. 
• Dispute settlement: The Agreement makes disputes between 
WTO Members about the respect of the TRIPs obligations subject 
to the WTO's dispute settlement procedures. 
3.5.1. Structure of TRIPs Agreement 
TRIPs includes a preamble and seven parts 
123 
TRIPS and Indian Patent Act, 1970 
Part I contains general provisions and basic principles (Article 1-
8). TRlPs set a minimuni standard of protection. Article 1.1 makes 
it clear that members may implement more extensive protection 
in their law than is required by TRIPs, provided however that 
such protection does not contravene its provisions. 
Part II (Article 9-40) "Standards concerning the availability, scope 
and use of intellectual property rights" has eight Sections dealing 
with specific areas of IP rights, including copyright trademarks, 
geographical indications, industrial designs, patent layout 
designs, protection of undisclosed information and control of 
anti-competitive practices in contractual licenses. Part II contains 
provisions relevant to the substantive law of WTO members. The 
most important changes seem to have affected the patent law, 
especially by expanding the scope of patentability (including 
pharmaceuticals and food) and the term of protection (20 years). 
Part III (Article 41-61) is devoted to the enforcement of 
intellectual property rights. This part is divided into five Sections 
(General Obligations, Civil and Administrative Procedures and 
Remedies, Provisional Measures, Special Requirements Related to 
Border Measures and Criminal Procedures). The emphasis on 
enforcement issues is a huge contribution of TRIPs to the 
124 
TRIPS and Indian Patent Act, 1970 
international system of IP rights protection. In practice, it is 
important both to enable the right holder to effectively pursue 
his/ her rights and to grant him/her these rights in the first place. 
It was perhaps the trade-related origin of TRIPs that was 
responsible for this change of perspective. 
• Part IV (Acquisition and Maintenance of Intellectual Property 
Rights and Related Inter-Parties Procedures - Article 62) TRIPs 
generally allows member states to require compliance with 
reasonable procedures and formalities as a condition of the 
acquisition or maintenance of intellectual property rights. 
• Part V is devoted to the dispute settlement mechanism (Article 
63-64). 
• Part VI (Article 65-67) contains transitional arrangements. 
• The last part VII (Article 68-73) is reserved for "Institutional 
Arrangements and Final Provisions". It contains all sorts of rules, 
from the creation of the Council of TRIPs to the protection of 
existing subject matter and security exceptions. 
3.5.Z Main Provisions of TRIPs Related to Pharmaceuticals 
The TRIPs cover almost all standard of IPR such as copyright and 
related rights, trademarks, geographical indications, industrial designs, 
patents, including the protection of new varieties of plants; the layout 
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designs of integrated circuits; and undisclosed information, including 
trade secrets and test data. But Researcher has view that among the 
various aspects of intellectual property rights the only patent relates to 
pharmaceutical industry. Therefore, in this study the Researcher study 
the main provisions of TRIPs, related to pharmaceutical patents only. 
The main provisions of TRIPS as they relate to pharmaceutical patents can be 
summarized as follows: 
Articles 3 and 4 
Among the general obligations. Articles 3 and 4 of TRIPs require 
member governments to apply the principles of national treatment, i.e. 
equal treatment of nationals and non- nationals, and most-favored-
nation (MFN) treatment, i.e. equal treatment of foreigners regardless of 
their country of origin. 
Article 27.1 
The TRIPs Agreement requires Member countries to make 
patents available for any inventions, whether products or processes, in 
all fields of technology without discrimination, subject to the normal 
tests of novelty, inventiveness and industrial applicability. It is also 
required that patents be available and patent rights enjoyable without 
discrimination as to the place of invention and whether products are 
imported or locally produced. 
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Article 27.2 
There are three permissible exceptions to the basic rule on 
patentability. One is for inventions contrary to ordre public or morality; 
this explicitly includes inventions dangerous to human, animal or plant 
life or health or seriously prejudicial to the environment. The use of this 
exception is subject to the condition that the commercial exploitation of 
the invention must also be prevented and this prevention must be 
necessary for the protection of ordre public or morality. 
Article 27.3(a) and (b) 
The second exception is that Members may exclude from 
patentability diagnostic, therapeutic and surgical methods for the 
treatment of humans or animals (Article 27.3(a)). The third is that 
Members may exclude plants and animals other than micro-organisms 
and essentially biological processes for the production of plants or 
animals other than non-biological and microbiological processes. 
However, any country excluding plant varieties from patent protection 
must provide an effective sui generis system of protection. Moreover, the 
whole provision is subject to review four years after entry into force of 
the Agreement (Article 27.3(b)). 
Article 28 
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The exclusive rights that must be conferred by a product patent 
are the ones of making, using, offering for sale, selling, and importing 
for these purposes. Process patent protection must give rights not only 
over use of the process but also over products obtained directly by the 
process. Patent owners shall also have the right to assign, or transfer by 
succession, the patent and to conclude licensing contracts. 
Article 30 
Members may provide limited exceptions to the exclusive rights 
conferred by a patent, provided that such exceptions do not 
unreasonably conflict with a normal exploitation of the patent and do 
not unreasonably prejudice the legitimate interests of the patent owner, 
taking account of the legitimate interests of third parties. 
Article 33 
The term of protection available shall not end before the 
expiration of a period of 20 years counted from the filing date. 
Article 29.1 
Members shall require that an applicant for a patent shall disclose 
the invention in a manner sufficiently clear and complete for the 
invention to be carried out by a person skilled in the art and may 
require the applicant to indicate the best mode for carrying out the 
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invention known to the inventor at the filing date or, where priority is 
claimed, at the priority date of the application. 
Article 34 
If the subject-matter of a patent is a process for obtaining a 
product, the judicial authorities shall have the authority to order the 
defendant to prove that the process to obtain an identical product is 
different from the patented process, where certain conditions indicating 
a likelihood that the protected process was used are met. 
Article 34.1 
This specifies that the burden of proof in case of process patent 
infringement rests with the defendant, i.e. the party accused of patent 
infringement. 
Article 31 
Compulsory licensing and government use without the 
authorization of the right holder are allowed, but are made subject to 
conditions aimed at protecting the legitimate interests of the right 
holder. The conditions are mainly contained in Article 31. These include 
the obligation, as a general rule, to grant such licences only if an 
unsuccessful attempt has been made to acquire a voluntary licence on 
reasonable terms and conditions within a reasonable period of time; the 
requirement to pay adequate remuneration in the circumstances of each 
129 
TRIPS and Indian Patent Act, 1970 
case, taking into account the economic value of the hcence; and a 
requirement that decisions be subject to judicial or other independent 
review by a distinct higher authority. Certain of these conditions are 
relaxed where compulsory licences are employed to remedy practices 
that have been established as anticompetitive by a legal process. These 
conditions should be read together with the related provisions of 
Article 27.1, which require that patent rights shall be enjoyable without 
discrimination as to the field of technology, and whether products are 
imported or locally produced. 
Article 41.1 and Article 62..2 
Article 41.1 requires member governments to ensure that 
enforcement procedures are available under their national laws so as to 
permit effective action against any act of infringement of intellectual 
property rights and Article 62.2 obligates members to ensure that the 
procedures for grant or registration permit the granting or registration 
of the right within a reasonable period of time so as to avoid 
unwarranted curtailment of the period of protection. 
The provisions of TRIPs became applicable to all signatories by 
the beginning of 1996. However, Articles 65.2 and 65.4 of the TRIPs 
Agreement entitle developing countries like India to a four-year 
transition period in implementing all obligations (except for obligations 
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pertaining to national and MFN treatment) and an additional five-year 
transitional period for product patents in fields of technology that were 
not protected at the date of application of the Agreement. Accordingly, 
India will have to amend its patent law to allow for the grant of 
pharmaceutical product patents by 2005. Article 70.3 does not require 
member countries to extend protection to subject matter in existence 
before the introduction of a new law, i.e. patent protection would not 
apply retroactively. Articles 70.8 and 70.9, however, also specify that 
members should provide a means for which patents for [pharmaceutical 
and agricultural chemical products] can be filed" (this 'means' is often 
referred to as a 'mail-box'). Moreover, for such 'mail-box' applications 
exclusive marketing rights shall be granted for a period of five years 
after obtaining market approval in that Member or until a product 
patent is granted or rejected in that Member, whichever period is shorter, 
provided that a patent application has been filed and a patent granted for 
that product in another Member and marketing approval obtained in 
such other Member. To the extent that exclusive marketing rights related to 
'mail-box' applications and exclusive rights conferred by a regular patent title 
are practically the same,5 Articles 70.8 and 70.9 effectively offset the 
transition period with regard to pharmaceutical product patent. 
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3.6. Flexibilities under TRIPs 
It is anticipated that with the introduction of full 
product patent protection in pharmaceuticals, as the generic 
companies are prevented from introducing new drugs, the lack of 
competition will result in high prices. Supply of low cost new drugs to 
the Indian market and to other countries will be threatened. But TRIPs 
provides for some flexibility to member countries of WTO to take 
action to tackle such negative consequences of product patent 
protection. Within the scope of TRIPs, the following are the main 
flexibilities which developing countries can use: 
3.6.1. Exemptions from Grant of Patents 
Under Article 27(1) of TRIPs, patents will have to be provided 
for inventions, which are "new, involve an inventive step and are 
capable of industrial application" The agreement however does not 
define these terms. This provides some flexibility. It has been 
suggested that a developing country can interpret these terms so as to 
restrict the number of patents.^ 
3.6.2. Exceptions to exclusive rights 
Article 30 of the TRIPs Agreement does not define the scope or 
nature of the permissible exceptions. The result is that countries have 
considerable freedom in this area. In addition, paragraph 5(a) of the 
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Doha Declarations stresses the importance of the object and purpose 
of the TRIPs Agreement in the implementation and interpretation the 
Agreement. In particular, the early working (or the Bolar) 
exception is an important mechanism in facilitating the production 
of, and accelerating the introduction of generic substitutes on patent 
expiry. This exception has important implications for developing 
countries, especially if they are currently or potentially producers of 
generic medicines. 
3.6.3. Parallel Import 
Parallel importing can be an important tool enabling access to 
affordable medicines because there still are substantial price 
differences for pharmaceutical products in different markets. 
Permitting some form of parallel imports provides opportunities 
to shop for better-priced pharmaceutical products. Developing 
countries should avail themselves of the widest scope in terms of 
parallel imports and incorporate explicit provisions to put into effect 
an international exhaustion regime in their national patent laws. It is 
important to remember that while this flexibility is allowed in the 
TRIPs Agreement and confirmed by the Doha Declaration, it does not 
automatically translate into the national regimes, and it will be 
necessary for specific legal provisions be enacted in national laws 
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3.6.4. Use without Authorization of the Right Holder (Compulsory 
Licensing) 
Article 31 of TRIPs dealing with compulsory licensing, does not 
place any restriction on the grounds under which a compulsory 
licenses can be given. In case there were any doubts, the Doha 
Declaration has made it clear that "Each member has the right to grant 
compulsory license and the freedom to determine the grounds upon 
which such licenses are granted." 
3.6.5. Public, non-commercial use of Patents (Government Use) 
The right of the state to use a patent without the consent of the 
patent holder for public health purposes is recognized to be an 
important public health safeguard by many countries. Those 
developing countries which have not done so should incorporate 
within their domestic legislation government and non-commercial 
use provisions that are no less broad than those currently applicable 
in the US or the United Kingdom (UK) legislation. Although Article 
31 of the TRIPs Agreement sets out the conditions'governing both 
government use of patents and compulsory licenses, one important 
difference is that government use of patents may be fast-tracked 
because of the waiver of the requirement for prior negotiations with 
patent holders. 
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3.6.6. Limiting Data Protection 
To get marketing approval for a new drug developed, innovator 
companies are required to submit test and clinical data relating to 
safety and efficacy to national health authorities. On the basis of 
paragraph 4 of Doha Declaration which provides that provisions of 
the Agreement be interpreted and implemented in a manner 
supportive of WTO Members right to protect public health and, in 
particular to promote access to medicines for all", developing 
countries should allow drug regulatory authorities to approve 
equivalent generic substitutes on the basis of reliance on the 
originator data from the time of its submission. They should 
implement data protection legislation that is consistent with public 
health objectives, that is, to facilitate the entry of generic competitors. 
3.7. Doha Declaration on Health 
The Doha Declaration is a direct consequence of the multiple 
controversies concerning patents in the health sector, in particular in the 
context of the HIV/AIDS epidemics. Its importance is linked to the 
recognition that the existence of patent rights in the health sector does 
not stop states from taking measures to protect public health. 
More specifically, it affirms that TRIPs should be "interpreted 
and implemented in a manner supportive of WTO members' right to 
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protect public health and, in particular, to promote access to medicines 
for all" 7 This strengthens the position of countries that want to take 
advantage of the existing flexibility within TRIPs. In other words, the 
declaration does not open new avenues within TRIPs but confirms the 
legitimacy of measures seeking to use to the largest extent possible the 
in-built flexibility found in TRIPs. 
The declaration (see appendix 2) focuses mainly on questions 
related to the implementation of patents, such as compulsory licensing. 
Compulsory licensing has long been used as a tool to regulate the 
exclusive rights conferred by patents. In the case of health, the rationale 
is to make sure that the existence of a patent does not create a situation 
where a protected medicine is not available to the public because of 
non-health related factors. The Patents Act, 1970 provided an elaborate 
regime that included both compulsory licences and licences of right. 
The TRIPs Agreement has not done away with the notion of 
compulsory licences but provides a more restrictive framework. The 
recognition in the Doha Declaration that TRIPs member-states can use 
the flexibility provided in the agreement and can, for instance, 
determine the grounds on which compulsory licences are granted must 
thus be understood in the context of a generally increasingly restrictive 
international patent regime. 
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The declaration has been hailed as a major step forward in the 
quest for making the TRIPs Agreement more responsive to the needs of 
developing countries and more specifically all individuals unable to 
afford the cost of patented drugs. In fact, it addresses a number of 
important issues related to the implementation of medical patents. 
However, it fails to take up the much more fundamental 
questions of the scope of patentability and the duration of patents in the 
health sector. 
3.8. History and Background of Indian Patent Act, 1970 
The Indian Patent is more than 150 years old. The Patent Act was 
first enacted in the year 1856 under the rule of British and subsequently 
amended several times. India had inherited The Patents and Designs 
Act 1911 from the colonial times that provided for protection of all 
inventions except those relating to atomic energy and a patent term of 
16 years from the date of application.^ After Independence of India 
there was a need to revise The Patents and Designs Act 1911 to facilitate 
the local industry and in accordance with the stage of development of 
the country. The Patents Act in India was framed after years of 
consideration in 1970 and on the basis of the recommendations made by 
the Justice Rajagopal Ayyangar Committee (1958).9 The Patent Act, 1970 
came into force on 20.4.1972 replacing Indian Patents and Designs Act 
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1911. The Indian Patent Act, 1970 contains 23 chapters, which are 
relating to Patenting procedure. International arrangement and other 
misc. matters. This Act is regulated by the Patents Rules 1972, which 
inter alias include five schedules concerning with fees, forms etc. Under 
the Patent Act, 1970 the Government of India is authorized to make 
rules for carrying out the purposes of the Act and regulating the Patent 
Administration. There are five Schedules to Patents Rules 1972. The 
Patent Act, 1970 provided for process patents for pharmaceuticals and 
agro-chemical products and for a short period i.e. 7 years for 
pharmaceutical, agro chemical and food products and 16 years for other 
categories. This enabled the growth of a strong local generic drug 
industry, which produced the same drugs as the MNCs at relatively 
low prices. India, since 1970, had a Patent law that was proclaimed by 
many as a model for other developing countries. The Indian Law 
stressed on the obligations of the Patent holder and had strong 
provisions that prevented the abuse of the Patent holder's monopoly 
rights. One of the important factors that contributed the growth of 
Indian pharma industry was the fact that The Patent Act 1970 did not 
provide for monopoly rights in the area of drugs and agro-chemicals as 
only process patents and not product patents were recognized. 
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3.9. Indian Patents Act, 1970 Main Features 
The Indian Patents Act, 1970 acted as a legitimate tool for the 
exponential growth of the Indian pharmaceutical industry and the 
'process patent regime' resulted in the development of competitive 
generic market focused on production of blockbuster drugs.^o The 
Indian patents Act has been hailed as model legislation for developing 
countries. It seeks to balance both the need for granting rewards for 
inventors while ensuring that India's developmental needs are not 
ignored. These are main features of The Indian Patent Act, 1970: 
• General Principle of Patent Grant- (a) that patents are granted to 
encourage inventions and to secure that the inventions are worked 
in India on a commercial scale and to the fullest extent that is 
reasonably practicable without under delay; and (b) that they a not 
granted merely to enable patentees to enjoy a monopoly for the 
importation of the patented article. 
• Principle of National Treatment - no limitations or restrictions on 
foreigners in applying for or obtaining patents in India. 
• Inventions Not Patentable - The following are not patentable: 
o An invention which is frivolous or which claims anything 
obviously contrary to will established natural laws. 
139 
TRIPS and Indian Patent Act, 1970 
o An invention the primary or intended use of which would be 
contrary to law or morality or injurious to public health. 
o The mere discovery of a scientific principle or the 
formulation of an abstract theory. 
o The mere discovery of any new property or new use for a 
known substance or of the mere use of a known process, 
machine or apparatus unless such known process results in a 
new product or employs at last one new reactant. 
o A substance obtained by a mere admixture resulting only in 
aggregation of the properties of the compounds thereof or a 
process for producing such substance. 
o The mere arrangement or re-arrangement or duplication of 
known devices each functioning independently of one 
another in a known way. 
o A method or process of testing applicable during the process 
of manufacture for rendering the machine, apparatus, or 
other equipment more efficient or for the improvement or 
control of manufacture. 
o A method of agriculture or horticulture. 
o Any process for the medicinal, surgical, curative, 
prophylactic or other treatment of human beings or any 
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process for a similar treatment of animals or plants to render 
them free of disease or to increase their economic value or 
that of their products. 
• Search for Novelty - compulsory search is required extending to 
prior publications not only in India but also in any other part of the 
world. 
• Patentability of Inventions in the Area of Chemicals, Food and 
Drugs - In case of inventions relating to substances intended for use 
as food, drug or medicines or substances produced by chemical 
process. Patentability will be limited to claims for the methods or 
processes of manufacture only. 
• Term of Patent - The term of the patent in 14 years from the date of 
patenting, i.e.,. the date of filling the complete specification. In the 
case of inventions in the field of food, drug or medicine, the term is 
7 years from the date of filing or 5 years from the date of sealing, 
whichever is shorter. 
• Licensing Provisions - 2 types of licenses: Compulsory Licenses and 
License of Rights. Compulsory licenses enabling another party to 
work the patent can be applied for any time after the expiry of 
three years from the date of sealing of the patent. 
• In the area of food, drug, medicine or chemical, after the expiry of 
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three years from the date of patent grant, they shall be endorsed 
with the word "License of Right". These enable any interested 
person as a matter of right to be entitled to work such patents. 
• Royalties - In the case of patents related to food, drug or medicines 
the royalty reserved to the patentee under a license shall not exceed 
4% of the net ex-factory sale price in bulk of the patented article. 
• Use of Patented Inventions by the Government - In order to 
ensure that scarcity of a patented article doesn't arise and lead to 
high prices, the government is vested with powers to make use of 
or exercise any patented invention merely for its own purpose. 
Appeals - In all cases, appeals will be only with the High Court. 
3.10. Comparison between TRIPs and Indian Patent Act, 
1970 
India's Patent system governs by the Indian Patent Act, 1970. The 
philosophy of India's Patent Act of 1970 varies enormously from the 
framework being established under TRIPs. There are several areas 
which India considers unpatentable. India has a large community of 
scientists and researchers among whom publication rather than gaining 
patents has been a concern. Industrialized nations conceive of patents as 
a fundamental right comparable to the right of physical property, 
whereas developing nations view it as "fundamentally as an economic 
142 
TRIPS and Indian Patent Act, 1970 
policy question."^i From the perspective of developed countries, 
intellectual property is a private right that should be protected as any 
other tangible property, but for developing nations, intellectual property 
is a public good that should be used to promote economic development.^^ 
The following table illustrates the basic differences between India's Patent 
Act, 1970 and TRlPs: 
Table 3.2 
Comparison between Indian Patent Act, 1970 and TRIPs 
Indian Patent Act of 1970 
Only process not product patents in 
food, medicines, chemicals 
Term of patents 14 years; 5-7 in 
chemicals, drugs 
Compulsory licensing and license of 
right 
Several areas excluded from patents 
(method of agriculture, any process 
for medicinal surgical or other 
treatment of humans, or similar 
treatment of animals and plants to 
render them free of disease or 
increase economic value of 
products) 
Government allowed to use 
patented invention to prevent 
scarcity 
TRIPS 
Process and product patents in 
almost all fields of technology 
Term of patents 20 years 
Limited compulsory licensing, no 
license of right 
Almost all fields of technology 
patentable. Only area conclusively 
excluded from patentability is plant 
varieties; debate regarding some 
areas in agriculture and 
biotechnology 
Very limited scope for governments 
to use patented inventions 
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India joined the World Trade Organisation (WTO) in 1995 
and automatically became a signatory of Agreement on Trade-
Related Intellectual Property Rights (TRIPs) in 1995. At that time, 
India's current enactment of the Patent Act of 1970 directly contravened 
Article 27 of the TRIPs Agreement that patents must be available for any 
inventions, whether products or processes, in all fields of technology . 
Therefore, India needed to amend its patent law to comply with TRIPs 
provisions. 
3.11. Amendments in Indian Patents Act, 1970 towards 
TRIPs Compliance 
India became a party to the TRIPs Agreement in April 1994. Upon 
coming into effect on January 1,1995, TRIPs set out transitional periods 
for WTO members to introduce legislation complying with the 
obligations under TRIPs. ^ -^  
For developing countries, like India, the deadline for complying 
with TRIPs was the year 2000. i^  In addition. Article 65.4 of TRIPs 
provided a special transitional provision for those countries that did not 
grant product patents. The provision provided an additional five years 
for India (until 2005), from the initial TRIPs transitional period, to 
introduce product patent protection.^^ India took advantage of this extra 
transition period.i6 But Articles 70.8 and 70.9 of TRIPs put a limitation 
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on the transition periods allowed under Articles 65.4 for two 
classes of products, pharmaceuticals and agricultural chemicals. 
Even though the developing countries, such as India had time till 1 
January, 2005 to introduce full product patents protection for 
pharmaceuticals and agricultural chennicals, they were required to 
introduce two provisions in its Patents Act. Article 70.8 of the TRIPs 
Agreement required India to provide "a means" by which product 
patent applications can be filed from January 1, 1995 (mailbox). If the 
products figuring in these applications were granted a patent in any of 
the WTO member countries and the products had obtained marketing 
approval in any of the WTO Member countries, then, according to 
Article 70.9, five years exclusive marketing rights (EMRs) had to be 
granted by India before the patent on the product was either granted 
or rejected in India. 
India's commitment to fully implement the TRIPs Agreement 
required 3 sets of amendments to Patents Act, 1970: 
• The first amendment in 1999 introduced the requirements 
under "transitional arrangements" through section 5(2), which 
allowed product patent applications to be filed through a 
'mailbox', while Chapter IV A provided for the grant of 
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Exclusive Marketing Rights' (EMRs) subject to fulfillment of 
certain conditions.!'' 
• The second amendment on January 1, 2002 provided for 
bringing the Patents Act in conformity with all the substantive 
provisions of the TRIPs Agreement: redefining patentable 
subject matter, extension of term of patent protection to 20 years, 
and amending the compulsory licensing system, except for, 
barring those related with the introduction of product patent.is 
• The third amendment in January 1, 2005 introduced product 
patent regime in areas, including pharmaceuticals that were 
hitherto covered under process patent.i^ 
3.11.1. Patent Amendment Act, 1999 
The TRIPs Agreement's transitional arrangements allowed India 
January 1, 2005 to begin granting patents on qualifying applications 
claiming pharmaceutical products. But Article 70.8 of the TRIPs 
Agreement required India to provide "a means" by which product 
patent applications can be filed from January 1, 1995 (mailbox). If the 
products figuring in these applications were granted a patent in any of 
the WTO member countries and the products had obtained marketing 
approval in any of the WTO Member countries, then, according to 
Article 70.9, five years exclusive marketing rights (EMRs) had to be 
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granted by India before the patent on the product was either granted or 
rejected in India. 
Accordingly, an Ordinance was circulated by India's President on 
December 31, 1994 planned to implement a mailbox facility and EMRs, 
the Ordinance came into effect on January 1, 1995. But the Ordinance 
subsequently lapsed. The Indian Parliament's Lok Sabha (Lower House) 
subsequently passed a bill to implement the mailbox facility but the 
legislation was never enacted because the Rajya Sabha (Upper House) 
did not pass it. Ultimately enacted in March 1999, India's Patents 
(Amendment) Act, 1999, formally implemented the mailbox procedure 
for patent applications claiming pharmaceutical and agro-chemical 
products and made it retroactive to January 1, 1995. The 1999 Act also 
formally implemented EMRs. Mailbox applications went into a 
symbolic "black box," not to be taken out for examination nor even 
published by the Indian Patent Office until on or after January 1, 2005.20 
3.11.2. Patent Amendment Act, 2002 
A Patent Bill was introduced in the Rajya Sabha (Upper House of 
the Parliament) in December, 1999 to bring about the other changes in 
the patent regime towards TRlPs compliance. This Bill faced hurdles 
and could not be passed immediately. The Bill had to be referred to a 
joint parliamentary committee. This committee consulted a large 
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number of people including, lawyers, economists, industry 
representatives, NGOs and others. Several objections were raised. Some 
of these were incorporated and the committee submitted a revised Bill 
in December, 2001 (Joint Committee 2001). This Bill with a few changes 
was approved by the Parliament in May, 2002. The amended Act (The 
Patents (Amendment) Act, 2002) came into force on May 20, 2003. 
The Patents (Amendment) Act, 2002 made 64 amendments to the 
Patents Act, 1970 relating to terms of patents (20 years), exceptions to 
exclusive rights, compulsory licensing and so on. The 2002 Act 
implemented a number of important changes, but most significant was 
the extension of patent term to twenty years. The 2002 Act amended the 
principal Act to provide that the term of all Indian patents would 
henceforth expire twenty years after their application filing date. Prior 
to this amendment, Indian process patents lasted only for the shorter of 
five years from sealing or seven years from the date of the patent, while 
the term of all other types of patents (e.g., mechanical devices) was 
fourteen years from the date of the patent. 
Another notable aspect of the 2002 amendments was formal 
recognition in India's Patents Act of the nation's accession to two 
leading international intellectual property treaties; both administered 
by the United Nations-affiliated World Intellectual Property 
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Organization (WIPO). The Patents (Amendment) Act, 2002, 
implemented a myriad of other changes intended to bring India's 
patents law into accordance with the TRIPs Agreement, including new 
definitions of "invention" and "inventive step," new exclusions from 
patentable subject matter, a new burden of proof provision for cases of 
process patent infringement, and a revised compulsory licensing 
framework. 
3,11.3, Patent Amendment Act, 2005 
A third amendment i n Indian Patent Act, 1970 was necessary 
by the end of 2004, to replace the EMR system and to introduce 
product patent regime in areas, including pharmaceuticals that were 
hitherto covered under process patent. A bill (The Patents 
(Amendment) Bill, 2003) was introduced in the parliament in 
December 2003. Before this bill could be passed, Lok Sabha (Lower 
House of Indian Parliament) was dissolved. After the elections, the new 
government which came into power in May 2004 refereed the issue of 
the Third Amendment to a Group of Ministers (GoM). Many public 
interest groups and others demanded that the recommendations of the 
GoM should be made public and a debate be held before finalizing the 
amendments. But this was not done. In order to timely implement the 
necessary changes in the face of widespread political disagreement 
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about the value of pharmaceutical product patent protection, India's 
President signed the Patents (Amendment) Ordinance, 2004, on 
December 26, 2004. Government officials described the Ordinance as 
"an interim measure to fulfill India's legal obligations within the 
stipulated time." 
Following the Ordinance's promulgation, a three-month 
maelstrom of intense public debate and last-minute political 
compromises ultimately led to significantly revised legislation, which 
was enacted April 5, 2005, as the Patents (Amendments) Act, 2005. 
Once the 2005 amendments were enacted in April 2005 (with 
retroactive effect from January 1, 2005), India's patents law stood in its 
current form. No further amendments to the Act have been 
promulgated as of August 2006, although some of the implementing 
Patent Rules have changed.^i 
3.12. References: 
1 Morris, Julian, Rosalind Mowatt, W Duncan Reekie, Richard Tren 
(2002). "Ideal Matter: Globalisation and the Intellectual Property 
Debate" Centre for the New Europe. 
2 World Trade Organisation (WTO) retrieved from www.wto.org on 
July 27, 2007. 
150 
TRIPS and Indian Patent Act, 1970 
3 Chatterjee, Sumana (2007), "Flexibilities under Trips [Compulsory 
Licensing]: The Pharmaceutical Industry in India and Canada", June 14. 
4 World Trade Organization, op.cit. 
5 Watal J. (1998), "The TRIPS Agreement and Developing Countries: 
Strong, Weak, or Balanced Protection," The Journal of World Intellectual 
Property. 
6 Correa, Carlos (2000), "Integrating Public Health Concerns into Patent 
Legislation in Developing Countries", Geneva: South Centre. 
7 Paragraph 4, WTO, "Declaration on the TRIPS Agreement and Public 
Health" Ministerial Conference - Fourth Session, WTO Doc 
WT/MIN(01)/DEC/2 (2001) (Doha Declaration). 
8 Nagesh Kumar, "Intellectual Property Rights, Technology and 
Economic development: Experiences of Asian countries". Study Paper 
IB, Commission on Intellectual Property Rights, Pp.25. 
9 Siddharth, Narrain (2005), "A costly prescription" Frontline, 22 (4), 
Feb 12-25. 
10 Jean O. Lanjouw (1998), "The Introduction of Pharmaceutical Product 
Patents in India: Heartless Exploitation of the Poor and Suffering?" Natl. 
Bureau of Econ. Research, Inc. Working Paper No. 6366, retrieved from 
http://www.dklevine.com/archive/laniouw.pdf on March 2, 2007. 
11 R. Gadbow and Richards, eds. (1988), "Intellectual Property Rights: 
Global Consensus, Global Conflict" Boulder, p. 2 
151 
TRIPS and Indian Patent Act. 1970 
12 Terence P. Stewart, ed., (1993) "The GATT Uruguay Round: A 
Negotiating History 1986-1992" Vol. 2 Commentary, Netherlands, p. 
2255 
13 World Trade Organisation'Understanding the WTO: Least-
Developed Countries', retrieved from 
http: / /www.wto.org/english/thewto e/whatis. e/tif e/org7 e.htm 
on July 15, 2006. 
14 Agreement on Trade-Related Aspects of Intellectual Property Rights 
Annex IC, Art. 65 §2, retrieved from 
http: / / www.wto.org/english/ tratop_e/ trips_e/1 agm2_e.htm on July 
15, 2006. 
15 Ibid. 
16 WTO "WTO fact sheet: TRIPS and Pharmaceutical Patents", 
retrieved from 
http://www.wto.org/english/tratop_e/trips_e/factsheet pharm04 e. 
htm on May 20, 2007. 
17 Text of the Patents (Amendment) Act, 1999, (Act. No. 17 of 1999) 
notified in the Gazette of India on March 26, 1999, retrieved from 
http:/ /patentoffice.nic.in/ipr/patent/patact 99.PDF on Mar. 7, 2007. 
18 Text of the Patents (Amendment) Act, 2002, (Act. No. 38 of 2002) 
notified in the Gazette of India on June 25, 2002 retrieved from 
http: / /patentoffice.nic.in/ ipr/ patent/ patentg.pdf on March 7, 2007. 
19 Text of the Patents (Amendment) Act, 2005, (Act. No. 15 of 2005) 
notified in the Gazette of India on April 5, 2005, retrieved from 
152 
TRIPS and Indian Patent Act, 1970 
http://www.ipindia.nic.in/ipr/patent/patent 2005.pdf on March 7, 
2007. 
20 Sree Nivasa Rao Vepachedu & Martha Rumore (2004), "Patent 
Protection and the Pharmaceutical Industry in the Indian Union" 
Intellectual Property Today, October, Pp.44 
21 The Patents (Amendment) Rules, 2003, 24B(l)(i) (amended 2006), 
retrieved from 
http://patentoffice.nic.in/ipr/patent/patent rules_.2006.pdf 
153 
Chapter-IV 
Impact Assessment of TRIPs on 
Indian Pharmaceutical Industry 
154 
Chapter-IV 
Impact Assessment of TRIPs on Indian 
Pharmaceutical Industry 
4.1. Introduction 
In the preceding chapter an endeavour was made to discuss the 
concept of Intellectual Property Rights. It particularly dealt with the 
overview of TRIPs and Indian Patent Act, 1970 with special reference to 
pharmaceutical's Patents. The present chapter is devoted to study the 
pattern and trends in pharmaceutical production, export, import and 
R&D expenditure of Indian pharmaceutical industry. It also asses the 
impact of TRIPs on Indian pharmaceutical industry. The study has been 
made since economic liberalization in India i.e. from 1991-92 to 2005-06. 
For the purpose of analysis and testing of the hypothesis, the above 
period of Indian pharmaceutical industry has been bifurcated into two 
periods i.e. Pre TRIPs Period and Post TRIPs Period. The Pre TRIPs 
Period (1991-92 to 1998-99) of Indian pharmaceutical industry starts 
immediately after the liberalisation of Indian economy and ends in 
1998-99, when India started amendments in its Patent Act, 1970 towards 
TRIPs compliance. During this period the Indian pharmaceutical 
industry was governed by the Indian Patent Act, 1970 which recognized 
process patent only, and term of patent was 7 years from date of 
Impact Assessment of TRIPs on Indian Pharmaceutical Industry 
application of patent and 5 years from date of grant of patent. The Post 
TRIPs Period (1999-00 to 2005-06) of Indian pharmaceutical industry 
begins from 1999-00 onwards with implementation of TRIPs provisions 
in pharmaceutical sector. Government of India amended Patent Act, 
1970 in 1999, 2002 and finally in 2005 towards TRIPs compliance. 
During this period the Indian Government fully implemented the TRIPs 
provisions in pharmaceutical sector, which recognised product patent 
only and term of patent is 20 years.^ 
4.2. Impact of TRIPs on Pharmaceutical Production 
In order to cater to the testing requirements and to find out clear 
trend in pharmaceutical production (Bulk and formulation) the 
Researcher has done trend analysis in general and period wise in 
particular. Further, Researcher has tested the hypothesis at 1 percent 
level of significance using the Interrupted Time Series model. 
4.2.1. Pattern and Trend in Production of Indian Pharmaceutical 
Industry: Analysis and Interpretations 
This analysis consists of tables and graphs which highlight the 
pattern and trend of pharmaceutical production in general and period 
wise trends in particular. In order to cater to the testing requirements 
and to find out clear trends in total pharmaceutical production, the 
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tables contain total amount, index number, (1991-92 as base year) and 
growth rate. 
Graphs also have been prepared to determine the pattern and 
trends in pharmaceutical production during 1991-92 to 2005-06. The 
data presented in table 4.1 shows continuous increase in pharmaceutical 
production. The index number (1991-92 as base year) which was 100 in 
1991-92 reached up to 946.91 points in 2005-06, it shows that 
pharmaceutical production grew approximately 10 times during 1991-
92 to 2005-06. Figure 4.1 shows that production of Indian 
pharmaceutical industry has an upward increasing trend. The 
Combined Annual Growth Rate (CAGR) 16.39 percent is showing a 
moderate growth during the same period. 
From table 4.1 and figure 4.1, it becomes crystal clear that the 
total pharmaceutical production during the period under review has 
been wavering. Pharmaceutical production registered a phenomenal 
increase during 1992-93 with a growth rate of 25.44 percent and reached 
a level of Rs. 71,500 million. Index number has also turn up at 125.44 
percent corresponding to increase in growth rate during the same year. 
From 1993-94 to 2001-02 the growth rate of pharma production has been 
gradually increased. During this period growth rate has been increased 
from 14.96 to 15.97 percent. From 2002-03 to 2003-04 growth rate shows 
a decreasing trend, the growth rate which was 15.97 percent in 2001-02 
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declined to 15.71 in 2002-03 and 15.32 percent in 2003-04. This 
decreasing trend in growth rate during this period may be due to the 
second amendment in Indian Patent Act, 1970 which increased term of 
patent to 20 years. In 2004-05 growth rate of pharma production again 
increased and reached at 15.69 percent. During 2005-06, the 
pharmaceutical production shows extraordinary growth of 31.71 
percent, during this year production reached at Rs. 550,000 million. The 
index number also touched the highest of 946.91 in the year 2005-06. 
The major cause for this extraordinary growth was an increase in 
production of off-patented drugs by Indian companies to setoff the 
losses from drugs patented elsewhere due to product patent regime 
from January 2005. 
From the table 4.1, it is discernible that during the period 1991-92 to 
2005-06, the average production was amounts to Rs. 211,432.7 million 
with an Average Annual Growth Rate (AAGR) 17.5 percent, the 
maximum production amounts to Rs. 550,000 million was in 2005-06 
with maximum growth rate of 31.71 percent for the referred period. 
Further, the other statistic such as Standard Deviation (SD) and 
Coefficient of Variance (CV) of pharmaceutical production were 
142466.9 and 67.38 respectively whereas SD and CV of growth rate 
were 4.86 and 27.76 respectively during the period under review. 
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Table 4.2 and figure 4.2 present the Pre TRIPs period details with 
regard to pharmaceutical production. This period contains eight years 
starting from 1991-92 to 1998-99. The data presented in table 4.2 shows 
continuous increase in pharmaceutical production during this period. 
The index number (1991-92 as base year) which was 100 in 1991-92 
reached up to 298.7 points in 1998-99, it shows that pharmaceutical 
production grew approximately 3 times during 1991-92 to 1998-99 and 
reached a level of Rs. 170,260 million. Figure 4.2 shows that 
pharmaceutical production has an upward increasing trend. The 
Combined Annual Growth Rate (CAGR) 16.33 percent is showing a 
moderate growth during the same period. 
From table 4.2 and figure 4.2, it is clear that total pharmaceutical 
production during the period under review has been increased with a 
increasing growth rate. Pharmaceutical production registered a 
phenomenal increase during 1992-93 with a growth rate of 25.44 percent 
and reached a level of Rs. 71,500 million. Index number has also turn up 
at 125.44 percent corresponding to increase in growth rate during the 
same year. This may be outcome of economic reforms done by Indian 
Government. From 1993-94 to 1998-99 the growth rate of pharma 
production has been gradually increased. During this period growth 
rate has been increased from 14.96 to 15.89 percent. 
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It is clear from the table 4.2, that average production during Pre 
TRIPs Period was amounts to Rs. 107,333.8 million with a 16.97 percent 
Average Annual Growth Rate (AAGR). Minimum Growth rate of 
production was in 1993-94. The maximum production amounts to Rs. 
170,260 million was in 1998-99 and maximum growth rate 25.44 percent 
was recorded in 1992-93. Further, the other statistic such as Standard 
Deviation (SD) and Coefficient of Variance (CV) of pharmaceutical 
production were 38771.63 and 36.12 percent respectively whereas SD 
and CV of growth rate were 3.76 and 22.15 percent respectively during 
the period under review. 
The trend analysis of Post TRIPs Period (1999-00 to 2005-06) with 
the help of table 4.3 and figure 4.3, shows that pharmaceutical 
production during this period has an upward increasing trend. The 
data presented in Table 5.3 shows continuous increase in 
pharmaceutical production. The index number (1991-92 as base year) 
which was 346.26 in 1999-00 reached up to 946.91 points in 2005-06, it 
shows that pharmaceuticals production grew approximately 2.7 times 
during 1999-00 to 2005-06 and reached a level of Rs. 550,000 million. 
The Combined Annual Growth Rate (CAGR) 17.55 percent is showing a 
moderate growth during the same period. 
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From table 4.3 and figure 4.3, it is clear that growth rate of 
pharmaceutical production during the period under review has been 
wavering. Growth rate shows an increasing trend during 1999-00 to 
2001-02 and decreasing trend during 2002-03 to 2003-04. Growth rate of 
pharmaceutical production which was 15.92 percent in 1999-00 
gradually increased year by year and reached at 15.97 percent in 2001-
02. During 2002-03 to 2003-04 growth rate of production declined and 
turn down a level of 15.32 percent. This decreasing trend in growth rate 
during this period may be due to the second amendment in Indian 
Patent Act, 1970 which increased term of patent to 20 years. In 2005-06 
the pharmaceutical production shows surprising growth of 31.71 
percent, during this year production reached at Rs. 550,000 million. The 
index number also touched the highest of 946.91 in the year 2005-06. 
The major cause for this surprising growth was increase in production 
of off-patented drugs by Indian companies to setoff the losses from 
drugs patented elsewhere due to product patent regime from January 
2005. 
It is clear from the Table 4.3 that average production during Post 
TRIPs Period was amounts to Rs. 330,402.9 million with an Average 
Annual Growth Rate (AAGR) of 17.5528 percent. Minimum Growth 
rate of production was recorded in 2003-04 and maximum growth rate 
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was in 2005-06. Further, the other statistic such as Standard Deviation 
(SD) and Coefficient of Variance (CV) of pharmaceutical production 
were 121,011.6 and 36.62 percent respectively whereas SD and CV of 
growth rate were 6.03 and 33.44 percent respectively during the period 
under review. 
A comparative analysis of Pre TRIPs period and Post TRIPs 
period shows that Post TRIPs period has Average, Combined Annual 
Growth Rate (CAGR) and AAGR higher than of the Pre TRIPs period. It 
means production of pharmaceutical has been increased with a higher 
growth rate in Post TRIPs period compare to the Pre TRIPs period. 
Coefficient of Variance (CV) of growth rate 22.15 percent in Pre TRIPs 
period is less than to 33.44 percent in Post TRIPs period shows that Pre 
TRIPs has stable growth rate in comparison to Post TRIPs period. 
4.2.2. Testing of Hypothesis 
The following paragraphs are devoted to test the first hypothesis 
of the study: 
"The Null Hypothesis of the study (Ho)^ assumes that there is no 
significant impact of TRIPs regime on production of Indian 
pharmaceutical industry whereas the alternative Hypothesis of the 
study (Hi) assumes that there is a significant impact of TRIPs regime 
on production of Indian pharmaceutical industry." 
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The Researcher has prepared dummy variable to find out the 
impact of the TRIPs Agreement on pharmaceutical production for the 
period from 1991-92 to 2005-06. The dummy variable is assumed 
keeping in view that there are two periods, i.e. Pre TRIPs (Pre-
Intervention) Period and the Post TRIPs (Post-Intervention) period. To 
test the hypothesis the Researcher assumed Production as dependent 
variables whereas Time, Dummy and Post-Intervention variables as 
independent variables. Further, the Researcher used a mathematical 
linear function that lends itself to statistical analysis by means of a 
general linear regression model (or ordinary least squares (OLS) 
multiple regression methods) to assess the impact of the invention 
variables (TRIPs regime) on the dependent variable (Production). The 
interrupted time series design can be represented by the following 
general regression model: 
Y = d + PiXi + P2X2 + P3X3+ E 
Where Y is the dependent variable, measured annually; Xi is a 
time counter (continuous) variable indicating time in years from the 
beginning of the observation period. The value of this variable is coded 
1 for the first year in the series, 2 for the second year, 3 for the third 
year, and so forth until the last year in the series. X2 (intervention) is a 
dummy predictor variable indicating for time before policy intervention 
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and after time intervention (coded 0 for all observations before 
intervention, and coded 1 for all observations after intervention. 
Table 4.4 
Application of Time, Dummy and Post-Intervention Variable in 
Pharmaceutical Production (1991-92 to 2005-06) 
Years 
1991-92 
1992-93 
1993-94 
1994-95 
1995-96 
1996-97 
1997-98 
1998-99 
1999-00 
2000-01 
2001-02 
2002-03 
2003-04 
2004-05 
2005-06 
Production in 
Million 
Indian Rs. 
57,000 
71,500 
82,200 
94,530 
109,470 
126,800 
146,910 
170,260 
197,370 
228,870 
265,430 
307,140 
354,210 
409,800 
550,000 
Time 
Xi 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Dummy 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
1 
Post 
Intervention 
X3 
0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
3 
4 
5 
6 
7 
Source: Same as table 4.1 
Xs (post-policy intervention) indicates a continuous predictor 
variable representing the years after intervention (coded 0 during the 
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pre-intervention period, and 1, 2, 3, and so on until all the post-policy 
intervention observations are accounted. Last, E denotes the error of the 
model i.e., residuals unexplained by the model. 
This interrupted time series model contains a constant a, and 
three coefficients — pi, ^2 and ^3. The constant a, estimates the intercept 
at time zero; Pi, estimates the annual change in pharmaceutical 
production before TRIPs; Pi, measures any immediate or short-term 
effects of TRIPs regime; and P3 estimates the trend or slope of the 
observations during the Post-Intervention period, i.e. it measures any 
long-term effects of TRIPs regime on production of Indian 
pharmaceutical industry. 
Table 4.4 provides a critical analysis regarding the model. By 
applying the multiple regressions on the Production, Time, Dummy 
and Post-Intervention variables (Table 4.4) the following summary of 
table emerges: 
Table 4.5 
Model Summary 
R 
.988 
R Square 
.976 
Adjusted R 
Square 
.970 
Standard 
Error of the 
Estimate 
24794.2359 
Source: Table 4.4 
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It has been seen that from the model summary ( Table 4.5) the 
Coefficient of Determination i.e. R-square stood at 97.6 percent which 
means that whatever changes have happened in the total 
pharmaceutical production during the period under review the time 
and invention variables (TRIPs regime) are responsible up to 97.6 
percent. This implies that there are a few other micro and macro 
economic factors which have indirectly affected the production of 
Indian pharmaceutical industry. 
Table 4.6 
Coefficients 
a 
(Constant) 
Xi 
(Time) 
(Dummy) 
X3 
(Post 
Intervention) 
Unstandardized 
Coefficients 
B 
36693.929 
15697.738 
-47377.3 
38178.333 
Std. Error 
19319.513 
3825.834 
26367.739 
6049.174 
Standardized 
Coefficients 
P 
Beta 
-
.493 
-.172 
.671 
t 
1.899 
4.103 
-1.797 
6.311 
Sig. 
.084 
.002 
.100 
.000 
Source: Table 4.4 
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The t- static of the time i.e. 4.103, is significant at 0.2 percent level 
of significance and the t-static of dummy variable X2 i.e. for immediate 
impact of TRIPs regime is -1.797, which is insignificant up to 10 percent 
level of significance; i.e. far beyond the level of significance. But in case 
of Post-Intervention variable X3 i.e. for impact of TRIPs regime in long 
run the t-static is 6.311, which is significant at any percent level of 
significance. Therefore, Null Hypothesis of the study (Ho) is rejected 
and alternative hypothesis is accepted. Hence, TRIPs Agreement has 
significant impact on production of Indian pharmaceutical industry in 
the long run. 
In essence, TRIPs Agreement has no immediate significant impact 
on the production of Indian pharmaceutical industry. But, in the long 
run TRIPs Agreement has significant impact on the production of 
Indian pharmaceutical industry. From the Table 4.6, Positive value of 
Coefficient of Post-Intervention variable (X3) suggests that under the 
TRIPs regime the production of Indian pharmaceutical industry has 
grown more compare to the Pre TRIPs regime growth. 
4.3. Impact of TRIPs on Pharmaceutical Export 
In order to cater to the testing requirements and to find out clear 
trend in pharmaceutical Export (Bulk and formulation) the Researcher 
has done trend analysis in general and period wise in particular. 
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Further, Researcher has tested the hypothesis at 1 percent level of 
significance using the Interrupted Time Series model. 
4.3.1. Pattern and Trend in Export of Indian Pharmaceutical Industry: 
Analysis and Interpretations 
Tables and graphs have been prepared to determine the pattern 
and trend in total pharmaceutical export during 1991-92 to 2005-06. In 
order to cater to the testing requirements and to find out clear trends in 
total pharmaceutical export, the tables contain total amount, index 
number, (1991-92 as base year) and growth rate. 
The data presented in table 4.7 shows continuous increase in 
pharmaceutical export. The index number (1991-92 as base year) which 
was 100 in 1991-92 reached up to 1684.41 points in 2005-06, it shows that 
pharmaceutical export grew approximately 17 times during 1991-92 to 
2005-06. Figure 4.4 shows an upward increasing trend in total 
pharmaceutical export. The Combined Annual Growth Rate (CAGR) 
22.54 percent is showing a high growth during the same period. 
From table 4.7 and figure 4.4, it becomes crystal clear that growth 
rate of pharmaceutical export during the period under review has been 
wavering. Pharmaceutical export registered an extraordinary increase 
during 1995-96 with a growth rate of 45.46 percent and reached a level 
of Rs. 31,777 million. Index number has also turn at 248.05 point 
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corresponding to increase in growth rate during the same year. During 
1996-97 to 1999-00, the growth rate of pharma export declined and 
reached at 14.74 percent. This may be due to the implementation of 
TRIPs Agreement by developed world which prevent the import of 
generic version of patented drugs from other countries like India. From 
2000-01 to 2001-02 growth rate of export has been increased, growth 
rate which was 14.74 percent in 1999-00 reached at 20.99 percent in 
2001-02. During 2002-03 to 2004-05, growth rate of pharmaceutical 
export again declined, growth rate which was 20.99 in 2001-02 declined 
to 19.99 in 2003-04 and 16.42 percent in 2004-05. In 2005-06 growth rate 
of pharmaceutical export has been increased and reached at 29.36 
percent. Pharmaceutical export touched a level of Rs. 215,789.6 million 
during the same year. The major cause for this high growth of 
pharmaceutical export in 2005-06 was the outcome of high production 
of pharmaceutical during this year. 
Further analysis of table 4.7 presents that during the 1991-92 to 
2005-06, average export of pharmaceutical was Rs. 76,381.57 million 
with an Average Annual Growth Rate (AAGR) of 22.61 percent. Other 
statistic such as Standard Deviation (SD) and Coefficient of Variance 
(CV) of pharmaceutical export were 61,552.16 and 80.58 respectively 
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whereas SD and CV of pharmaceutical export growth rate were 8.54 
and 37.78 respectively. 
Table 4.8 with figure 4.5 present the Pre TRIPs period details with 
regard to pharmaceutical export. This period contains eight years 
starting from 1991-92 to 1998-99. The data presented in table 4.8 shows 
continuous increase in pharmaceutical export. The index number (1991-
92 as base year) which was 100 in 1991-92 reached up to 466.15 points in 
1998-99, it shows that pharmaceuticals export grew approximately 4.6 
times during 1991-92 to 1998-99 and reached a level of Rs. 59,718 
million. Figure 4.5 shows that export of pharmaceutical has an upward 
increasing trend. The Combined Annual Growth Rate (CAGR) 27.04 
percent is showing a high growth during the same period. 
From table 4.8 and figure 4.5, it is clear that the pharmaceutical 
export during the period under review has been increased with an 
unsteady growth rate. Pharmaceutical export registered an 
extraordinary increase during 1995-96 with a growth rate of 45.46 
percent and reached a level of Rs. 31,777 million. Index number has also 
turn up at 248.5 point corresponding to increase in growth rate during 
the same year. This may be due to the implementation of TRIPs 
Agreement by developed world which prevent the import of generic 
version of patented drugs from other countries like India. 
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From 1996-97 to 1998-99, the growth rate of pharmaceutical export 
declined from 28.37 to a level of 16.15 percent. 
Table 4.8 presents that in Pre TRIPs period average export was 
amounts to Rs. 31,284.88 million with an Average Annual Growth Rate 
(AAGR) of 25 percent. Further, other statistic such as Standard 
Deviation (SD) and Coefficient of Variance (CV) of pharmaceutical 
export were 17,773.94 and 56.81 percent respectively whereas SD and 
CV of pharmaceutical export growth rate were 11.10 and 44.39 percent 
respectively. 
The trend analysis of Post TRIPs Period (1999-00 to 2005-06) with 
the help of table 4.9 and figure 4.6, shows that pharmaceutical export 
during this period has an upward increasing trend. The data presented 
in Table 5.9 shows continuous increase in pharmaceutical export. The 
index number (1991-92 as base year) which was 534.85 in 1999-00 
reached up to 1684.41 points in 2005-06, it shows that pharmaceutical 
export grew more than 3 times during 1999-00 to 2005-06 and reached a 
level of Rs. 215,789.6 million.. The Combined Annual Growth Rate 
(CAGR) 20.50 percent is showing a high growth in pharmaceutical 
export during the same period. 
From table 4.9 and figure 4.6, it is clear that growth rate of 
pharmaceutical production during the period under review has an 
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unsteadiness. Growth rate shows an increasing trend during 1999-00 to 
2001-02 and decreasing trend during 2002-03 to 2004-05, growth rate 
which was 14.74 percent in 1999-00 has been gradually increased year 
by year and reached at 20.99 percent in 2001-02. During 2002-03 to 2004-
05 growth rate of pharmaceutical export declined and turn down a level 
of 16.62 percent. This decreasing trend in pharmaceutical export growth 
rate during this period may be due to the decline in pharmaceutical 
production during the same period. In 2005-06 the pharmaceutical 
export shows surprising growth of 20.36 percent, during this year 
export reached at Rs. 215,789.6 million. The index number also touched 
the highest of 1684.41 in year 2005-06. This surprising growth was due 
to increase in production of off-patented drugs by Indian companies to 
setoff the losses from drugs patented elsewhere due to product patent 
regime from January 2005. 
It is clear from the Table 4.9 that average production during Post 
TRIPs period was amounts to Rs. 127,920.7 million with an Average 
Annual Growth Rate (AAGR) of 20.21 percent. Minimum Growth rate 
of pharmaceutical export 14.74 was recorded in 1999-00 and maximum 
growth rate 29.36 was recorded in 2005-06. Further, other statistic such 
as Standard Deviation (SD) and Coefficient of Variance (CV) of 
pharmaceutical export were 51,585.41 and 40.33 percent 
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respectively whereas SD and CV of pharmaceutical export growth rate 
were 4.63 and 22.92 percent respectively. 
A comparative analysis of Pre TRIPs period and Post TRIPs 
period shows that Post TRIPs period has an Average export more than 
to Pre TRIPs period. Combined Annual Growth Rate (CAGR) and 
AAGR are higher in Pre TRIPs period compare to Post TRIPs period. It 
means growth rate of pharmaceutical export declined in Post TRIPs 
period. Coefficient of Variance (CV) of growth rate 22.92 percent in Post 
TRIPs period is less than to 44.39 percent in Pre TRIPs period shows 
that Post TRIPs has stable growth rate in comparison to Pre TRIPs 
period. 
4.3.2. Testing of Hypothesis 
The following paragraphs are devoted to test the second 
hypothesis of the study: 
"The Null Hypothesis of the study (Ho) assumes that there is 
no significant impact of the TRIPs regime on export of Indian 
pharmaceuticals industry whereas the alternative Hypothesis of the 
study (H2) assumes that there is a significant impact of TRIPs regime 
on export of Indian pharmaceuticals industry." 
The Researcher has prepared dummy variable to find out the 
impact of the TRIPs Agreement on the total Export of Indian 
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pharmaceutical industry for the period from 1991-92 to 2005-06. The 
dummy variable is assumed keeping in view that there are two periods, 
i.e. Pre TRIPs (Pre-Intervention) Period and the Post TRIPs (Post-
Intervention) period. To test the hypothesis the Researcher assumed 
Export as dependent variables whereas Time, Dummy and Post-
Intervention variables as independent variables. Further, the 
Researcher used a mathematical linear function that lends itself to 
statistical analysis by means of a general linear regression model (or 
ordinary least squares (OLS) multiple regression methods) to assess the 
impact of the invention variables (TRIPs regime) on the dependent 
variable (Export). The interrupted time series design can be represented 
by the following general regression model: 
Y = d + PiXi + P2X2 + P3X3+ E 
Where Y is the dependent variable measured annually; Xi is a 
time counter (continuous) variable indicating time in years from the 
beginning of the observation period. The value of this variable is coded 
1 for the first year in the series, 2 for the second year, 3 for the third 
year, and so forth until the last year in the series. X2 (intervention) is a 
dummy predictor variable indicating for time before policy intervention 
and after time intervention (coded 0 for all observations before 
intervention, and coded 1 for all observations after intervention. X3 
186 
Impact Assessment of TRIPs on Indian Pharmaceutical Industry 
(post-policy intervention) indicates a continuous predictor variable 
representing the years after intervention (coded 0 during the pre-
intervention period, and 1, 2, 3, and so on until all the post-policy 
intervention observations are accounted. Last, E denotes the error of the 
model i.e., residuals unexplained by the model. 
Table 4.10 
Application of Time, Dummy and Post-Intervention Variables in 
Pharmaceutical Export (1991-92 to 2005-06) 
Years 
1991-92 
1992-93 
1993-94 
1994-95 
1995-96 
1996-97 
1997-98 
1998-99 
1999-00 
2000-01 
2001-02 
2002-03 
2003-04 
2004-05 
2005-06 
Export in 
Million Indian 
Rs. 
12,811 
14,103 
17,814 
21,847 
31,777 
40,793 
51,416 
59,718 
68,520 
82,224 
99,485 
119,374 
143,242 
166,810 
215,789.6 
Time 
Xi 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Dummy 
X2 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
1 
Post 
Intervention 
X3 
0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
3 
4 
5 
6 
7 
Source: Same as table 4.7 
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This interrupted time series model contains a constant a, and 
three coefficients — ^i, P2 and P3. The constant a , estimates the intercept 
at time zero; Pi, estimates the annual change in Export before TRIPs 
Agreement; Pi, measures any immediate or short-term effects of TRIPs 
regime; and P3 estimates the trend or slope of the observations during 
the Post TRIPs (Post-Intervention) period, i.e. it measures any long-term 
effects of TRIPs regime on Export of Indian pharmaceutical industry. 
Table 4.10 provides a critical analysis regarding the model. By 
applying the multiple regressions on the Export, Time, Dummy and 
Post-Intervention variables the following summary of table emerges: 
Table 4.11 
Model Summary 
R 
.993 
R Square 
.986 
Adjusted R 
Square 
.982 
Standard 
Error of the 
Estimate 
8361.1537 
Source: Table 4.10 
It has been seen that from the model summary (Table 4.11) the 
coefficient of determination i.e. R-square stood at 98.2 percent which 
means that whatever changes have happened in the total Export during 
the period under review the time and invention variables (TRIPs 
regime) are responsible up to 98.2 percent. This implies that there are a 
very few other micro and macro economic factors which have indirectly 
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affected the Export of Indian pharmaceutical industry. The high value 
of Coefficient of Determination (R Square) .982 indicates that 98.2 
percent of the variations are explained by this model. 
From the table 4.12, the t- static of the time i.e. -.081, is significant 
at any percent level of significance and the t-static of dummy variable 
X2 i.e. for immediate impact of TRIPs regime is -2.434, which is 
insignificant at 1 percent level of significance. But in case of Post-
Intervention variable X3 i.e. for impact of TRIPs regime in long run the 
t-static is 7.998, which is significant at any percent level of significance. 
Table 4.12 
Cofficients 
a 
(Constant) 
Xi 
(Time) 
X2 
(Dummy) 
X3 
(Post 
Intervention) 
Unstandardized 
Cofficients 
B 
-524.821 
7068.821 
-21639.1 
16314.671 
Std. 
Error 
6514.958 
1290.154 
8891.773 
2039.913 
Standardized 
Cofficients 
Beta 
P 
-
.514 
-.182 
.664 
t 
-.081 
5.479 
-2.434 
7.998 
Sig. 
.937 
.000 
.033 
.000 
Source: Table 4.10 
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Therefore, Null Hypothesis of the study (Ho) is rejected and alternative 
hypothesis is accepted. TRIPs has significant impact on export of Indian 
pharmaceutical industry in the long run. 
In essence, TRIPs Agreement has no immediate significant impact 
on the export of Indian pharmaceutical industry. But, in the long run 
TRIPs Agreement has significant impact on the export of Indian 
pharmaceutical industry. From Table 4.12, positive value of Coefficient 
of Post-Intervention variable (X3) suggests that TRIPs Agreement has 
increased the export of Indian pharmaceutical industry in the long run. 
On the other hand, under the TRIPs regime the export of Indian 
pharmaceutical industry has grown more compare to the Pre TRIPs 
regime growth. 
4.4. Impact of TRIPs on Pharmaceutical Import 
In order to cater to the testing requirements and to find out clear 
trend in pharmaceutical import (Bulk and formulation) the Researcher 
has done trend analysis in general and period wise in particular. 
Further, Researcher has tested the hypothesis at 1 percent level of 
significance using the Interrupted Time Series model. 
4.4.1. Pattern and Trend in Import of Indian Pharmaceutical Industry: 
Analysis and Interpretations 
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Tables and graphs have been prepared to determine the pattern 
and trend in total pharmaceutical import during 1991-92 to 2005-06. In 
order to cater to the testing requirements and to find out clear trends in 
total pharmaceutical import, the tables contain total amount, index 
number, (1991-92 as base year) and growth rate. 
The data presented in table 4.13 shows continuous increase in 
pharmaceutical import during 1991-92 to 1998-99 and sudden downfall 
in 1999-00. The index number (1991-92 as base year) which was 100 in 
1991-92 reached up to 559.24 points in 2005-06, it shows that 
pharmaceutical import grew approximately 5.5 times during 1991-92 to 
2005-06 and reached from a level of Rs. 8,073.8 to a level of Rs. 45,152.2 
during the same period. Figure 4.7 shows upward increasing trend in 
pharmaceutical import. The Combined Annual Growth Rate (CAGR) 
8.88 percent is showing a law growth during the same period. 
From table 5.13 and figure 4.7, it becomes crystal clear that the 
pharmaceutical import during the period under review has been 
wavering. From the initial study years of 1991-92 to 1998-99, the 
phenomenal increase has been registered with a growth rate of 40.87 
percent in 1992-93 and 86.73 percent in 1995-96. The maximum increase 
in pharmaceutical import was registered just after establishment of 
WTO. In the year 1999-00 the pharmaceutical import plummeted to Rs. 
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16,162.1 million registering a negative growth of 48.33 percent. Index 
number has also declined to 200.18 percent corresponding to the 
decrease in growth rate. There are many reasons for this slump in 
pharmaceutical import. However, the noticeable reasons are attributed 
to first amendment in Indian Patent Act, 1970, political upheavals and 
instability at the centre and also the financial crisis in the Newly 
Industrialized Economies which covertly affected Indian economy too. 
From 2000-01, the recovery period in pharmaceutical import is 
discernible. Pharmaceutical import has been increased from a level of 
Rs. 16,162.1 million in 1999-00 to a level of Rs. 17,014.6 million in 2000-
01, registering an increase of 5.27 percent over the year. The succeeding 
years starting from 2001-02 to 2002-03 went into positive growth in the 
range of 17.61 percent to 43.18 percent. The major cause for this high 
growth of pharmaceutical import may be ascribed to the passing of 
Indian Patent Amendment Act, 2002 by Indian Government which 
increased term of patent to 20 years. 2003-04 to 2004-05, the span of two 
years has shown a very law growth in pharmaceutical import. In 2005-
06 pharmaceutical import shows a remarkable growth and reached a 
level of Rs. 45,152.2 with a growth rate of 42.46 percent. The index 
number also peaked at this year to the tune of 559.24. Remarkable 
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growth in pharmaceutical import in 2005-06 is an outcome of passing 
Indian Patent Amendment Act, 2005 which introduced product patent 
in pharmaceutical sector. 
Further analysis of table 4.13 presents that during 1991-92 to 
2005-06 average import of pharmaceutical was Rs. 22,874.45 million 
with an Average Annual Growth Rate (AAGR) of 17.04 percent. 
Further, other statistic such as Standard Deviation (SD) and Coefficient 
of Variance (CV) of pharmaceutical import were 10,060.74 and 43.98 
percent respectively whereas SD and CV of pharmaceutical import 
growth rate were 30.25 and 177.5 percent respectively during the period 
under review. 
Table 4.14 with figure 4.8 present the Pre TRIPs period (from 
1991-92 to 1998-99) details with regard to pharmaceutical import. This 
period contains eight years starting from 1991-92 to 1998-99. The data 
presented in table 4.14 shows continuous increase in pharmaceutical 
import. The index number (1991-92 as base year) which was 100 in 1991-
92 reached up to 387.42 points in 1998-99, it shows that pharmaceutical 
export grew approximately 4 times during 1991-92 to 1998-99 and 
reached from a level of Rs. 8,073.8 million to a level of Rs. 31,280 
million. Figure 4.8 show that pharmaceutical import has an upward 
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increasing trend. The Combined Annual Growth Rate (CAGR) is 22.55 
percent showing a high growth during the same period. 
From table 4.14 and figure 4.8, it is clear that pharmaceutical 
import during the period under review has been increased with an 
unsteady growth rate. Pharmaceutical import has registered a 
remarkable growth during 1992-93 with a growth rate of 40.87 percent 
and reached a level of Rs. 11,373.8 million. Index number has also turn 
up to a level of 140.87 point corresponding to increase in growth rate 
during the same year. This remarkable growth in pharmaceutical 
import may be result of liberalisation of Indian economy in 1991. 
During 1993-94 to 1994-95, pharmaceutical import confirms a very low 
growth. In 1995-96 phenomenal increase in growth of pharmaceutical 
import was registered. Pharmaceutical import reached a level of Rs. 
24,050 million with 86.73 percent growth rate in 1995-96 due to 
establishment of WTO. Succeeding three year 1996-97 to 1998-99 
recorded a pharmaceutical import growth between 8.36 to 10.07 
percent. 
Table 4.14 presents that in Pre TRIPs period average import was 
amounts to Rs. 19,358.14 million with an Average Annual Growth Rate 
(AAGR) of 24 percent. Further, other statistic such as Standard 
Deviation (SD) and Coefficient of Variance (CV) of pharmaceutical 
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import were 9,089.35 and 46.95 percent respectively whereas SD and CV 
of pharmaceutical import growth rate were 30.35 and 126.44 percent 
respectively during the period under review. 
The trend analysis of Post TRIPs Period (1999-00 to 2005-06) with 
the help of table 4.15 and figure 4.9, show that pharmaceutical import 
during this period has an upward increasing trend. The data presented 
in Table 5.15 shows continuous increase in pharmaceutical import. The 
index number (1991-92 as base year) which was 200.18 in 1999-00 
reached up to 559.24 points in 2005-06, it shows that pharmaceutical 
import grew more than 2.5 times during 1999-00 to 2005-06 and reached 
from a level of Rs. 16,162.1 million to a level of Rs. 45,152.2 million. The 
Combined Armual Growth Rate (CAGR) 18.34 percent is showing a 
moderate growth during the same period. 
From the table 4.15 and figure 4.9, it is clear that growth rate of 
pharmaceutical import during the period under review has been 
wavering. Pharmaceutical import shows a negative growth of 48.33 
percent in 1999-00 due to first amendment in Indian Patent Act, 1970 
toward TRIPs compliance. During 2000-01 to 2002-03 growth of 
pharmaceutical import shows an upward increasing trend, growth rate 
which was 5.27 percent in 2002-01 reached at 43.8 percent in 2002-03. 
Remarkable growth in import of pharmaceutical in 2002-03 may be due 
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to the passing of Patent Amendment Act, 2002 by Indian Government 
according to TRIPs compliance, which increased term of patent to 20 
years. In the succeeding year 2003-04 and 2004-05 growth of 
pharmaceutical import was recorded between 3.19 to 7.19 percent. In 
2005-06 the pharmaceutical import again shows surprising growth of 
42.46 percent, during this year import reached at Rs. 45,152.2 million. 
The index number also touched the highest of 559.24 during 2005-06. 
This surprising growth in pharmaceutical import was due to the 
product patent regime from January 2005 which prevents 
manufacturing generic version of patented drugs. 
It is clear from the Table 4.15 that average import of 
pharmaceutical during Post TRIPs Period was amounts to Rs. 26,893.1 
million with an Average Annual Growth Rate (AAGR) of 10.08 percent. 
Minimum Growth rate of pharmaceutical import -48.33 was recorded in 
1999-00 and maximum growth rate 43.18 was in 2002-03. Further, other 
statistic such as Standard Deviation (SD) and Coefficient of Variance 
(CV) of pharmaceutical import were 10220.74 and 38 percent 
respectively whereas SD and CV of pharmaceutical import growth rate 
were 30.80 and 305.5 percent respectively during the period under 
review. 
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Impact Assessment of TRIPs on Indian Pharmaceutical Industry 
A comparative analysis of Pre TRIPs period and Post TRIPs 
period shows that Post TRIPs period has Average import more than to 
Pre TRIPs period. Combined Annual Growth Rate (CAGR) and AAGR 
are higher in Pre TRIPs period compare to Post TRIPs period. It means 
growth of pharmaceutical import has been decreased in Post TRIPs. 
Coefficient of Variance (CV) of pharmaceutical import growth rate in 
Post TRIPs period is more than to Pre TRIPs period, it shows that Post 
TRIPs period has instable growth rate in comparison to Pre TRIPs 
period. 
4.4.2. Testing of Hypothesis 
The following paragraphs are devoted to test the third hypothesis 
of the study: 
"The Null Hypothesis of the study (Ho) assumes that there is 
no significant impact of the TRIPs regime on import of the Indian 
pharmaceutical industry whereas the alternative Hypothesis of the 
study (H2) assumes that there is a significant impact of the TRIPs 
regime on import of the Indian pharmaceutical industry." 
The Researcher has prepared dummy variable to find out the 
impact of the TRIPs Agreement on the total pharmaceutical import for 
the period from 1991-92 to 2005-06. The dummy variable is assumed 
keeping in view that there are two periods, i.e. Pre TRIPs (Pre-
Intervention) Period and the Post TRIPs (Post-Intervention) period. To 
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test the hypothesis the Researcher assumed Import as dependent 
variables whereas Time, Dummy and Post-Intervention variables as 
independent variables. Further, the Researcher used a mathematical 
linear function that lends itself to statistical analysis by means of a 
general linear regression model (or ordinary least squares (OLS) 
multiple regression methods) to assess the impact of the invention 
variables (TRIPs regime) on the dependent variable (Import). The 
interrupted time series design can be represented by the following 
general regression model: 
Y = d + piXi + P2X2 + P3X3+ E 
Where Y is the dependent variable measured annually; Xi is a time 
counter (continuous) variable indicating time in years from the 
beginning of the observation period. The value of this variable is coded 
1 for the first year in the series, 2 for the second year, 3 for the third 
year, and so forth until the last year in the series. X2 (intervention) is a 
dummy predictor variable indicating for time before policy intervention 
and after time intervention (coded 0 for all observations before 
intervention, and coded 1 for all observations after intervention. X3 
(post-policy intervention) indicates a continuous predictor variable 
representing the years after intervention (coded 0 during the pre-
intervention period, and 1, 2, 3, and so on until all the post-policy 
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intervention observations are accounted. Last, E denotes the error of the 
model i.e., residuals unexplained by the model. 
Table 4.16 
Application of Time, Dummy and Post-Intervention Variables in 
Pharmaceutical Import (1991-92 to 2005-06) 
Years 
1991-92 
1992-93 
1993-94 
1994-95 
1995-96 
1996-97 
1997-98 
1998-99 
1999-00 
2000-01 
2001-02 
2002-03 
2003-04 
2004-05 
2005-06 
Import in 
Million 
Indian Rs. 
8,073.8 
11,373.8 
11,665.3 
13,687.2 
24,050 
26,055 
28,680 
31,280 
16,162.1 
17,014.6 
20,011 
28,652 
29,566.3 
31,693.5 
45,152.2 
Time 
Xi 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Dummy 
X2 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
1 
Post 
Intervention 
Variable 
X3 
0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
3 
4 
5 
6 
7 
Source: Same as table 4.13 
This interrupted time series model contains a constant a, and 
three coefficients - pi, p2 and p3. The constant a , estimates the intercept 
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at time zero; (3i, estimates the annual change in Pharmaceutical Import 
before TRIPs; Pi, measures any immediate or short-term effects of TRIPs 
regime; and P3 estimates the trend or slope of the observations during 
the Post-Intervention period, i.e. it measures any long-term effects of 
TRIPs regime on Import of Indian pharmaceutical industry. 
Table 4.16 provides a critical analysis regarding the model. By 
applying the multiple regressions on the Production, Time, Dummy 
and Post-Intervention variables the following summary of table 
emerges: 
Table 4.17 
Model Summary 
R 
.966 
R Square 
.933 
Adjusted R 
Square 
.915 
Standard 
Error of the 
Estimate 
2930.1188 
Source: Table 4.16 
It has been seen that from the model summary (Table 4.17) the 
Coefficient of Determination i.e. R-square stood at 91.5 percent which 
means that whatever changes have happened in the total 
pharmaceutical import during the period under review the time and 
invention variables (TRIPs regime) are responsible up to 91.5 percent. 
This implies that there are a few other micro and macro economic 
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factors which have indirectly affected the Import of Indian 
pharmaceutical industry. The high value of Coefficient of 
Determination (R Square) .912 indicates that 91.2 percent of the 
variations are explained by this model. 
Table 4.18 
Cofficients 
a 
(Constant) 
(Time) 
X2 
(Dummy) 
X3 
(Post 
Intervention) 
Unstandardized 
Cofficients 
6 
3152.443 
3601.265 
-23052.8 
894.570 
Std. 
Error 
2283.130 
452.127 
3116.071 
714.876 
Standardized 
Cofficients 
Beta 
P 
-
1.601 
-1.183 
.223 
t 
1.381 
7.965 
-7.398 
1.251 
Sig. 
.195 
.000 
.000 
.237 
Source: Table 4.16 
The t- static of the time i.e. 4.103, is significant at any percent level 
of significance and the t-static of dummy variable X2 i.e. for immediate 
impact of TRIPs regime is -7.398, which is significant at any percent 
level of significance. But in case of Post-Intervention variable X3 i.e. for 
impact of TRIPs regime in long run the t-static is .223 insignificant at 1 
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percent level of significance. Therefore, Null Hypothesis of the study 
(Ho) is rejected and alternative hypothesis is accepted. In case of Post-
Intervention variable X3 i.e. for impact of TRIPs regime in long run the 
t-static is 1.251, which is insignificant at 1 percent level of significance. 
Hence TRIPs has affected the import of Indian pharmaceutical industry 
in short term. 
In essence, TRIPs Agreement has immediate significant impact on 
import of Indian pharmaceutical Industry. From Table 4.18, negative 
value of Coefficient of dummy (intervention) variable (X2) suggests that 
TRIPs Agreement has decreased the import of Indian pharmaceutical 
industry in the short run. But, in the long run TRIPs Agreement has no 
significant impact on the import of Indian pharmaceutical industry. 
4.5. Impact of TRIPs on Pharmaceutical R&D 
Expenditure 
In order to cater to the testing requirements and to find out clear 
trend in pharmaceutical R&D expenditure the Researcher has done 
trend analysis in general and period wise in particular. Further, 
Researcher has tested the forth and last hypothesis regarding the R&D 
expenditure at 1 percent level of significance using the Interrupted Time 
Series model. 
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4.5.1. Pattern and Trend in R&D Expenditure of Indian 
Pharmaceutical Industry: Analysis and Interpretations 
This analysis consists of tables and graphs which highlight the 
pattern and trend of R&D expenditure of Indian pharmaceutical 
industry in general and period wise trends in particular. Graphs also 
have been prepared to determine the pattern and trends in R&D 
expenditure during 1991-92 to 2005-06. In order to cater to the testing 
requirements and to find out clear trends in total pharmaceuticals R&D 
expenditure, the tables contain total amount, index number, (1991-92 as 
base year) and growth rate. 
The data presented in table 4.19 shows continuous increase in 
R&D expenditure of Indian pharmaceutical industry. The index number 
(1991-92 as base year) which was 100 in 1991-92 reached up to 2740.5 
points in 2005-06, it shows that R&D expenditure grew approximately 
27.5 times during 1991-92 to 2005-06 and touched a level of Rs. 21,924 
million. Figure 4.10 shows that R&D expenditure of pharmaceutical 
industry has an upward increasing trend. The Combined Annual 
Growth Rate (CAGR) 24.84 percent is showing a high growth in R&D 
expenditure during the same period. 
From table 4.19 and figure 4.10, it becomes crystal clear that the 
R&D expenditure during the period under review has been increased 
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with an increasing growth rate. R&D expenditure registered a 
phenomenal increase during 1993-94 with a growth rate of 32.08 percent 
and reached a level of Rs. 125,071 million. Index number has also turn 
up at 156.85 points corresponding to the increase in growth rate during 
the same year. From 1994-95 to 2001-02 the growth rate of R&D 
expenditure remained between 11.57 and 23.02 percent. Span of three 
years 2002-03 to 2004-05 shows a remarkable increase in growth rate of 
R&D expenditure, this period maintained a higher growth rate between 
54.48 and 59.96 percent. In 2005-06 R&D expenditure touched a level of 
Rs. 21,924 million with a growth rate of 30.04 percent. Remarkable 
growth in R&D expenditure of Indian pharmaceutical industry from 
2002-03 and onwards was the outcome of Indian Patent Amendment 
Act, 2002 and Indian Patent Amendment Act, 2005 towards TRIPs 
compliance. These amendments fully implemented the TRIPs 
provisions in pharmaceutical sector. Therefore, Indian companies 
increased their R&D budget to develop new drugs. 
From table 4.19, it is discernible that during 1991-92 to 2005-06 the 
average R&D expenditure was amounts to Rs. 5,329.6 million with an 
Average Annual Growth Rate (AAGR) of 27.64 percent. The other 
statistics such as Standard Deviation (SD) and Coefficient of Variance 
(CV) of R&D expenditure were 6,327.95 and 118.73 percent respectively 
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whereas SD and CV of R&D expenditure growth rate were 16.95 and 
61.34 percent respectively during the period under review. 
Table 4.20 with figure 4.11 present the Pre TRIPs period details 
with regard to R&D expenditure of Indian pharmaceutical industry. 
This period contains eight years starting from 1991-92 to 1998-99. The 
data presented in table 4.20 shows continuous increase in R&D 
expenditure. The index number (1991-92 as base year) which was 100 in 
1991-92 reached up to 325 points in 1998-99, it shows that R&D 
expenditure has been increased more than 3 times during 1991-92 to 
1998-99 and reached from a level of Rs. 800 million to a level of Rs. 2,600 
million. Figure 4.11 shows that R&D expenditure of Indian 
pharmaceutical industry has an upward increasing trend. The 
Combined Annual Growth Rate (CAGR) 17.8 percent is showing a 
moderate growth during the same period. 
From table 4.20 and figure 4.11, it is clear that the total R&D 
expenditure during the period under review has been increased with 
growth rate between 11.57 and 32.08. R&D expenditure registered a 
phenomenal increase during 1993-94 with a highest growth rate of 32.08 
percent and reached a level of Rs. 1,250 million. Index number has also 
turn up at 156.85 percent corresponding to increase in growth rate 
during the same year. In the succeeding years 1994-95 to 1998-99, R&D 
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expenditure shows a moderate growth rate ranging between 11.57 and 
18.18 percent. 
It is clear from the table 4.20 that average R&D expenditure of 
Indian pharmaceutical industry during Pre TRIPs Period was Rs. 
1,581.25 million with an Average Annual Growth Rate (AAGR) of 18.48 
percent. Maximum Growth rate of R&D expenditure was registered in 
1993-94 and minimum growth rate was in 1998-99. The other statistics 
such as Standard Deviation (SD) and Coefficient of Variance (CV) of 
R&D expenditure were 614.66 and 38.87 percent respectively whereas 
SD and CV of R&D expenditure's growth rate were 6.57 and 35.93 
percent respectively during the Pre TRIPs period. 
The trend analysis of Post TRIPs Period (1999-00 to 2005-06) with 
the help of table 4.21 and figure 4.12 shows that R&D expenditure has 
an upward increasing trend. The data presented in table 4.21 shows 
continuous increase in R&D expenditure. The index number (1991-92 as 
base year) which was 400 in 1999-00 reached up to 2740.5 points in 
2005-06, it shows that R&D expenditure has been increased 
approximately 7 times during 1999-00 to 2005-06 and reached from a 
level of Rs. 3,200 million to a level of Rs. 21,924 million. The Combined 
Annual Growth Rate (CAGR) 41.36 percent is showing a very high 
growth during the same period. 
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From Table 4.21 and figure 4.12, it is clear that growth rate of 
R&D expenditure during the period under review has been wavering. 
R&D expenditure of Indian pharmaceutical industry shows a moderate 
growth during 1999-00 to 2001-02 ranging between 15.62 and 23.02 
percent. During 2002-03 to 2005-05 growth rate of R&D expenditure 
shows a remarkable increase, this period of three years maintained a 
higher growth rate between 54.48 to 59.96 percent. In 2005-06 R&D 
expenditure touched a level of Rs. 21,924 million with a growth rate of 
30.04 percent. The major causes for this surprising growth in R&D 
expenditure during 2002-03 to 2005-06 were the Indian Patent 
Amendment Act, 2002 and Indian Patent Amendment Act, 2005. These 
Patent Acts fully implemented the TRIPs provisions in pharmaceutical 
sector. Therefore, Indian companies increased their R&D budget to 
develop new drugs. 
It is clear from the Table 4.21 that average R&D expenditure of 
Indian pharmaceutical industry during Post TRIPs Period was amounts 
to Rs. 9,613.429 million with an Average Annual Growth Rate (AAGR) 
of 36.79 percent. Minimum Growth rate in R&D expenditure was 
recorded in 2000-01 and maximum growth rate was in 2004-05. The 
other statistics. Standard Deviation (SD) and Coefficient of Variance 
(CV) of R&D expenditure were 7,269.77 and 75.62 percent respectively 
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whereas SD and CV of R&D expenditure's growth rate were 19.60 and 
53.27 percent respectively. 
A comparative analysis of Pre TRIPs period and Post TRIPs 
period shows that Post TRIPs period has Average, Combined Annual 
Growth Rate (CAGR) and AAGR higher than of the Pre TRIPs period. It 
means R&D expenditure increased with a higher growth rate in Post 
TRIPs period compare to the Pre TRIPs period. Coefficient of Variance 
(CV) of growth rate 35.62 percent in Pre TRIPs period is less than to 
53.27 percent in Post TRIPs period shows that Pre TRIPs period has 
stable growth rate in comparison to the Post TRIPs period. 
4.5.2. Testing of Hypothesis 
The following paragraphs are devoted to test the hypothesis 
"The Null Hypothesis of the study (Ho) assumes that there is 
no significant impact of the TRIPs regime on Research and 
Development (R&D) expenditure of Indian pharmaceuticals industry 
whereas the alternative Hypothesis of the study (H4) assumes that 
there is a significant impact of the TRIPs regime on Research and 
Development (R&D) expenditure of Indian pharmaceuticals 
industry." 
The Researcher has prepared dummy variable to find out the 
impact of the TRIPs Agreement on the total R&D Expenditure of Indian 
pharmaceutical industry for the period from 1991-92 to 2005-06. The 
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dummy variable is assumed keeping in view that there are two periods, 
i.e. Pre TRIPs (Pre-Intervention) Period and the Post TRIPs (Post-
Intervention) period. To test the hypothesis the Researcher assumed 
R&D Expenditure as dependent variables whereas Time, Dummy and 
Post-Intervention variables as independent variables. Further, the 
Researcher used a mathematical linear function that lends itself to 
statistical analysis by means of a general linear regression model (or 
ordinary least squares (OLS) multiple regression methods) to assess the 
impact of the invention variables (TRIPs regime) on the dependent 
variable (R&D Expenditure). The interrupted time series design can be 
represented by the following general regression model: 
Y = d + piXi + P2X2 + P3X3+ E 
Where Y is the dependent variable measured annually; Xi is a 
time counter (continuous) variable indicating time in years from the 
beginning of the observation period. The value of this variable is coded 
1 for the first year in the series, 2 for the second year, 3 for the third 
year, and so forth until the last year in the series. X2 (intervention) is a 
dummy predictor variable indicating for time before policy intervention 
and after time intervention (coded 0 for all observations before 
intervention, and coded 1 for all observations after intervention. X3 
(post-policy intervention) indicates a continuous predictor variable 
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representing the years after intervention (coded 0 during the pre-
intervention period, and 1, 2, 3, and so on until all the post-policy 
intervention observations are accounted. Last, E denotes the error of the 
model i.e., residuals unexplained by the model. 
Table 4.22 
Application of Time, Dummy and Post-Intervention Variables in 
Total R&D Expenditure of (1991-92 to 2005-06) 
Years 
1991-92 
1992-93 
1993-94 
1994-95 
1995-96 
1996-97 
1997-98 
1998-99 
1999-00 
2000-01 
2001-02 
2002-03 
2003-04 
2004-05 
2005-06 
R&D 
Expenditure in 
Million Indian 
Rs. 
800 
950 
1,250 
1,400 
1,600 
1,850 
2,200 
2,600 
3,200 
3,700 
4,350 
6,720 
10,540 
16,860 
21,924 
Time 
Xi 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Dummy 
X2 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
1 
1 
1 
1 
1 
Post 
Intervention 
Variable 
X3 
0 
0 
0 
0 
0 
0 
0 
0 
1 
2 
3 
4 
5 
6 
7 
Source: Same as table 4.19 
222 
Impact Assessment of TRIPs on Indian Pharmaceutical Industry 
This interrupted time series model contains a constant a, and 
three coefficients — {3i, p2and p3. The constant a, estimates the intercept 
at time zero; Pi, estimates the annual change in R&D Expenditure before 
TRIPs; Pi, measures any immediate or short-term effects of TRIPs 
regime; and P3 estimates the trend or slope of the observations during 
the Post-Intervention period, i.e. it measures any long-term effects oi 
TRIPs regime on R&D Expenditure of Indian pharmaceutical industry. 
Table 4.22 provides a critical analysis regarding the model. By 
applying the multiple regressions on the R&D Expenditure, Time, 
Dummy and Post-Intervention variables the following summary oJ 
table emerges: 
Table 4.23 
Model Summary 
R 
.967 
R Square 
.935 
Adjusted R 
Square 
.918 
Standard 
Error of the 
Estimate 
1816.0890 
Source: Table 4.22 
It has been seen that from the model summary (Table 4.23) the 
Coefficient of Determination i.e. R-square stood at 91.8 percent which 
means that whatever changes have happened in the tota' 
pharmaceutical production during the period under review the time 
and invention variables (TRIPs regime) are responsible up to 91.^ 
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percent. This implies that there are a few other micro and macro 
economic factors which have indirectly affected the R&D Expenditure 
of Indian pharmaceutical industry. The high value of Coefficient of 
Determination (R Square) .918 indicates that 91.8 percent of the 
variations are explained by this model. 
Table 4.24 
Cofficients 
a 
(Constant) 
Xi 
(Time) 
X2 
(Dummy) 
X3 
(Post 
Intervention) 
Unstandardized 
Cofficients 
B 
466.286 
248.214 
-5505.429 
2919.000 
Std. 
Error 
1415.085 
280.229 
1931.342 
443.080 
Standardized 
Cofficients 
Beta 
P 
-
.175 
-.449 
1.155 
t 
.328 
.886 
-2.851 
6.588 
Sig. 
.749 
.395 
.016 
.000 
Source: Table 4.22 
From the table 4.24, the t- static of the time i.e. .886, is 
insignificant at 1 percent level of significance and the t-static of dummy 
variable X2 i.e. for immediate impact of TRIPs regime is -2.851, which is 
insignificant at 1 percent level of significance. But in case of Post-
Intervention variable X;^  i.e. for impact of TRIPs regime in long run the 
t-static is 6.588, which is significant at any percent level of significance. 
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Therefore, Null Hypothesis of the study (Ho) is rejected and alternative 
hypothesis is accepted. Hence, TRIPs has significant impact on R&D 
expenditure of Indian pharmaceutical industry in the long run. 
In essence, TRIPs Agreement has no immediate significant impact 
on R&D expenditure of Indian pharmaceutical industry. But, in the long 
run TRIPs Agreement has significant impact on the R&D expenditure of 
Indian pharmaceutical industry. From Table 4.24, positive value of 
Coefficient of Post-Intervention variable (X3) suggests that TRIPs 
Agreement has increased the R&D expenditure of Indian 
pharmaceutical industry in the long run. On other words R&D 
expenditure of Indian pharmaceutical industry under TRIPs regime has 
grown more compare to the Pre TRIPs regime growth. 
4.6. References: 
1. Agreement on Trade-Related Aspects of Intellectual Property Rights 
Annex IC, Art. 65 §2, retrieved from 
http://www.wto.org/english/tratop e/trips e/t..agm2 e.htm on July 
15, 2006. 
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Findings, Conclusions, Suggestions and 
Recommendations 
5.1 Introduction 
This chapter brings out major findings including the problems 
and prospects of pharmaceutical industry in India. The suggestions 
along with the strategies for overcoming the existing problems, coping 
with challenges have also been offered for further strengthening the 
Indian pharmaceutical industry under new product patent regime. The 
present chapter also summarizes the earlier chapters discussed at 
length. 
5.2. Main Findings 
From the first hypothesis of the study regarding the impact of 
Trade Related Intellectual Property Rights (TRlPs) on pharmaceutical 
production of Indian pharmaceutical industry, it has been inferred that 
the TRIPs Agreenient has no immediate significant impact on the 
production of Indian pharmaceutical industry. But, in the long run 
TRIPs Agreement has significant effect on the production of Indian 
pharmaceutical industry. From the coefficients, it is indicative of the fact 
that TRIPs Agreement has increased the production of Indian 
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pharmaceutical industry in the long run, compare to the production of 
Pre TRIPS period. It means under the TRIPs regime the production of 
Indian pharmaceutical industry has grown more compare to the Pre 
TRIPs regime growth. 
By testing of second hypothesis of the study regarding the export 
of Indian pharmaceutical industry, it can be safely deduced that the 
TRIPs regime has no immediate significant impact on the export of 
Indian pharmaceutical industry. But, in the long run TRIPs Agreement 
has significant impact on the export of Indian pharmaceutical industry. 
From the model summary, it is indicative that TRIPs Agreement has 
increased the export of Indian pharmaceutical industry in the long run. 
On the other hand, under the TRIPs regime the export of Indian 
pharmaceutical industry has grown more than to Pre TRIPs regime 
growth. 
The testing of third hypothesis of the study regarding the impact 
of Trade Related Intellectual Property Rights (TRIPs) on 
pharmaceutical import of Indian pharmaceutical industry presents that 
TRIPs Agreement has significantly affected the import of the Indian 
pharmaceutical Industry in short term i.e. sudden downfall in import 
during 1999-00 when TRIPs was implemented. But, in the long run 
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TRIPs Agreement has no significant impact on the import of Indian 
pharmaceutical industry. 
From the forth and final hypothesis of the study regarding the 
impact of Trade Related Intellectual Property Rights (TRIPs) on 
Research and Development (R&D) Expenditure of Indian 
pharmaceutical, it has been inferred that the TRIPs Agreement has no 
immediate significant impact on R&D expenditure of Indian 
pharmaceutical industry. But, in the long run TRIPs Agreement has 
significant impact on the R&D expenditure of Indian pharmaceutical 
industry. From the coefficient it is indicative that R&D expenditure of 
Indian pharmaceutical industry under TRIPs regime has grown more 
compare to the Pre TRIPs regime growth. 
The other major findings of the study are discussed below under 
the heads: Problems, upcoming opportunities and prospects for Indian 
pharmaceutical industry. 
Problems 
After studying comprehensive review of literature and overall 
business environment of Indian pharmaceutical industry, the 
Researcher has found that pharmaceutical industry is facing a lot of 
problems 
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• Due to very law barrier to entry, Indian pharmaceutical industry 
is highly fragmented with about 300 large manufacturing units 
and about 23,000 small units spread across the country.. This 
makes Indian pharmaceutical market increasingly competitive 
and reduced the profitability of the companies. 
• Small manufacturers that were dependent only on the marketing 
of process inventions are facing survival concerns after the 
introduction of product patent rights. 
• The new MRP based excise duty regime threatens the existence of 
many small scale pharmaceutical units, especially in the states of 
Andhra Pradesh and Maharashtra, which were involved in 
contract manufacturing for the larger, established players. 
• A drug regulatory system is an essential part of the 
pharmaceutical sector. Drug discovery and drug development are 
risky, complex, and not fully understood. The Indian regulatory 
system is not set up to accommodate the drug development 
processes and therefore does not have the proper infrastructure, 
enough manpower, or financial support to effectively move drug 
development operations forward. As a result, industry is facing 
problem of delay in the approval process. 
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The Indian pharmaceutical companies are marred by the price 
regulation. Over a period of time, this regulation has reduced the 
pricing ability of companies. The NPPA (National Pharmaceutical 
Pricing Authority), which is the authority to decide the various 
pricing parameters, sets prices of different drugs, which leads to 
lower profitability for the companies. 
The Indian pharmaceutical industry's efforts to seek approval to 
market drugs in the United States is time consuming because of 
FDA constraints, and the approval process could be major 
bottleneck for India's drug development industry. 
Although the Indian pharmaceutical industry is large by Indian 
standards, in the world market its share is merely 1-2 %. Even if 
25 % of gross sales are invested in R&D, the Indian 
pharmaceutical industry's total R&D budget is comparatively 
very small. Individual R&D budgets of many US companies 
probably amount to much more than the cumulative R&D budget 
of all the companies in India. Thus, unavailability of funds is a 
major problem of the Indian pharmaceutical industry. 
Indian pharmaceutical market is one of the least penetrating in 
the world. However growth has slow to come by. As a result, 
Indian majors are relying on export for growth. 
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• The Indian pharmaceutical market is facing problem of the 
dumping of bulk drugs and formulations by neighboring country 
China. 
• Indian pharmaceutical industry is lacking of quality manpower. 
The quality of technical manpower coming from our colleges and 
universities is very poor. In many cases the reason is due to lack 
of budgetary support and poor infrastructure. The younger 
generation instead of concentrating on life sciences is going for 
engineering and medical courses. 
• Indian pharmaceutical companies also facing problem from 
outdated labour law and animal law. 
Upcoming Opportunities for Indian Pharmaceutical Industry 
The international pharmaceutical scenario is changing due to cost 
pressures, leading to consolidation of companies, out sourcing and 
growth of generics. Other changes taking place internationally are 
globalization of market product, patent expiry and increased use of IT. 
These changes offer excellent opportunities for pharma companies in 
India. Though it is not possible for India to be a world leader in all 
aspects of Pharma industry, it is possible for India to become a leader in 
certain niche areas. Large number of drugs going off-patent in Europe 
and in the US between 2005 and 2009 offers a big opportunity for the 
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Indian companies to capture this market. Indian pharmaceutical 
industry can emerges as centre of development of law cost bulk drugs 
and formulations, since R&D and clinical studies are cheaper in India. 
Since generic drugs are commodities by nature, Indian producers have 
the competitive advantage, as they are the lowest cost producers of 
drugs in the world. Opening up of health insurance sector and the 
expected growth in per capita income are key growth drivers from a 
long-term perspective. This leads to the expansion of healthcare 
industry of which pharmaceutical industry is an integral part. 
Prospects for Indian Pharmaceutical Industry 
The recent successes of India in the realm of information 
technology and growth of services have proved that India has a great 
potential for development of knowledge based industrial sectors. This 
prospective is not only restricted to information technology but it is 
uniformly applicable to pharmaceutical sector. The Researcher is of 
belief that future of Indian Pharmaceutical Industry is bright provided 
that there is a presence of a globally competitive high technology and 
globally competitive human resource capital. Secondly largest english 
speaking, scientific and technical human resource in the globe is found 
in India and Indian manufacturers are one of the lowest cost producers 
of drugs in the world. In large number of research laboratories scientific 
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and technical research is being carried to develop new drugs. Initiatives 
taken by the Government is continuously formulating policies to 
strengthen Indian pharmaceutical companies. 
5.3. Suggestions and Recommendations 
On the basis of present study, the Researcher gives certain 
suggestions for strengthening the Indian pharmaceutical Industry 
under the product patent regime. 
Suggestions for Industry 
• The industry should update its technology to meet the new 
process technology requirements like Process Analytical 
Techniques (PAT). Indian companies should concentrate on 
supply of advanced R&D equipment to be produced 
domestically. 
• Indian manufacturers should tie up with foreign companies to 
produce some advanced instruments as well as sophisticated 
machinery for which there is a growing demand. 
• Transition from "Process" patent to "Product" patent is the 
major threat Indian pharmaceutical industry is facing. Indian 
companies especially Small and Medium Enterprises (SMEs) do 
not have capabilities to develop new drugs. Therefore, these 
SMEs should concentrate on production of off-patented drugs. 
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Small manufacturers those are dependent only on the producing 
and marketing generic version of patented drugs should tie up 
with major players for contract manufacturing to survive under 
TRlPs regime. 
Indian pharmaceutical companies should look into economies of 
scale. Merging with a complementary domestic or international 
company may provide sufficient funding and resources to 
manufacture formulations and bulk drugs on a large scale, which 
would decrease the cost of manufacture. This would help make 
bulk drug or formulation costs competitive in the world market, 
which then would boost the amount of export. 
WTO led global trading system resulted in import tariffs coming 
down. For Indian companies to compete with cheap imports, 
they should to invest in cost effective technology and processes. 
Under the new product patent regime the research component in 
the area of drug discovery and technology development assumes 
critical importance. Therefore, every pharmaceutical company of 
the industry should invest in R&D for new drugs. 
R&D in pharmaceutical has an important characteristic namely 
IPR including getting patents for the products. To reap more 
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benefits it is necessary that industry should filed patents in 
advanced countries like US, Europe and the like. 
• The Pharmacy services available to the citizens should be 
upgraded to the levels provided to the public in other developed 
countries of the world. This applies specially to community and 
institutional Pharmacy. 
• Attractive salary and incentives should be given to the technical 
manpower from life science to attract qualitative and competent 
workforce. 
Suggestions for Government 
• To ensure production from the basic stage, ratio parameters 
between manufacture of formulation and bulk drugs should be 
reintroduced. 
• Under the Product Patent Regime, Public Sector Units (PSUs) 
should be used as an arm of the Government in manufacturing 
certain patented drugs required to meet emergencies through the 
grant of compulsory licenses. An important role can be played by 
Pharma PSUs in ensuring quality medicines at reasonable prices 
for various health care programmes of the Government. 
• In order to encourage exports of pharmaceuticals. Pharmaceuticals 
Export Promotion Council has been set up. A Pharma Export 
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Promotion Cell is also operating in the Department with only a 
token budget. There is need to give a major thrust to exports of 
pharmaceuticals from India. Department of Chemicals and 
Petrochemicals should play a more active role in this regard. The 
budget for the cell should be raised for sharper focus of the efforts 
of the Cell. The Cell may also attend to the issue of serious threat 
on account of dumping of some bulk drugs and formulations by 
some countries adversely affecting Indian Pharma exports. A 
permanent consultative mechanism to look into specific and 
general issues and to recommend remedial measures is 
recommended. 
• Bulk Drug manufactures in anti-infectives are facing a serious 
threat on account of dumping of these drugs by some countries. 
Since some of these drugs have strategic importance as cost 
effective and largely needed by the general public, a permanent 
consultative mechanism to look into specific and general issues in 
association with industry, trade, consumers and other stake 
holders to recommend remedial measures is hence recommended. 
• Restrictions in the form of tariffs and other non-tariff measures 
should be imposed on the import of bulk drugs or formulation for 
which adequate production capacities exist in the country. 
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• Recognized R&D centers can be given same benefits as units in 
special economic zones for tax purposes where they can be given 
exemption on customs, excise duties and similar benefits for 
promoting R&D. 
• New technologies of drug discovery and development are very 
cost prohibitive and require high investment in R&D. There is need 
to extend the fiscal incentives being given for R&D by another 10 
years i.e. up to 31st March 2017. 
• Apart from high cost of R&D and patent filings there are also 
litigation issues. To meet these costs there should be some 
mechanism of funding. Government should provide soft loans to 
mitigate the difficulties faced by Drug Discovery Companies from 
India in the area of patents. 
• A major national effort should be made to increase original drug 
research based on the strength of our national research 
institutes, laboratories and the Universities and also on the 
biodiversity and the medicinal plant wealth of our country. The 
research institutions should be provided with adequate funds 
for drug research. Regional drug research centers may be 
established in states where infrastructural facilities are already 
available. 
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• Suggestion has come that Central Government should have fully 
equipped laboratories with all facilities. The small scale firms 
should be given access to testing facilities available with the State 
Governments on payment of prescribed fees since many small scale 
firms find it difficult to get their drugs tested 
• Regulatory infrastructure has to be strengthened to ensure good 
quality of products and check production of spurious drugs. 
• Drastic changes are needed in the regulatory system to keep 
abreast with the changing trends in the industry with the objective 
of maintaining uniform parameters to produce quality drugs. 
Since systems followed in different states are different, a new 
approach will be needed to bring out uniformity in the procedures 
to be followed by state licensing authorities. To achieve this, there 
will be need for proper training facilities for drug regulatory 
personnel. 
• The NPPA (National Pharmaceutical Pricing Authority), which is 
the authority to decide the various pricing parameters, sets prices 
of different drugs, which leads to lower profitability for the 
companies. The pressure to reduce prices must end and 
government should provide incentives and allow companies to 
make additional profits which they can put back into research. 
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• The amendments already passed by the Indian Parliament in 
compliance of TRIPS, must be read in the context of the Doha 
Declaration. 
• However, there is a greater need to assist small scale units for 
which Planning Commission can provide some funds to help small 
scale units in their efforts to improve infrastructure. For medium 
companies Government should consider sanctioning soft loans 
through financial institutions to upgrade their infrastructure 
pertaining to quality. 
• Tax benefits should be such as to attract Multinational companies 
to get clinical trials and research done through Indian companies. 
• Income tax exemptions should be given on clinical trials and 
contract research done outside the company and abroad. This is 
because India is seen as emerging as a major center for outsourcing 
of clinical trials for the pharmaceutical MNCs. 
• There is a need to conduct regular workshops, technical seminars 
in collaboration with the Central Drugs Standards & Control 
Organization & State Licensing Authorities on the quality issues to 
educate the small scale units. There is also an urgent need to set up 
a technical and trade information centre, which can be a 
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collaborative effort of Government and Industry and can be 
covered under this activity. 
• Universities should be encouraged to offer courses so as to 
produce adequate and high quality human resource pool for 
modem drug research related activities. 
• Outdated and restrictive labour laws and animal laws are 
hampering pharmaceutical industry. Therefore, Government 
should review these laws according to international standards. 
5.4. Directions for Future Researches 
The present study is an empirical work based on the secondary 
sources of information which may prove to be a gateway for future 
researches on the following aspects: 
The Researcher is concerned only about the impact assessment of 
TRIPs on production, export, import and R&D expenditure of Indian 
pharmaceutical industry. FDI inflows, drug prices, profitability and 
performance of Indian companies under the new regime, and impact on 
SMEs have not been covered in the present study. Hence, there is a 
scope for more researches on these aspects. 
The researches on the basis of all the five aspects, such as, 
production, export, import and R&D expenditure as presented in the 
study can be done separately at individual company level with primary 
241 
Findings, Conclusions, Suggestions & Recommendations 
survey. 
5.5. Conclusions 
The present section essentially summarizes the chapters of the 
study discussed at length. 
The first chapter is introductory in nature that provides statement 
of the problem. It highlights that during the process patent regime the 
Indian pharmaceutical industry became world's leading producer and 
exporter of less expensive copies of the world's best-selling patent-
protected drugs. India signed TRIPs Agreement of WTO in April 1994, 
which took effect from January 1, 1995. India amended its patent laws 
towards compliance with TRIPs provisions. Under the new patent law, 
Indian drug makers can no longer manufacture and market reverse-
engineered versions of drugs patented by foreign drug producers. It 
would affect Indian generic pharmaceutical industry. The chapter 
further presents the literature review available on this issue. Most of the 
work concentrates to analyze the impact of new regime on SMEs, prices 
of the drugs, availability and accessibility of the drugs. There is a clear 
gap, the issues such as impact of TRIPs on pharmaceutical production, 
research and development, export and import of Indian pharmaceutical 
industry have not been covered in-depth with analytical framework 
under any of the studies, creating scope for the present research. The 
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chapter also discusses objectives, hypotheses and research methodology 
of the present project. 
The second chapter presents an overview of Indian 
pharmaceutical industry. It presents an introduction to global 
pharmaceutical industry, evolution and history of Indian 
pharmaceutical industry, Indian pharmaceutical industry current 
status, pharmaceutical production cycle, SWOT analysis of Indian 
pharmaceutical industry. Further, Mc Kinsey projection and brief 
profiles of top five leading pharmaceutical companies in India have also 
been discussed in detail. This chapter concluded that Indian 
pharmaceutical industry is one of the developing world's largest and 
most developed industries. It is one of the fastest growing segments of 
the Indian economy. Dominated by domestic companies, the industry 
supply nearly all the country's demand. Production, export, import and 
R&D expenditure of Indian pharmaceutical industry growing at a very 
high rate. Indian pharmaceutical industry having a large number of 
intellectual and technical workforce which insures the bright future of 
the industry. 
The third chapter attempts to highlights the concept of 
intellectual property rights, pros and cons of pharmaceutical patents, 
main provisions of TRlPs related to pharmaceutical patent, difference 
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between TRIPs and Indian Patent Act, 1970. While presenting the 
overview of Indian Patent Act, 1970 amendments in Patent Act towards 
TRIPs compliance are also highlighted. This chapter highlights that 
India had process patent system prior to TRIPs Agreement but being a 
signatory of TRIPs Agreement India implemented product patent 
system in pharmaceutical sector. Various flexibilities for health purpose 
available in TRIPs Agreement have also been discussed in this chapter. 
The fourth chapter attempts to assess the impact of TRIPs on 
production, export, import and R&D expenditure of Indian 
pharmaceutical industry. Trend analysis has been done in this chapter 
which shows an upward increasing trend in production, export, import 
and R&D expenditure of Indian pharmaceutical industry. The chapter 
concluded that TRIPs has significant positive effect on Indian 
pharmaceutical industiy in the long run. 
The fifth chapter discussed the main findings of the study. It also 
discussed the problems and prospects of Indian pharmaceutical 
industry. Finally, this chapter gives some suggestion for strengthening 
the Indian pharmaceutical industry under the TRIPs regime. The 
direction for future researches has also been identified by the 
Researcher in this chapter. 
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Appendix - 1 
EXCHANGE RATE OF THE INDIAN RUPEE VIS-A-VIS US 
DOLLAR ($) (Financial year - Annual average rate) 
Year 
1970-71 
1971-72 
1972-73 
1973-74 
1974-75 
1975-76 
1976-77 
1877-78 
1978-79 
1979-80 
1980-81 
1981-82 
1982-83 
1983-84 
1984-85 
1985-86 
1986-87 
1987-88 
Rupees per unit 
of US Dollar ($) 
7.5578 
7.4731 
7.6750 
7.7925 
7.9408 
8.6825 
8.9775 
8.5858 
8.2267 
8.0975 
7.9092 
8.9683 
9.6660 
10.3400 
11.8886 
12.2349 
12.7782 
12.9658 
Year 
1988-89 
1989-90 
1990-91 
1991-92 
1992-93 
1993-94 
1994-95 
1995-96 
1996-97 
1997-98 
1998-99 
1999-00 
2000-01 
2001-02 
2002-03 
2003-04 
2004-05 
2005-06 
Rupees per unit 
of US Dollar {$) 
14.4817 
16.6492 
17.9428 
24.4737 
30.6488 
31.3655 
31.3986 
33.4498 
35.4999 
37.1648 
42.0706 
43.3327 
45.6844 
47.6919 
48.3953 
45.9516 
44.9315 
44.2735 
Source: Data from 1970-71 to 1991-92 are based on official exchange 
rates Government of India. Data from 1992-93 onwards are based on 
FEDAI (Foreign Exchange Dealers' Association of India) indicative 
rates. 
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Doha Declaration on Health 
WORLD TRADE 
WT/MIN(01)/DEC/2 
ORGANIZATION 20 November 2001 
(01-5860) 
MINISTERIAL CONFERENCE 
Fourth Session 
Doha, 9 -14 November 2001 
DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC 
HEALTH 
Adopted on 14 November 2001 
1. We recognize the gravity of the public health problems afflicting 
many developing and least-developed countries, especially those 
resulting from HIV/AIDS, tuberculosis, malaria and other epidemics. 
2. We stress the need for the WTO Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS Agreement) to be part of 
the wider national and international action to address these problems. 
3. We recognize that intellectual property protection is important 
for the development of new medicines. We also recognize the concerns 
about its effects on prices. 
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4. We agree that the TRIPS Agreement does not and should not 
prevent Members from taking measures to protect public health. 
Accordingly, while reiterating our commitment to the TRIPS 
Agreement, we affirm that the Agreement can and should be 
interpreted and implemented in a manner supportive of WTO 
Members' right to protect public health and, in particular, to promote 
access to medicines for all. 
In this connection, we reaffirm the right of WTO Members to use, 
to the full, the provisions in the TRIPS Agreement, which provide 
flexibility for this purpose. 
5. Accordingly and in the light of paragraph 4 above, while 
maintaining our commitments in the TRIPS Agreement, we recognize 
that these flexibilities include: 
(a) In applying the customary rules of interpretation of public 
international law, each provision of the TRIPS Agreement 
shall be read in the light of the object and purpose of the 
Agreement as expressed, in particular, in its objectives and 
principles. 
(b) Each Member has the right to grant compulsory licences 
and the freedom to determine the grounds upon which 
such licences are granted. 
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(c) Each Member has the right to determine what constitutes a 
national emergency or other circumstances of extreme 
urgency, it being understood that public health crises, 
including those relating to HIV/AIDS, tuberculosis, 
malaria and other epidemics, can represent a national 
emergency or other circumstances of extreme urgency. 
(d) The effect of the provisions in the TRIPS Agreement that 
are relevant to the exhaustion of intellectual property rights 
is to leave each Member free to establish its own regime for 
such exhaustion without challenge, subject to the MFN and 
national treatment provisions of Articles 3 and 4. 
6. We recognize that WTO Members with insufficient or no 
manufacturing capacities in the pharmaceutical sector could face 
difficulties in making effective use of compulsory licensing under the 
TRIPS Agreement. We instruct the Council for TRIPS to find an 
expeditious solution to this problem and to report to the General 
Council before the end of 2002. 
7. We reaffirm the commitment of developed-country Members to 
provide incentives to their enterprises and institutions to promote and 
encourage technology transfer to least-developed country Members 
pursuant to Article 66.2. We also agree that the least-developed country 
264 
Members will not be obliged, with respect to pharmaceutical products, 
to implement or apply Sections 5 and 7 of Part II of the TRIPS 
Agreement or to enforce rights provided for under these Sections until 1 
January 2016, without prejudice to the right of least-developed country 
Members to seek other extensions of the transition periods as provided 
for in Article 66.1 of the TRIPS Agreement. We instruct the Council for 
TRIPS to take the necessary action to give effect to this pursuant to 
Article 66.1 of the TRIPS Agreement. 
Source: World Trade Organisation 
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